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Abbreviations 
∆HA   amorphous material formation energy 
∆Hd   relative lattice distortion energy 
∆HP   new phases formation energy 
∆HS   specific surface area  
∆HT   macroenergy state of activated solid 
API   active pharmaceutical ingredient 
AUC   area under curve 
C   constant for the milled material 
Cryst. %  crystallinity of the API 
d(0.1)   particle diameter below which 10% of the sample volume exists 
d(0.5)   particle diameter below which 50% of the sample volume exists 
d(0.9)   particle diameter below which 90% of the sample volume exists 
E   milling energy 
fluidMel  a solid-state meloxicam containing product produced by fluidization 
HPC   hydroxypropyl cellulose 
HPH   high pressure homogenization 
HPMC   hydroxypropyl methylcellulose 
LD50   the amount of a material that is sufficient to kill 50 percent of the  
   treated population.    
lyoMel   a solid-state meloxicam containing product produced by lyophilization 
Mel   meloxicam 
MelD   meloxicam dispersion 
Mel-PVA PM  meloxicam–poly(vinyl alcohol) physical mixture 
microMel  micro-sized raw meloxicam 
nanoMel  milled nano-sized meloxicam 
n   constant for mill 
NSAID  non-steroidal anti-inflammatory drug 
PEG   poly(ethylene glycol) 
PM   physical mixture 
Poloxamer  poly(ethylene)–poly(propylene glycol) 
  
PS   particle size 
PSD   particle size distribution 
PVA    poly(vinyl alcohol) 
PVP   polyvinylpirrolidone 
rawMel  untreated raw meloxicam 
SDS   sodium dodecylsulfate  
SLS   sodium lauryl sulphate 
SSA    specific surface area 
XRPD   X-ray powder diffraction 
ZrO2   zirconium-oxide 
 
 1 
 
1. INTRODUCTION 
Particle design techniques are widely used to modify the physicochemical and 
biopharmaceutical properties of APIs (Maghsoodi et al., 2008). Particle engineering 
techniques that control the crystal size distribution and morphology and make use of different 
additives can offer improvements as concerns the solubility, rate of dissolution and 
permeability of poorly water-soluble drugs and can open up new, alternative administration 
routes as well (Pomázi et al., 2011, Ghosh et al., 2012, Maggi et al., 2013). From the early 
2000’s synthesis of poorly water-soluble drugs has been rapidly increased, therefore the 
particle size reduction especially the nanonization (particle size < 1000 nm) may be the 
solution to reach rapid saturation concentration and better bioavailability of these drugs.  
The nanonization techniques can be classified as bottom-up and top-down techniques. 
During the bottom-up processes nanoparticles are built from dissolved agent. Top-down 
processes comprise disintegration techniques, where the raw material is broken down via 
mechanical forces. Milling belongs among top-down methods. Due to the reduced particle 
size, the increased specific surface area and the surface charge of the particles can be occurred 
particle aggregation. To prevent the particle aggregation, the addition of stabilizing agents 
(polymers, surfactants) is needed (Ujhelyi et al., 2012).  
New approach in a wet milling process is the combined techniques, where the 
planetary ball mill is combined with pearl milling technology to reach nanosize range. 
Planetary ball milling is mainly used in laboratory-scale research work. Pearl milling is a 
commonly used milling process for industrial purposes. Separately, both techniques are well 
known but we do not yet know enough about a combinative technique as optimization of 
process parameters, testing for robustness and selection of additives (polymer, surfactant). 
 Present PhD thesis shows new results on this topic, which may help nanonization of 
active ingredients, stabilization of nanoparticles without surfactant, and improved 
bioavailability of the final product. 
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2. THEORETICAL BACKGROUND  
2.1. Strategies to increase the dissolution/solubility of poorly water-soluble active agent 
A significant and increasing percentage of the synthetized small molecule APIs are poorly 
water soluble (Merisko-Liversidge et al., 2011, Junghanns et al., 2008). Consequently, the 
liberation, the absorption, hence the bioavailability of these drugs is not satisfying (Liu et al., 
2011). 
The most important available routes to optimize the dissolution characteristics or/and the 
solubility properties of the APIs are the followings: 
• particle size reduction (most commonly used route) (Khadka et al., 2014), 
• amorphization – breakdown of the crystal structure (Jójárt-Laczkovich et al., 2016), 
• polymorphism - developing a new crystal structure of the API to achieve higher 
solubility (Bhatia et al., 2018),  
• salt forming - in the case of active substances which tend to form salt, this method can 
be used to enhance the water solubility (Horváth et al., 2016). 
Particle size reduction techniques are widely used to produce micro- or nanoparticles in order 
to increase the specific surface area thereby improve the dissolution characteristics of poorly 
soluble drugs. According to the Noyes–Whitney equation, the dissolution rate is directly 
proportional to the specific surface area, therefore improved dissolution rate, higher saturated 
concentration and better bioavailability of the API can be achieved (Shegokar et al., 2010, 
Dokoumetzidis et al., 2006).  
The size reduction techniques can be also classified as bottom-up and top-down 
techniques. During the bottom-up processes micro- or nanoparticles are built from dissolved 
agent with gas anti-solvent recrystallization, aerosol solvent extraction system (Yim et al., 
2014f), atomized rapid injection for solvent extraction, rapid expansion of supercritical 
solution (Chan et al., 2011) and depressurization of an expanded liquid organic solution 
(Ventosa et al., 2001). Due to the complexity of these methods, as per our knowledge there 
are no pharmaceutical products on the market based on this technology (Shegokar et al., 2010, 
Finke et al., 2017). 
Top-down processes comprise disintegration techniques, where the raw material is broken 
down via mechanical forces. The most known top-down processes: dry (Suryanarayana et al., 
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2001) and wet ball milling (Peltonen et al., 2010), jet milling (Moorthi et al., 2013), high 
pressure homogenization (Müller et al., 2006) and high-energy sonication (Bartos et al., 
2015). 
2.2. Milling 
Milling is a commonly applied technique to produce micro- or nanosized drug crystals. The 
main effect of the process is the comminution of particles, which results in changes in 
physicochemical properties of the ground material. Due to the mechanical activation, the 
initial structure of the material usually becomes disordered, amorphization or generation of 
other metastable forms can be registered (Baláž, 2008). One possible description for 
characterizing the macro-energy state of activated solid (∆HT) equals to the sum of the energy 
of microstates (Pourghahramani, 2007) calculated according to the following equation: 
∆HT = ∆Hd + ∆HS + ∆HA + ∆HP 
where ∆Hd is the relative lattice distortion (dislocation density), ∆HS is the specific surface 
area (grain boundary) and ∆HA is the formation of amorphous material (Heegn, 1979) and 
∆HP is the formation of new phases. There are numerous types of milling techniques; dry and 
wet milling can be distinguished (Dahiya, 2017): 
• Dry milling – the conventional method of particle size reduction. 
• Wet milling – in this method, a sufficiently concentrated dispersion of drug particles 
in an aqueous or non-aqueous liquid medium is treated. Increased mill capacity, lower 
energy consumption, and easier handling of materials can be perceived as advantages 
of the process. However, it must be said, in the course of the milling process, 
increased wear of the milling medium and corrosion can occur, and the liquid agent is 
needed as a milling medium due to the properties of the milled materials: high residual 
moisture content, high potency of degradation in dry milling conditions. 
2.2.1. Dry milling 
Dry milling techniques are usually used for micronization and nanonization (Naik et al., 2015, 
Liu et al., 2014). Criteria of the dry milling nanonization are the use of an additive and a long 
milling time, furthermore, during the nanonization changes may occur in the physicochemical 
structure of the drug (Kürti et al., 2011). Cutter mill, roller mill and planetary ball mill can be 
mentioned, as machines for dry milling processes. 
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The general milling law is defined by Walker et al. (Perry, 1963): 
𝑑𝐸 = −C
𝑑𝑥
𝑥𝑛
 
where E is grinding energy per unit mass, x is particle size and C and n are constants for a 
given material and mill. It is impossible to produce a differential decrease in particle size by 
grinding because mass is conserved, so that a finite quantity of small material is produced in 
addition to the particle of near original size. In this form, the equation is absurd (Perry, 1963). 
Three sub-definitions are commonly used to determine the energy consumption of the 
milling: Rittinger’s, Bond’s and Kick’s and Kirpicsov’s law. In case of micronization, the 
Rittinger theory describes the PS reduction produced relative to the energy (E) input of 
milling: the new surface area generated is directly proportional to the E required for the PS 
reduction. As the surface area of a quantity of particles of uniform diameter x is proportional 
to 1/x, the E required for PS reduction is therefore also proportional (Austin, 1973): 
𝑑𝐸 = 𝐶 (
1
𝑥1
) − (
1
𝑥2
) 
In dry co-milling (the poorly water-soluble API is milled with water-soluble additives for 
preparation of dry nanodispersions) PVP, SDS, PEG, HPMC, and cyclodextrin derivatives are 
used as additives (Dahiya, 2017). 
In case of milling hygroscopic or heterogenic materials (during the milling process these 
materials tend to stick) and nanonization (due to the high SSA and decreased particle size, 
instabilities can be occurred), additives need to be added. Ethylene-glycol, Aerosil® and 
magnesium-stearate are the most commonly used additives for dry milling processes. (Fritsch 
GmbH). In general, many areas of industrial production avoid dry milling processes due to the 
higher energy demand risk of environmental contamination (Duroudier et al., 2016) and the 
long process time. 
Planetary ball milling belongs to high energy milling methods. The working principles of 
the mill: during the operation the milling container rotates about its own and an external axel, 
so it carries out a planetary movement (Broseghini et al., 2016). According to the rotation 
direction, horizontal and vertical type planetary ball mill can be distinguished. In the 
conventional use the total kinetic energy of the milling components consists of the centrifugal 
force of the vial, the centrifugal force of the vial, the centrifugal force of the disk and the 
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Coriolis force (Harris, 2013) (Figure 1). In terms of the energy used by the mill to achieve 
particle size reduction, the collision energy can be defined. The collision energy is the sum of 
the kinetic energy of the beads acting perpendicular to the direction of the disk rotation and 
the collision heat generated by the milling components and the container wall. The process is 
mainly used in laboratory-scale research work. It is a common technique for dry milling 
(Suryanarayana et al., 2001), nevertheless it is suitable for wet milling processes as well (Liu 
et al., 2011, Ghosh et al. 2012, George et al., 2013). 
 
 
 
Figure 1. Energies occurring during a planetary ball milling process 
2.2.2. Wet milling 
Wet milling is a method, in which a sufficiently concentrated dispersion of drug particles in 
an aqueous or non-aqueous liquid medium is treated. Increased mill capacity, lower energy 
consumption and easier handling of materials can be perceived as advantages of the process. 
However, it shall be mentioned, to carry out the milling process, increased wear of the milling 
medium and corrosion can occur, and API instability can present difficulties. 
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Wet milling is applicable for micronization (Pomázi et al., 2013), but is usually used for 
nanonization (Bilgili et al., 2006, Loh et al., 2015).  
Drug pre-dispersions produced by wet milling can be formulated as capsules, granules, 
tablets, injectables, sprays and gels (Wang et al., 2013, Junyaprasert et al., 2015). The colloid 
mill, the toothed high-shear inline mixers, the cone mill, high-pressure homogenization and 
the pearl mill can be classified as wet milling equipments. 
Media milling is a commonly used milling process in pigment-, photo- and magnet industry. 
Commercially, in pharmaceutical industry the media milling is exemplified by the 
NanoCrystal® technology from Elan Pharma International Ltd. (Dublin, Ireland) (Junghanns 
et al., 2008). In terms of the machine size, originally the mill was constructed for industrial 
purposes. The labor scale machine production due to extensive usability was launched (Figure 
2). The milling is executed by a high energy rotating stirrer in the milling chamber, which 
induces the motion of the milling components. Micro-sized beads are used as milling media 
(100-500 µm). The process is time-consuming and requires lot of energy (Merisko-Liversidge 
et al., 2011, Azad et al., 2014).  
 
Figure 2. Schematic illustration of the wet media milling process (Loh et al. 2015). 
A major drawback of media milling is the erosion of the mostly zirconia, glass or pearl 
milling media arising from the intensive mixing forces. Residues of the milling media may 
result in product contamination (Peltonen et al., 2010, Shegokar et al., 2010) leading to 
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chemical destabilization of the newly formed particle surfaces and possibly affecting critical 
product characteristics such as PS and PSD. In case of wet milling processes, stabilizing 
agents are needed to prevent the physicohemical changes of the API. The main functions of a 
stabilizer in nanodispersions/suspensions are to wet drug particles during the milling process, 
and to prevent Ostwald’s ripening (crystal growth in colloidal suspensions) (Kim, 2004) and 
agglomeration in order to yield a physically stable formulation by providing steric or ionic 
barriers. Different concentrations of stabilizer agents (e.g. polymers) can also influence the 
viscosity and the electrokinetic property of the particles, according to the DLVO theory 
(Derjaguin et al., 1941), and thus the stability of the nanosuspension as well. Surfactants help 
to wet the particles and thus reduce their aggregation tendency (Table 1) (Van Eerdenbrugh et 
al, 2008, Merisko-Liversidge et al., 2011). In addition to the advantages of surfactants, they 
have the biggest disadvantage of increasing the speed/energy of motion of the milling balls 
during wet milling, which can lead to the degradation of the active ingredient. When used as 
an external surfactant to solidify the nanosuspension, its solubility-enhancing effect may be 
emphasized, thereby increasing the degree of crystallinity of active agent in the solid product 
and reducing its dissolution rate (Verma et al., 2011). It should be noted, that the presence of 
surfactants is also contraindicated in some cases e.g. pediatric therapy, hypersensitivity, 
irritation, etc. 
Conventional formulations contain these excipients in common, but the new tendency is to 
ignore the surfactants and look for other options to stabilize the nanoparticles in the products 
and achieve the desired biological effect (Bhakay et al., 2014, Azad et al., 2015, Kim et al., 
2018). 
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Table 1. List of additives used in wet media milling 
Polymer Concentration 
(%) 
Literature reference 
HPC 2.4 -19.6 Lee et al. (2006), Lee (2003) 
PVA 50 Wiedmann et al. (1997), Bartos et al. (2018) 
PVP 30 Liversidge et al. (1995), Ding et al. (2019) 
 
Surfactant   
Cremophor® 100  Wahlstrom et al. (2007), Chiang et al. (2007) 
Poloxamer 188 60 Liversidge et al. (1995), Zhang et al. (2018) 
Poloxamer 338 50 Merisko-Liversidge et al. (1996), Mouton et al. 
(2006) 
Poloxamer 407 20 Jia et al. (2002), Zheng et al. (1997) 
Poloxamine 908 20 Na et al. (1999), Girdhar et al. (2018) 
Polyglyceryl-10 
laurate 
16.7 Kondo et al. (1993),  
Tyloxapol 20 Ostrander et al. (1999) 
SLS 0.15 Vergote et al. (2001) 
Polysorbate 80 1 Merisko-Liversidge et al. (1996), Sievert et al. 
(2018) 
Sorbitan 
monooleate 
1 Merisko-Liversidge et al. (1996) 
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Crystalline state is one of the most important parameters affecting drug stability, dissolution 
extent, and efficacy. The high energy wet milling techniques tend to create a partially 
amorphous active agent. The high energy amorphous particles are unstable, especially in the 
presence of crystalline particles, and inclined to convert to low energy crystalline state over 
time. The saturation solubility between amorphous and crystalline nanoparticles is different, 
therefore the diffusion process will be similar to Oswald’s ripening, leading to a rapid 
conversion of amorphous nanoparticles to crystalline state (Wu et al., 2011). 
2.2.3. Combined wet milling process 
The original meaning of the term “combined milling process” is the combination of two 
consecutive individual milling processes. Recently a group of combinative nanonization 
technologies were developed. There are five known groups: NANOEDGER 
(microprecipitation followed by HPH), microprecipitation immediately followed by HPH, 
spray-drying followed by HPH, lyophilization followed by HPH, and the combinative 
technology (media milling followed by HPH) (Shegokar and Muller, 2010).  
The combined wet milling process used in this research work is a fusion of two basic 
milling techniques, in both cases the milling is performed in presence of grinding media 
(beads). In the Retsch method recommendation list, combination of the planetary ball mill and 
the grinding media of the pearl mill is preferred as a novel milling technique in order to 
prepare pre-dispersions with nanoparticle size of the API (Retsch GmbH, Haan, Germany). 
This combined milling technique unites the advantageous properties of the basic milling 
processes: 
• Particle size reduction with high energy transfer in labor-scale conditions, produced by 
the planetary ball mill.  
• The micro-sized beads of the wet stirred media milling give a higher reduction rate 
according to the basically used millimeter-scale beads – the particle size reduction rate 
is inversely proportional to the size of the bead size (Gao et al., 1995). 
The milling is followed by a bead-elimination process: the concentrated milled dispersions are 
filtered by a sieve with 150 μm mesh size in order to remove the pearls. For the washing of 
the pearls, purified water is used. Due to the dilution, the particle-stabilizing effect of the 
applied additive will not be satisfactory. 
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The robustness testing of the milling process is a necessary method to discover the limits of 
the process parameters variabilities while the product quality can be maintained (Nalluri et al., 
2010). During the optimization process, beside the optimal process parameters, the range of 
parameters can also be determined, and as a result, a nanosuspension can be provided which 
as an intermediate product, with further modification or stabilization routes can be 
transformed into a liquid, semi-solid or solid state drug delivery systems (Bartos et al., 2019). 
2.3. Transformation of nanosuspension as an intermediate product into solid state product 
(fluidization, lyophilization) 
Nanosuspensions can be defined as colloidal dispersions of nanosized drug particles (< 500 
nm) that are produced by different nanonization processes and stabilized by various excipients 
(Müller et al., 1998). Nanocrystals also enhance adhesiveness to the gastrointestinal mucosa, 
resulting in prolonged gastrointestinal residence and, thus, increased uptake via the 
gastrointestinal tract (Malamatari et al., 2018). 
Despite the advantages of drug nanoparticles, they present various drawbacks including 
sedimentation, particle agglomeration or crystal growth. During the wet nanonization, due to 
the reduced particle size, the increased specific surface area, the surface charge of the 
particles and the high particle mobility, particle aggregation can be occurred. To prevent the 
particle aggregation, further stabilization is needed (Peltonen et al., 2010). 
Nanosuspensions can be applied as final liquid dosage forms using further different excipients 
(viscosity enhancer, flavoring, preservative agents, etc.), however, their stabilization is a 
major challenge (Wang et al. 2013, Zheng et al., 2013). It is well known that, despite the 
stabilization, nanosuspensions have a short expiration time, and there are patients who do not 
prefer this form or the presence of a surfactant. One way to overcome the instability and 
surfactant problem is to design solid dispersion (Nagy et al., 2012) produced by spray drying, 
spray freeze drying and freeze drying (lyophilization) (Fülöp et al. 2018) It is well known that 
the dry nanosuspensions can cause difficulty in hydration and redispersibility (Kim et al., 
2018, Van Eerdenbourgh et al., 2008). Other processes for transforming a nanosuspension 
into solid-state forms (tablets, capsules) are very different: deposition as coatings, 
incorporation in granules and pellets and the 3D printing technologies (Prasad et al., 2016).  
Spray drying and lyophilization (freeze drying) are the commonly used techniques for the 
solidification of nanosuspension because of their easy application and industrial acceptability  
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(Colombo et al., 2017) The powders produced by these processes often suffer from poor 
flowability and high hygroscopicity, therefore other technologies are applied to transform 
nanosuspensions into oral dosage forms as tablets and capsules (Kayaert et al., 2011). 
Layering of nanosuspension onto the surface of granules, pellets, sugar beads, etc. using a 
fluidization technique is used as an alternative method for solidification of nanosuspension  
(Möschwitzer et al, 2006, Kayaert et al., 2011, He et al., 2013, A. Azad et al., 2014, Mittal, 
2017). The advantage of this process that may be used various additives in order to achieve 
the desired purpose, e.g. i) different polymers stabilize the nanosuspension, and act as a 
coating materials resulted in fast dissolution rate, ii) surfactants prevent the aggregation of 
nanoparticle and can modify the drug release (Vergote et al., 2001, Bose et al., 2012).  In any 
case, the fluidization technique also provides an opportunity to stabilize the broken structure 
of the ground crystals in the nanosuspension by using crystallization inhibitors (Jójárt-
Laczkovich et al., 2011). 
The water solubility of NSAIDs is poor or very poor in general but increasing pH results in 
higher solubility (Szabó-Révész, 2018). Mel, a member of the oxicam family of NSAIDs, as a 
moderately selective cyclooxygenase (COX-2) inhibitor can have a role in acute pain therapy 
but a basic requirement is rapid absorption through the gastric mucosa. Mel has a weak acidic 
character with pKa of 3.43, therefore its solubility in gastric juice (pH=1.2) is very poor but 
its logPapp is 2.43 (pH=2.0), which predestines the fast absorption from the stomach (Simmons 
et al., 2004, Bartos et al., 2016, Szabó-Révész, 2018). Since the solubility of Mel is very poor 
in gastric juice, the preparation of a nanosuspension with a fast dissolution rate may be a 
solution. 
PVA is a polymer, which is frequently used as a stabilizer, coating the particles and 
promoting their separation from each other (Bartos et al., 2015).  
The acute oral toxicity of PVA is very low, with LD50s in the range of 15–20 g/kg. Orally 
administered PVA is very poorly absorbed from the gastrointestinal tract and it does not 
accumulate in the body when it is administered orally. The PVA is not mutagenic or 
clastogenic. It can be concluded, that the orally distributed PVA is nontoxic (De Merlis et al., 
2003).  
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 3. AIMS 
The aim of this work was to study the wet milling process, where the planetary ball mill was 
combined with pearl milling technology and optimize the process parameters and predict the 
robustness of the process and design the amount of the additive (PVA) in order to produce 
Mel containing nanosuspension. PVA as a protective polymer had a dual function, partly to 
increase the efficiency of milling (without any pre-milling procedure, surfactant free samples) 
and partly to stabilize the Mel containing nanosuspension as an intermediate product.  
Furthermore, the optimized Mel formulations were tested on the cell culture model of 
intestinal epithelium. 
The purpose of the work was further to produce a surfactant-free product by solidifying of 
Mel containing nanosuspension. Critical product parameters were considered to be the 
particle size distribution of the drug (d(0.9) < 500 nm), stabilization of the degree of 
crystallinity altered during milling, and enhancement of the bioavailability of the solid 
product with fast absorption from the stomach for rapid analgesia. The transformation of the 
nanosuspension was done by fluidization and lyophilization.  
The main steps in the experiments were as follows: 
i. Optimization of the critical process parameters of the combined wet milling (ratio of pre-
dispersion and pearls, milling time and rotation speed) in order to produce Mel containing 
nanosuspension as an intermediate product without any pre-treating procedure and surfactant 
(nanoMel). 
ii. Investigation of the influence of the PVA amount on the milling effectiveness and the PSD 
and crystallinity of the Mel in the ground products which does not contain any additional 
excipients, thus surfactant. 
iii. Perform in vitro dissolution test and cell culture studies (cell viability and permeability) to 
control the amount of PVA. 
iv. Testing the robustness of combined wet milling process to determine the interval of the 
Mel amount and to predict the degree of crystallinity of the milled products. 
v. Transformation of the surfactant-free nanoMel sample into solid-state products by 
fluidization and lyophilization and investigation of the product stability (particle size, 
crystallinity), and in vitro release of Mel  
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vi. Bioavailability of the products was studied by in vivo animal tests to justify applicability of 
the surfactant-free samples containing nanonized Mel. 
4. MATERIALS AND METHODS 
4.1. Materials 
The characteristics of Mel and the used additives are shown in Table 2. All other reagents 
used during the work were purchased from Sigma-Aldrich, Ltd. (Budapest, Hungary) 
Table 2. Properties of the materials used in the research work 
 Mel PVA MCC Trehalose 
Chemical 
structure 
  
 
 
 
 
Chemical 
name 
4-hydroxy-2-
methyl-N-(5-
methyl-2-
thiazolyl)-2H-1,2 
benzothiazine-3-
carboxamide-1,1-
dioxide 
Poly(vinyl 
alcohol) 
Microcrystalline 
cellulose 
 
Alpha-D-
trehalose-
dihydrate 
Manufacturer EGIS Ltd. 
(Budapest, 
Hungary) 
Sigma Aldrich 
Co. LLC, St. 
Louis MO, USA 
FMC 
Biopolymer, 
Philadelphia USA 
Karl Roth GmbH 
+ Co. KG. 
(Karlsruhe, 
Germany) 
Physical 
properties 
Mw:351.4 g/mol 
a yellow powder 
poor solubility in 
water 
Mw:44.05 g/mol 
a white powder 
soluble in water, 
slightly soluble in 
ethanol semi-
crystalline 
Mw:370.35 g/mol 
a white powder, 
insoluble in water 
Mw:342.3 g/mol 
a white powder, 
soluble in water,  
 
4.2. Methods 
4.2.1. Optimization of combined wet-milling process 
The samples were milled with the steel jar with 50 ml volume of the Retsch PM 100 planetary 
ball mill (Retsch PM 100 MA, Retsch GmbH, Germany) combined with 0.3 mm ZrO2 beads 
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as the grinding media. The concentrated (10 % w/w) pre-dispersions (2 g of Mel suspended in 
18 g of aqueous dispersant medium containing PVA) were added to the ZrO2 beads. In the 
first step, the effect of different amount of ZrO2 pearls on the particle size reduction was 
investigated. The ratio of the amount of pre-dispersion and pearls (w/w) was 1:0.5, 1:1, 1:2 
and 1:4; and the milling times were 10, 30 and 50 min. In these cases, the concentration of 
PVA solution was 2.5% (w/w), and the rotation speed was 400 rpm. In the second step, design 
and analysis of experiments with three levels were used to optimize the milling time (10, 30 
and 50 min) and the rotation speed (200, 350 and 500 rpm) as independent variables. The 
amount of the pearls was chosen on the basis of the optimization study. The temperature of 
the samples was measured immediately after milling. This value did not exceed 39°C. 
4.2.2. Optimization of PVA concentration 
After optimizing the process parameters, the determination of the adequate PVA 
concentration was executed. Various amounts of PVA (2.5-7.5%) were applied to prepare the 
concentrated pre-dispersions. The concentration of the PVA solutions was increased with a 
half percent in the range. Mel content was 10% (w/w) and the optimized process parameters 
were used during the milling. The degree of particle size reduction and particle size 
distribution were the main factors for the optimization of the PVA concentration (Figure 3). 
 
Figure 3. Protocol of sample preparation in optimization of PVA content  
Each milled product was filtered by a sieve with 150 μm mesh size in order to remove the 
pearls. For the washing of the pearls, 180 g of purified water was used. In all cases, the milled 
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dispersions were ten-fold diluted products with 1 % of Mel (w/w) content.  The samples were 
selected on the basis of the particle size range (100-500 nm) and the holding time (2 weeks).   
4.2.3. Robustness determination of the process 
Eight samples were prepared from 0.5 to 4.0 g of Mel with 0.5 g increment per sample. As the 
stabilizing agent, 5% of PVA aqueous solution was added up to 20.0 g to each sample, which 
was selected on the basis of our previous experiments. The Mel and PVA concentrations of 
the samples are shown in Table 3.  
Table 3. Mel and PVA concentrations in the samples 
Sample name 
Mel% 
(w/w) 
PVA% 
(w/w) 
Mel_0.5g 2.50 5.42 
Mel_1.0g 5.00 5.28 
Mel_1.5g 7.50 5.14 
Mel_2.0g* 10.00 5.00 
Mel_2.5g 12.50 4.86 
Mel_3.0g 15.00 4.72 
Mel_3.5g 17.50 4.58 
Mel_4.0g 20.00 4.44 
*optimized sample 
4.2.4. Transformation of nanosuspension into solid compositions 
4.2.4.1. Fluidization (fluidMel) 
The Avicel PH 101 as the carrier material was used in a Strea-1 (Niro Aeromatic, Bubendorf, 
Switzerland) fluid bed chamber.  A batch size of 100 g was used. The powder was inserted 
and fluidized in the preheated chamber for a period of 10 min and at constant air velocity of  
2.5 m/s. NanoMel as liquid dispersion was implemented using a peristaltic pump (Roto 
Consulta Ebikon/Luzern, Schweiz), the applied pump speed was 9 rpm. The process took 50 
minutes, the inlet temperature was 55°C, the outlet temperature was 38°C. One batch of 
nanoMel sample (200g) was transferred onto the surface of the material, thus the fluidized 
solid-state product contained 2g of Mel, 1g of PVA and 100g of Avicel 101 (Table 4). 
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Table 4. Composition of the investigated samples 
Sample Mel 
(%) 
PVA 
(%) 
Water 
(%) 
MCC 
(%) 
Trehalose 
(%) 
fluidMela 1.94 0.97 - 97.09 - 
lyoMelb 15.38 7.70 - - 76.92 
a,bbased on dry material 
4.2.4.2. Lyophilization (lyoMel)  
Freeze-drying was performed in Scanvac CoolSafe 100-9 Pro type equipment (LaboGene 
ApS, Lynge, Denmark) equipped with a 3-shelf sample holder unit, recessed into the drying 
chamber. In each cuvette 750 mg of diluted milled suspension was filled (7.5 mg Mel content 
in every cuvette, the unit dose of Mel). As a cake-forming additive, 37.5mg of (5.0%) 
trehalose was dissolved in the nanosuspensions. The components of the final product can be 
seen in Table 4. The process was controlled by a computer program (Scanlaf CTS16a02), the 
temperature and pressure values were recorded continuously. The whole process took 71 
hours and 52 minutes. The initial temperature was 25 °C. During the freezing period, after 18 
hours and 34 minutes, the sample temperature was decreased to -40 °C. The subsequent 
drying process was conducted at 0.013 mbar air pressure for 50 hours and 50 minutes, the 
temperature increased from -40 °C to -7 °C. Finally, the secondary drying session took 2 
hours and 28 minutes. The final temperature of the dried products was 30 °C. 
4.2.5. Investigation of the samples 
4.2.5.1. Particle size distribution measurements  
The investigations on the particle size of raw Mel and nanoMel via laser diffraction were 
executed (Malvern Mastersizer S 2000, Malvern Instruments Ltd, Worcestershire, UK) with 
the following parameters: 300RF lens; small volume dispersion unit (1,000 rpm); refractive 
index for Mel: 1.720; and refractive index for dispersion medium: 1.330. During the 
measurements, distilled water was used as a dispersant, and obscuration was in the range of 
11%–16% for all measurements. In both cases, the particle size distributions were qualified by 
d(0.1), d(0.5), and d(0.9). 
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In the case of the solid-state products (fluidMel and lyoMel), the particle size of Mel was 
determined by using Scanning Electron Microscopy (SEM) images (Hitachi S4700, Hitachi 
Scientific Ltd., Tokyo, Japan). The size of the particles was calculated by ImageJ software for 
Windows (Phase GmbH, Lübeck, Germany) (Abramoff et al., 2004). By specifying the unit 
length, which is shown in each images (depending on the magnification this is a different 
value), the actual particle size can easily be determined by drawing the diameter of the 
captured particles. A diameter of a hundred captured particles was determined in the case of 
two solid phase samples. 
For nanoMel and lyoMel samples, the Z-average particle size and the polydispersity index 
(PDI) of Mel were measured using a Malvern Zeta Nano ZS (Malvern Instruments Ltd). In 
case of the particle size determination, Malvern DTS 1070 folded capillary cell was used. The 
samples were further diluted with water (25-fold) for the measurements. 
4.2.5.2. Image analysis (scanning electron microscopy - SEM)  
The particle morphology of milled dispersions and the solid-state samples were investigated. 
The diluted milled dispersions were dried in a vacuum dryer (Binder GmbH, Tuttlingen, 
Germany) at 40 °C in order to obtain solid products for physicochemical investigations. The 
shape and surface characteristics of the samples were visualized by SEM (Hitachi S4700, 
Hitachi Scientific Ltd., Tokyo, Japan). The samples were sputter-coated with gold–palladium 
under an argon atmosphere, using a gold sputter module in a high-vacuum evaporator, and the 
samples were examined at 10 kV and 10 mA. The air pressure was 1.3–13 MPa. 
4.2.5.3. X-ray powder diffraction analysis (XRPD) 
The crystallinity state of Mel in the samples was evaluated by XRPD. XRPD patterns were 
produced by a Bruker D8 Advance diffractometer (Bruker AXS GmbH, Karlsruhe, Germany) 
system with Cu K λI radiation (λ = 1.5406 Å). The samples were scanned at 40 kV and 40 
mA from 3 to 40 2θ, at a step time of 0.1 s and a step size of 0.010°. The instrument was 
calibrated by using Si standard. The semi-quantitative determination of Mel crystallinity 
(Cryst. %) was performed using the total area under the curve (AUC) of 3 characteristic peaks 
(13.06°, 14.94° and 18.61° 2Θ) of Mel. The AUC value of the peak of raw material without 
milling (rawMel) and the dried milled dispersions (MelD) was calculated and compared 
according the following formula (Rafiq et al., 2015) 
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𝐶𝑟𝑦𝑠𝑡.% =
𝐴𝑈𝐶𝑀𝑒𝑙𝐷
𝐴𝑈𝐶𝑟𝑎𝑤𝑀𝑒𝑙
∗ 100 
4.2.5.4. Stability test 
The products (fluidMel and lyoMel) were stored in a well-closed container, at room 
temperature (23 ± 2 °C, 45 ± 5% RH) for 6 months. The crystallinity of Mel was investigated 
compared to freshly measured products. 
4.2.5.5. Differential scanning calorimetry (DSC) 
DSC measurements were carried out with a Mettler Toledo DSC 821e thermal analysis 
system with the STARe thermal analysis software V9.0 (Mettler Inc. Schwerzenbach, 
Switzerland). Approx. 2-5 mg of pure Mel and PVA as well as dried samples were examined 
in the temperature range of 25-270°C. The heating rate was 10°C/min in the presence of argon 
as a carrier gas with a flow rate of 100 ml/min. 
4.2.5.6. Raman spectroscopy 
For the investigation of Mel degradation as a function of the pearl amount and milling time in 
the dispersion, Raman spectra were acquired with a Thermo Fisher DXR Dispersive Raman 
(Thermo Fisher Sco. Inc., Waltham, MA, USA) equipped with a CCD camera and a diode 
laser operating at a wavelength of 532 nm. Raman measurements were carried out with a laser 
power of 4 and 8 mW at 25 µm slit aperture size on a 2 µm spot size. The spectra of the 
individual substances as Mel and PVA were collected using a 2-sec exposure time, a total of 
48 scanning in the spectral range of 3300-200 cm-1 with cosmic ray and fluorescence 
corrections. 
4.2.5.7. Zeta potential measurements 
The zeta potential of the dispersions and the lyophilized product was measured via Malvern 
Zeta Nano ZS (Malvern Instruments Ltd, Worcestershire, UK). The refractive index was 
1.720.  For the zeta potential determination, Malvern DTS 1070 folded capillary cell was used 
at 25°C. The diluted milled dispersions were further diluted with water (25-fold) for the 
measurements. 
4.2.5.8. Rheological investigations 
To investigate the viscosity changes during the milling process, the initial and milled PVA 
solutions and the concentrated milled dispersions were used. Rheological measurements were 
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carried out with Physica MCR101 rheometer (Anton Paar, Austria, Graz). A concentric 
cylinder measuring device with a diameter of 17 mm was used. The flow curves of the 
samples were determined at 25 °C, where the shear rate was increased from 0.1 to 100 1/s. 
The shearing time was 300 s. In this paper, viscosity values were given at 100 1/s shear rate. 
Two parallel measurements were run. 
4.2.5.9. Solubility testing of Mel in the pre-dispersions  
The solubility of Mel in the samples (rawMel, nanoMel, fluidMel and lyoMel) was 
determined. The dispersions were stirred with a magnetic stirrer at 25 °C for 24 h and then 
filtered (0.1 μm, FilterBio PES Syringe Filter) (Labex Ltd., Budapest, Hungary), and the 
dissolved drug content was analyzed spectrophotometrically (Unicam UV/VIS) (Thermo 
Fisher Scientific Inc., Waltham, MA, USA) at 364 nm wavelength (n = 3). 
4.2.5.10. Drug content determination  
The Mel content of the samples was controlled in the following way. The unit dose of the 
products with 0.75 mg of theoretical Mel was dissolved in 100 mL of phosphate buffer pH 7.4 
± 0.1. The sample was stirred with a magnetic stirrer at 25 °C for 24 h and then filtered (0.1 
μm, FilterBio PES Syringe Filter) (Labex Ltd., Budapest, Hungary), and the concentration of 
the dissolved Mel was analyzed spectrophotometrically (Unicam UV/VIS) (Thermo Fisher 
Scientific Inc., Waltham, MA, USA) at 364 nm wavelength. The investigations were repeated 
three times. 
4.2.6. In vitro studies 
4.2.6.1. In vitro dissolution studies of Mel 
To determine the dissolution extent of Mel from dispersions, the paddle method (USP 
dissolution apparatus, type II Pharma Test, Heinburg, Germany) was used. 750 mg of the 
dispersion with 7.5 mg of Mel (therapeutic dose) was filled into hard gelatin capsules within 5 
sec and put promptly into the medium. The medium was 900 ml of artificial gastric fluid at 
pH 1.2 ± 0.1 and intestinal fluid (pH 6.8 ± 0.1). The paddle was rotated at 100 rpm and 
sampling was performed up to 60 min. The Mel contents of the samples were determined by 
spectrophotometer (ATI-UNICAM UV/VIS Spectrophotometer, Cambridge, UK) at 362 nm 
(gastric juice) and 364 nm (enteric fluid). The number of parallels was three. 
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4.2.6.2. In vitro cell culture studies 
4.2.6.2.1. Human Caco-2 intestinal epithelial cell line 
Caco-2 intestinal epithelial cell line was purchased from ATCC (cat.no. HTB-37) and used 
until passage 60 for the experiments. The cells were grown in Dulbecco’s Modified Eagle’s 
Medium (Gibco, Life Technologies, Carlsbad, California, USA) supplemented with 10 % 
fetal bovine serum (Pan-Biotech GmbH, Aidenbach, Germany) and 50 μg/ml gentamycin in a 
humidified incubator with 5 % CO2 at 37°C. All plastic surfaces were coated with 0.05 % rat 
tail collagen in sterile distilled water before cell seeding in culture dishes and the medium was 
changed every 2 days. The stock solutions for cell culture experiments were the following: 
Mel, 100 mg/ml; PVA, 5% (w/w) and three products containing 100 mg/ml Mel with various 
amounts of PVA (2.5, 5 or 7.5%). The working solutions were diluted in cell culture medium 
or Ringer-Hepes buffer and contained 1 mg/ml of meloxicam for the Mel and formulation 
groups. The final concentration of PVA was 0.025, 0.05 and 0.075% (w/w). 
4.2.6.2.2. Cell viability measurement by impedance  
Impedance was measured at 10 kHz by RTCA SP instrument (RTCA-SP instrument, ACEA 
Biosciences, San Diego, CA, USA). This method is label-free, non-invasive and follows cell 
adherence, growth, number and viability real time. We have successfully tested the cellular 
effects of peptides and pharmaceutical excipients by impedance kinetics.28,29,30 For 
background measurements 50 μl cell culture medium was added to the wells, then cells were 
seeded at a density of 6 × 103 cells/well to 96-well plate with gold electrodes (E-plate 96, 
ACEA Biosciences) coated with collagen. Cells were cultured for 5 days in CO2 incubator at 
37°C and monitored every 10 minutes until the end of experiments. At the beginning of 
plateau phase of growth cells were treated with Mel, PVA and Mel+PVA samples diluted in 
cell culture medium and the effects were followed for 8 hours. Triton X-100 detergent (1 
mg/ml) was used as a reference compound to induce cell toxicity. Cell index was defined as 
Rn-Rb at each time point of measurement, where Rn is the cell-electrode impedance of the 
well when it contains cells and Rb is the background impedance of the well with the medium 
alone. 
4.2.6.2.3. Permeability study on cell culture model 
Transepithelial electrical resistance (TEER) reflects the tightness of the intercellular junctions 
closing the paracellular cleft, therefore the overall tightness of cell layers of biological 
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barriers. TEER was measured every 2 day to check the barrier integrity by an EVOM volt-
ohmmeter (World Precision Instruments, Sarasota, FL, USA) combined with STX-2 
electrodes, and was expressed relative to the surface area of the monolayers as Ω × cm2.  
Caco-2 cells were seeded onto Transwell inserts (polycarbonate membrane, 0.4 µm pore size, 
1.12 cm2 surface area; Corning Life Sciences, Tewksbury, Massachusetts) and cultured for 
three weeks (Hellinger et al., 2012, Kiss et al., 2014). The culture medium was changed and 
TEER was checked every second day. 
For permeability experiment inserts were transferred to 12-well plates containing 1.5 ml 
Ringer-Hepes buffer in the lower (basal) compartments. In the upper (apical) compartments 
culture medium was replaced by 0.5 ml buffer containing treatment solutions of Mel, PVA 
and Mel formulation groups for 1 hour. Permeability marker molecules fluorescein (10 μg/ml; 
Mw: 376 Da) and albumin (10 mg/ml; Mw: 65 kDa) labeled with Evans blue (167.5 μg/ml) 
were used for verifying the cell layer integrity. Treatment solutions from both compartments 
were collected and the Mel level was detected by Thermo Spectronic Helios Alpha UV-VIS 
spectrophotometer (Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA). 
4.2.6.3. Holding time determination of Mel in the pre-dispersions 
Since the diluted dispersions are intermediate products, it was necessary to specify the 
“holding time” of the sample through the particle size distribution.  The products were stored 
in sealed glass bottles at room temperature (25°C ± 1°C) for 2 weeks. The particle size 
distribution of the Mel in the samples was analyzed on the day of production (day 0) and after 
14 days of storage. 
4.2.7. In vivo study of Mel 
Each sample contained 60 µg/ml of Mel and 30 µg/ml of PVA in purified water. For per os 
delivery, the different formulations were individually diluted and were given at a single dose 
of 300 μg/kg of Mel to male Sprague–Dawley rats (8 weeks old, 240-260 g, n = 6) in a 
volume of 0.5 ml by gastric gavages. All animals fasted 16 hours before the per os 
administration of drugs. In order to facilitate the absorption, the solid-state forms were re-
dispersed in water immediately before administration. In a comparison study for intravenous 
administration, animals were treated with a 300 µg/kg bolus of Mel via the tail vein. 
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Intravenous (IV) injection was prepared by the dilution of passable injection with a 
concentration of 15 mg/1.5 mL (Meloxicam-Zentiva, Prague, Czech Republic) to reach the 
final concentration (0.15 mg/mL). The ingredients of the injection were meglumine, 
poloxamer 188, glycine, sodium hydroxide (for pH adjustment), sodium chloride, 
glycopherol, and water for injection. Blood samples were collected from the tail vein before 
and at 15, 30, 60, 75, 90, 120 and 180 minutes post-dosing. The experimental protocols and 
animal care methods used in the present study were approved by the National Scientific 
Ethical Committee on Animal Experimentation (permission number IV/1247/2017).). The 
animals were treated in accordance with the European Communities Council Directives 
(2010/63/EU) and the Hungarian Act for the Protection of Animals in Research (Article 32 of 
Act XXVIII).  
Plasma samples were collected into EDTA containing polyethylene tubes, centrifuged at 
1,500 g for 10 min at 5 °C. Separated plasma samples were stored at -80 °C until extraction 
and analysis. 
Determination of Mel from rat plasma  
Preparation of plasma samples, calibration standards and quality control samples  
To 90 µL of plasma sample, 10 µL of 0.1 % aqueous formic acid and 300 µL of acetonitrile 
containing piroxicam (internal standard at 12.5 ng/mL concentration) were added and the 
mixture was vortex-mixed for 60 s. The mixture was allowed to rest for 30 min at -20 °C to 
support protein precipitation. Supernatant was obtained by the centrifugation of the mixture 
for 10 min at 10,000 g at 4 °C and 20 µL was diluted with 380 µL of 0.1 % aqueous formic 
acid. Finally, 5 µL was injected into the LC–MS/MS system for analysis. 
Rat plasma calibration standards of meloxicam were prepared by spiking the working 
standard solutions (1–1000 ng/mL) into a pool of drug-free rat plasma and the procedure 
described above was followed. Calibration standards consisted of 90 µL of pooled drug-free 
plasma, 10 µL of meloxicam standard solution (in 0.1 % aqueous formic acid) and 300 µL of 
acetonitrile containing piroxicam (internal standard at 12.5 ng/mL concentration). Solutions 
containing 6.25 ng/mL and 25 ng/mL of meloxicam were used as QC samples. 20 µL of 
supernatant was taken out from both of the calibration standards and the QC samples, diluted 
with 380 µL of 0.1 % aqueous formic acid, and 5 µL was analysed by LC–MS/MS. 
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4.2.7.1. In vitro-in vivo correlation calculation 
In vitro–in vivo correlation (IVIVC) is a biopharmaceutical tool for the investigation of the 
mutual relationship of the dissolution characteristics of the in vitro and in vivo absorption 
studies (Cardot et al., 2012). In our case, the Pearson’s correlation coefficient of the AUC 
values of the in vitro and in vivo results was calculated by Microsoft Excel (Microsoft 
Corporation, Redmond, Washington, U.S.) and Statistica for Windows (StatSoft GmbH, 
Hamburg, Germany). The three prepared samples were correlated with each other in groups of 
in vitro and in vivo. To determine statistical significance, the unpaired t-test was used 
4.2.8. Statistical analyses 
Data were expressed as means ± SD, and groups were compared by using Student's t-test. For 
the evaluation of cell culture results GraphPad Prism 5.0 software (GraphPad Software Inc., 
San Diego, USA) was used. All culture data presented are means ± SD, values were compared 
using analysis of variance followed by Bonferroni posttest. Differences were considered 
statistically significant when p < 0.05. 
5. RESULTS 
5.1. Optimization of the combined wet milling process 
5.1.1. Effects of milling parameters on PSD 
The effect of pearl amount and milling time on particle size of d(0.5) was investigated. This 
study was performed using 2.5% PVA solution (Bartos et al., 2016). The ratio of the 
concentrated pre-dispersion (2.0 g of Mel+18.0 g of aqueous PVA solution) and pearl amount 
was alternated: 1:0.5, 1:1, 1:2, and 1:4 (w/w). It can be established that the pearl amount and 
the milling time have a great effect of on the d(0.5) value (Table 6). The milling efficiency 
was not satisfactory in case of ratio 1:0.5, but it increased linearly on increasing the amount of 
the milling media and the milling time except in case of ratio 1:4. It was found that the 
increase of the amount of the milling media (up to 1:2 w/w or more) causes gray coloring 
because of the high friction between the pearls and the wall of the steel jar. Therefore, the 
pearl milling amount was optimized at the ratio of 1:1 (20 g of concentrated pre-dispersion 
and 20 g of pearls), and the milling time was investigated as an independent variable in the 
factorial experimental design. Another advantage of the small amount of the grinding media 
may be the reduction of the product loss. 
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Table 6. Particle size of Mel (d(0.5)) in milled dispersion as a function of different pearl 
amount and milling time (d(0.5) of raw Mel was 34.260 ± 4.860 µm) 
 Ratio of pre-dispersion and pearl amount (w/w) 
1:0.5 1:1 1:2 1:4 
Particle size (µm) 
10 min 4.015±0.06 2.426±0.029 2.383±0.016 0.149±0.03 
30 min 0.293±0.008 0.145±0.007 0.190±0.003 0.137±0.006 
50 min 0.202±0.003 0.140±0.004 0.140±0.002 0.130±0.004 
 
During the factorial experimental design, the influence of the milling time and the rotation 
speed on the particle size reduction was investigated. The ratio of the pre-dispersion and the 
pearls was also 1:1 (w/w). Figure 4. shown that the efficiency of the particle size reduction 
was improved by increasing the milling time and the rotation speed.  
 
Figure 4. 3D illustration of the particle size changes during the second factorial experimental 
design 
Based on the results, 437 rpm and 43 min are the optimal parameters of the milling process. 
With 10% Mel amount and 5% PVA concentration the pre-dispersion – pearl ratio is 1:1. The 
PSD values of the sample produced on mathematically pre-determined parameters are as 
follows: d(0.1) – 0.067±0.001 µm; d(0.5) – 0.130±0.005 µm; d(0.9) – 0-371±0.010 µm.  
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5.1.3. Effects of PVA on PSD 
Concentrated pre-dispersions with different PVA amounts (2.5%–7.5%) were milled with 
optimized parameters (2 g of Mel+18 g of PVA aqueous solution, 20 g pearls, 437 rpm, 43 
min). The results show (Figure 5) that the lower concentration of PVA (from 2.5% to 3.5%) 
was not suitable to reach the nanosize range (< 500 nm). A higher concentration of PVA 
(6.0%–6.5%) also resulted in unsatisfactory milling effectiveness. Over 6.5% a robust 
protecting layer was probably formed on the solid particles, and nanonization was not 
possible. The curve of the Span values follows the different particle size distribution of the 
samples. The best particle size distribution was measured in the range of 4.0% and 5.5% of 
PVA. Based on the results, the concentrated milled dispersion containing 5.0% of PVA was 
selected as the optimized PVA amount. After the optimization of the wet milling process and 
the PVA amount, in order to understand the influence of the amount of PVA on the 
physicochemical properties of the samples, the milled dispersions with 3 different 
concentrations of PVA were investigated. These were the following: 2.5%, 5.0% (as 
optimized) and 7.5% of PVA. 
 
 
Figure 5. Particle size reduction effectiveness according to PVA concentrations and the Span 
values for the demonstration of particle size distribution (d(0.1) values are not shown 
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5.1.4. Rheology 
In order to exclude the viscosity changes because of the high mechanical forces during the 
milling, the viscosity of 3 raw PVA solutions (2.5%, 5%, and 7.5%) was investigated before 
the milling process, after the process (437 rpm, 43 min), and after the milling with the 
addition of Mel. The polymer solutions showed Newtonian flow behavior as their shear 
viscosity was independent of the applied shear rate. The viscosity of the polymer solutions 
increased with increasing the polymer concentration (Table 7). There were no remarkable 
differences between the viscosity of the polymer solution before and after the milling 
procedure, which may indicate there are no changes in the polymer structure. 10% Mel 
amount in the dispersions increased the viscosity of the systems and did not change the flow 
behavior – they remained Newtonian. Adding Mel to the polymer solutions, the smallest shift 
in the viscosity could be detected in case of the highest polymer concentration. This can be 
explained by the more considerable viscosity changing effect of the polymer concentration 
than that of the Mel particles. It can be concluded that the mechanical influence did not 
change the viscosity of the polymer solutions, and therefore, the structure of the PVA chains 
did not change. 
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Table 7. Viscosity values (ƞ) of the raw PVA solutions before milling (PVA %), after milling 
(PVA % milled) and the PVA solutions after milling in addition with Mel (Mel PVA % 
milled) 
  ƞ SD ± 
  mPa*s mPa*s 
PVA 2.5% 3.14 0.02 
PVA 5.0% 7.38 0.02 
PVA 7.5% 20.55 0.07 
PVA 2.5% milled 3.12 0.27 
PVA 5.0% milled 7.09 0.02 
PVA 7.5% milled 20.05 0.07 
Mel PVA 2.5% milled 4.42 0.07 
Mel PVA 5.0% milled 8.46 0.01 
Mel PVA 7.5% milled 21.65 0.07 
 
5.1.5. DSC 
DSC was used to investigate the melting of raw Mel and raw PVA and the dried samples 
(Figure 6). The DSC curve of the raw Mel revealed a sharp endothermic peak at 268.66°C, 
reflecting its melting point and an instantly following exothermic peak at 278.09°C can be 
observed. The DSC curve of raw PVA as a semi-crystalline polymer has 2 endothermic peaks 
at 169.51°C and at 222.74°C. The first peak of PVA signifies a particular decrystallization of 
PVA and the second peak is the melting temperature (Tretinnikov et al., 2012). The DSC 
curves of the dried products exhibited lower melting points of Mel than that of raw Mel. It is 
connected to the pre-melting of PVA, which induces the earlier melting of Mel in proportion 
to the amount of PVA and decreases the crystallinity degree of Mel 
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Figure 6. DSC curves of raw Mel and PVA and dried dispersions with different PVA 
concentrations 
5.1.6. XRPD 
The XRPD investigations justified the change of crystallinity degree of Mel in the dispersions 
with different PVA amounts. Figure 7 shows the fingerprints of raw materials (Mel and PVA) 
and the dried dispersions. The samples show the characteristic peaks of Mel at 2θ values: 
13.06°, 14.94°, and 18.61°. It was found that the PVA content of the samples fundamentally 
influenced the decrease of the crystallinity degree of Mel. As it was established earlier in this 
study, low (2.5%) and high (7.5%) concentrations of PVA in the milled dispersion did not 
result in suitable milling efficiency. In this case, the crystallinity degree of Mel was 75.82% at 
low PVA content (2.5%), and it decreased to 51.44% at high concentration of PVA (7.5%). 
These results are connected to the milling effectiveness. In this study, the 5.0% PVA-
containing milled dispersions showed smaller crystallinity (13.43%) and the highest milling 
efficiency. 
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Figure 7.  XRPD diffractograms of the Mel, PVA and the dried dispersion  
5.1.7. Zeta potential changes 
To determine the electrokinetic changes of the diluted dispersions, the zeta potential of the 
samples was measured. The results show that the increase of the PVA amount decreases the 
zeta potential in comparison to the sample without PVA (Table 8). The main reason for the 
zeta potential reduction can be linked to the nonionic polymer adsorption on the surface of the 
solid particles, which causes a decrease of the diffuse layer charge. A greater zeta potential-
lowering effect can be observed between 0% and 0.25% of PVA than between 0.25% and 
0.50. At 0.50% of PVA, the surface of particles is saturated by the PVA chain; therefore, the 
change of zeta potential is smaller. In case of a higher concentration of PVA (.0.50%), the 
steric hindrance stabilizes the system but hampers the disintegration/abrasion of the particles. 
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Table 8. Zeta potential values of the diluted dispersions as a function of the PVA 
concentration and particle size distribution of Mel (±SD) 
Samples 
Particle size distribution Zeta 
potential 
(mV) 
d(0.1) d(0.5) d(0.9) 
Particle size (μm) 
Mel PVA 0% 
2.508±1.100 5.762±2.700 135.640±12.90
0 
-30.7 
Mel PVA 
0.25% 
0.070±0.001 0.150±0.009 1.478±0.0400 
-20.9 
Mel PVA 
0.50% 
0.067±0.001 0.130±0.005 0.371±0.010 
-16.1 
Mel PVA 
0.75% 
1.235±0.006 2.611±0.018 5.560±0.070 
-15.7 
 
5.1.8. Raman spectroscopy 
Raman spectra and chemical maps of raw materials and products are presented in Figures 8 
and 9. The individual spectrum of Mel (a) shows that the absorption peaks are concentrated in 
the region from 1,600 to 1,000 cm-1 (fingerprint region), whereas the individual spectra of 
PVA (b and c) show only one characteristic and extended peak from 3,000 to 2,800 cm-1. 
This is the CH stretching vibration region that results a medium-to-strong intensity in Raman 
spectra. The spectra of diluted dispersions (d, e, and f) show the same characteristic region 
with the spectra of Mel – there are no detectable differences among them. Two peaks (one 
more characteristic in 2,437 cm-1 and another smaller one in 482 cm-1) appear in the spectra of 
PVA-containing dispersions and in spectra of aqueous Mel dispersion as well. The chemical 
mapping of dried dispersions profiled to this peak in 2,437 cm-1 shows that this peak cannot 
detected in this map. This peak can show a dissociated -OH group of enolic form which is 
presented when Mel is in an aqueous medium, but it is disappeared in dried form, so the 
change is reversible. The chemical map of dispersion profiled to Mel spectrogram shows 
homogenous distribution of Mel. It can be summarized that there is no chemical degradation 
or interaction in dispersion which could be detectable with Raman technique. 
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Figure 8. Investigation with Raman spectroscopy: 1. A: spectrum of raw Mel, B: spectrum of 
raw PVA, C: spectrum of raw PVA (0.50%) containing solution. 2. Comparison study of raw 
materials (Mel, PVA) and the dispersions, D: spectrum of dispersion containing 1% Mel and 
0.25 % PVA, E: spectrum of dispersion containing 1% Mel and 0.50% PVA, F: spectrum of 
dispersion containing 1% Mel and 0.75% PVA  
 
 
 
Figure 9. Investigation with Raman spectroscopy: 1. Comparing raw Mel and aqueous 
dispersion of Mel and PVA containing dispersions, A: spectrum of raw Mel, D: spectrum of 
dispersion containing 1% Mel and 0.25% PVA, E: spectrum of dispersion containing 1% Mel 
and 0.50% PVA, F: spectrum of dispersion containing 1% Mel and 0.75% PVA, G: spectrum 
of aqueous 1% Mel containing dispersion without PVA. 2. Chemical mapping of Mel 
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containing dispersion (1% Mel and 0.50% PVA) and chemical mapping of its dried form 
profiled to peak in 2437 cm-1 
5.1.9. SEM investigation 
In order to investigate the effect of milling and PVA amount on the morphology of milled 
Mel, the water was evaporated from dispersion and the dried samples were characterized. 
Figure 10 shows the raw Mel in physical mixture (Mel PVA 0.50% PM) which has an 
irregular shape with 34.260±4.860 μm as average particle size. In this PM, the PVA particles 
with size, 6 μm are located on the surface of Mel crystals. After drying of the aqueous 
dispersions, the polymer formed non-coherent and coherent think film with Mel particles. In 
case of 0.25% containing PVA (Mel PVA 0.25%), the particle size of Mel has decreased, but 
aggregation of the fragmented particles can be observed. Mel particles are in homogeneous 
disperse distribution in sample (Mel PVA 0.50%) resulted in less than 500 nm (average 
particle size: 0.130±0.005 μm). High concentration of PVA (Mel PVA 0.75%) helped the 
recrystallization of Mel (nanocrystals with smooth surface) thanks to increased solubility of 
Mel in aqueous PVA solution. Otherwise, the sample shows heterogeneous disperse system 
with nano- and microparticles. 
 
Figure 10. SEM pictures of physical mixture (Mel PVA 0.25% PM) and different PVA 
containing dried dispersions 
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5.1.10. In vitro studies of the nanosuspensions 
In case of each sample, the liberation from the hard gelatin capsules occurred within 2 sec. 
Mel has a weak acidic character (pKa 4.8), and therefore, its solubility in gastric juice 
(pH=1.2) is very poor (1.6±0.2 mg/L, at 37°C). In this medium, the greatest dissolved amount 
of Mel with 0.25% and 0.50% PVA content was maximum, 37%, within 20 min (Figure 
11A). This result is due to the wetting effect of PVA (0.25% and 0.50%), which could 
increase the solubility of Mel, and the reduction of the particle size of Mel in the dispersions. 
In contrast, a higher amount of PVA (0.75%) hinders the dissolution because a thicker 
polymer layer is formed on the Mel particles. 
In intestinal fluid (pH=6.8), the dissolved amount was higher in all cases because of the better 
solubility of Mel (0.272±0.001 mg/mL, at 37°C). Figure 11B shows that the concentration of 
PVA influences the amount of dissolved. Mel as in the case of gastric juice, but its extent is 
bigger. In this study, the dispersion containing 0.50% of PVA had the most satisfying 
dissolution behavior from among the 4 samples. It is followed by the dispersions containing 
0.25% and 0.75% of PVA, and finally the dispersion without PVA. The results justify the 
need of the polymer (PVA) and the correct choice of its quantity. 
 
Figure 11. In vitro dissolution curves of Mel in artificial gastric juice (a) and intestinal juice 
(b) 
5.1.11. In vitro cell culture studies 
Impedance measurement, as a sensitive method to detect cellular effects, did not show 
significant cell damage after treatments with Mel, PVA, and Mel formulation groups, as 
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reflected by unchanged cell index values (Figure 12). As a comparison, cells treated with the 
detergent Triton X-100 were lysed and a 100% toxicity was measured. The curves show the 
kinetics of the cellular effects of treatment solutions (Figure 12A), whereas the columns show 
the effect of Mel, PVA and Mel formulations at the 8-h time point (Figure 12B).  
Caco-2 monolayers showed high TEER values (2,660±181 Ω×cm2, n=20) before 
permeability experiments, indicating tight barrier properties. The average apparent 
permeability coefficients of marker molecules were also low (fluorescein: 0.81±0.13×10-6 
cm/s; albumin: 0.08±0.03×10-6 cm/s), in agreement with the TEER values and the formation 
of tight cell layers. 
The permeability of Mel suspension and Mel formulations was significantly higher than that 
of marker molecules. The penetration of Mel from the 3 investigated products across cell 
layers was significantly increased as compared to Mel suspension. From all the tested 
samples, the Papp value of Mel was the highest in the formulation containing 0.05% PVA 
(Figure 13). 
 
Figure 12. Cell viability kinetics (a) and results 8 hours after treatment (b) of Caco-2 
intestinal epithelial cells with Mel, PVA and formulations measured by impedance. Values 
are presented as means ± SD, n = 6-12. Statistical analysis: ANOVA followed by Dunett’s 
test. Statistically significant differences are: *, p < 0.05, compared to control group. 
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Figure 13. Evaluation of permeability of meloxicam across Caco-2 epithelial cell layers 
treated with Mel and optimized Mel-PVA formulations for 1 hour. Values are presented as 
means ± SD, n = 4. Statistical analysis: ANOVA followed by Bonferroni posttest. Statistically 
significant differences are: ***, p < 0.01, compared to control group; ###, p < 0.01 compared 
to the indicated columns. 
5.1.12. Holding time determination 
Since the investigated dispersions are intermediate products, the change of particle size 
distribution and the crystallinity index are very important during storage. In general, the time 
period before the dispersion used for the preparation of different dosage forms is 1 or 2 h, or 
possibly longer. The measurements have proven that 0.50% of PVA-containing dispersion 
had no significant changes in the particle size, particle size distribution, and crystallinity up to 
2 weeks (Table 9). 
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Table 9. Particle size distribution changes (µm) during the stability testing 
 Day 0 2 weeks 
 d(0.1) d(0.5) d(0.9) d(0.1) d(0.5) d(0.9) 
Mel PVA 0.25% 0.070 0.150 1.478 0.080 0.152 2.073 
Mel PVA 0.50% 0.067 0.136 0.371 0.068 0.140 0.427 
Mel PVA 0.75% 1.207 2.232 5.224 0.244 2.611 5.560 
 
5.2 Results of the robustness testing experiments 
5.2.1. Effect of the API content on the PSD 
Using the optimized process parameters, based on the change in the amount of Mel, the 
particle size distribution is one of the critical parameters (Bartos at al.. 2019). In this respect, 
the comparison is based on the particle size of the optimized sample “Mel_2.0g”, which had 
10% of MEL and 5% of PVA (Table 10).  
After milling, the different Mel amounts containing nanosuspensions showed same d(0.5) 
value, which means that the maximum particle diameter of 50% of the sample volume is less 
than 150 nm. By contrast, the d(0.9) values, in the case of smaller and higher amounts of Mel, 
were already outside the upper range of the desired value (500 nm). It can be assumed that the 
smaller amount of Mel (<10%) decreased the number of successful collisions of Mel and the 
milling media. The larger amount of Mel (>17.5%), however, increased the density of the 
sample and reduced milling efficiency. Span values, which contain the d(0.1) values, confirm 
the suitability of particle size distribution in the range of 10% (Mel_2.0g) and 17.5% of Mel 
(Mel_3.5g).  
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Table 10. Results of the particle size measurements 
Sample name d(0.5)/µm d(0.9)/µm Span 
Mel_raw 34.26±4.86 73.59±27.11 1.815  
Mel_0.5g 0.138±0.027 1.273±0.134 8.662 
Mel_1.0g 0.142±0.023 1.949±0.117 10.207 
Mel_1.5g 0.141±0.018 0.87±0.076 5.676 
Mel_2.0g* 0.136±0.003 0.371±0.043 2.240 
Mel_2.5g 0.139±0.006 0.413±0.037 2.655 
Mel_3.0g 0.145±0.008 0.436±0.045 2.956 
Mel_3.5g 0.141±0.013 0.448±0.050 2.700 
Mel_4.0g 0.140±0.021 0.974±0.072 6.448 
* optimized sample 
5.2.2. Crystallinity changes according to the API content 
5.2.2.1. DSC measurements 
For the crystallinity characterization of Mel, first raw Mel and PVA were investigated (Figure 
14). The DSC curve of raw Mel has a sharp characteristic melting peak at 268.66 ºC (onset-
266.83, endset-273.27 ºC), and an instantly following exothermic peak can be observed at 
279.09 ºC. PVA has two endothermic peaks at 169.51 ºC and at 222.74 ºC.  The first peak 
belongs to a particular de-crystallization and the second one presents the melting point of 
PVA. It should be noted that PVA has deacetylation in the temperature range 160-400 ºC and 
the total degradation corresponds to the degradation of vinyl acetate and vinyl pyrrolidone at 
396 ºC and 484 ºC, respectively (McNeill et al., 1995). 
The DSC curves of the samples exhibit that the increase of the Mel amount results in a 
sharper endothermic peak, approaching the melting point of raw Mel. By decreasing the Mel 
amount, the endothermic peaks will be less sharp because of the pre-melting of the higher 
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amount of PVA, which induces the earlier melting of Mel in proportion to the PVA amount. 
The areas of the melting enthalpies already predict the change in the degree of crystallinity of 
Mel. 
 
Figure 14. DSC curves of raw Mel, PVA and different Mel containing milled samples 
In order to determine the degree of crystallinity of Mel, considering the influence of PVA, the 
physical mixtures of the milled samples formed the basis. 
The Figure 15 presents the degree of crystallinity as a function of the Mel amount in the 
sample. By increasing the Mel amount, the crystallinity of the milled products was increased. 
A close correlation (R2= 0.9587) was found between crystallinity and the Mel amount. It can 
be seen that increasing the amount of Mel (> 10%) significantly increased the degree of 
crystallinity of the milled sample (from 21.21% to 48.86%). However, the small amount of 
Mel lowered this value (from 21.21% to 10.28). 
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Figure 15. Relation between the crystallinity of Mel and its amount in the milled samples 
5.2.2.2. XRPD measurements 
To verify the DSC results, the crystallinity of the physical mixtures and the milled samples 
was investigated by XRPD analysis. Figure 16 presents the fingerprints of raw Mel and PVA 
and the milled samples. The characteristic peaks of Mel are at 2Θ value: 13.06º, 14.94º and 
18.61º and PVA has the typical diffraction peak at 2Θ value: 19.9º (Garcia-Cerda et al., 
2007). 
The intensity of the characteristic peaks shows a change in the crystallinity of the milled 
products. The quantitative analysis of the degree of crystallinity also resulted in a close 
correlation (R2= 0.9763) between the degree of crystallinity and the Mel amount (Figure 17). 
 40 
 
 
 
Figure 16. XRPD curves of raw Mel, PVA and different Mel containing milled samples 
 
 
Figure 17. Relation between the crystallinity of Mel and its amount in the milled samples 
5.2.2.3. Correlation between the two analytical methods 
As the result of the correlation calculations, it was found that the degree of crystallinity of 
Mel investigated by DSC and XRPD did not show any significant difference at 95% 
significance level. It can be related to the low degree of crystallinity (<50%). It is known that 
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the advantage of DSC over X-ray diffraction is that high amorphous content can be detected 
(Gombás et al., 2002). It should be noted that recently the characterization of the investigated 
materials (e.g. crystallinity) using DSC as a semi-quantitative conventional method has 
become common in scientific research (Katona et al., 2016, Gieszinger et al., 2017, Bartos et 
al., 2018). It provides a possibility to predict the crystallinity of the examined materials, but to 
verify the accuracy of thermoanalytical measurements, the X-ray powder diffraction test is 
required (Dávid et al., 2000). 
5.3. Results of the solid-state product characterizations 
5.3.1. Particle size measurements 
Different techniques have been used to determine the particle size of Mel for reasons of 
accuracy and comparability. The particle size distribution of the rawMel and nanoMel 
samples was investigated via laser diffraction. A combined wet milling process resulted in a 
200-fold particle size reduction in the case of nanoMel (d(0.50), 130±5 nm) compared to the 
raw drug particle size (d(0.50), 34.26±4.86 µm). The nanoMel product showed a 
monodisperse distribution (d(0.10), 67±1nm; d(0.50), 130 ± 5 nm; d(0.90), 371±12 nm).  
For fluidMel sample, Mel particles adhered to the carrier surface (MCC) was analyzed by 
ImageJ technique and the particle size of Mel in the nanoMel and lyoMel samples was 
compared with dynamic light scattering technique (Malvern nanoZS), too. The results 
demonstrate that the d(0.50) value of the Mel nanoparticles measured on the surface of solid 
phase product (fluidMel) does not show a significant difference regarding the d(0.50) value of 
the nanoMel (Figure 18A). In the case of lyoMel, compared to the Z-average of Mel in 
nanoMel, a significant difference can already be detected which was caused by the 
recrystallization of the Mel (Figure 18B). Both samples have a same polydispersity index 
(nanoMel: 0.273 and lyoMel: 0.287) which also confirms the monodispersity of nanoMel and 
shows the excellent redispersibility of lyoMel. The 6-month storage did not cause any further 
changes in the mean particle size of the products (Figure 18A, 18B). 
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(A) 
 
(B) 
Figure 18. (from left to the right)  
Main particle size of nanoMel (measured by laser diffraction), fluidMel fresh and fluidMel 
stored (6 months) (measured by SEM images) (A) and Z-average of nanoMel, lyoMel fresh, 
and lyoMel stored (6 months) measured by Zeta nano ZS) (B)  
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5.3.2. SEM measurements 
Figure 19A and Figure 19B clearly show the particle size difference between the rawMel and 
nanoMel and the change in the particle habit. The latter particles have smooth surfaces with 
rounded edges and corners. High mechanical impact results in the fracture and abrasion of the 
crystals. 
 
Figure 19. SEM image of rawMel (A), nanoMel (B), fluidMel (C1 and C2) and lyoMel (D1 
and D2) 
During the fluidization process, the nanoparticles are uniformly adhered to the surface of 
MCC (Figure 19C1). Their habit is the same as that of the nanoparticles in the nanoMel 
(Figure 19C2). There is no sign indicating the aggregation of the nanoparticles on the surface 
of MCC. The adhesion of the Mel particles to the carrier surface is also supported by the 
effect of the PVA adhesive property and the rapid evaporation of water. 
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The SEM image of the lyoMel sample (Figure 19D1) shows large, consistent formulas at low 
magnification. The texture at higher magnification contains smaller, larger pores resulting in a 
big surface with honeycombed structure, where the surface area is determined by the size of 
the ice crystals (Kevin, 2018). The SEM picture does not show any trehalose-like crystals in 
the structure (Figure 19D2). 
5.3.3. DSC measurements, crystallinity determination 
The DSC curves of the components and the products are shown in Figure 3. The rawMel has a 
relative high melting point at 268°C, PVA as semi-crystalline material has two endothermic 
peaks at 169°C and at 222°C. MCC shows any characteristic peaks, in contrast the trehalose is 
a crystalline material (Figure 20A).  
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Figure 20. DSC curves of rawMel (black), PVA (red), MCC (blue) and trehalose (purple) 
(A), and nanoMel (orange) fluidMel (green) and lyoMel (yellow) (B) 
The thermograms of the products are shown in Figure 20B. It is clear, that the melting point 
and the enthalpy of Mel in the case of the nanoMel decreased due to the partial 
amorphization.  
The curve of the fluidMel shows the peak of MCC and the decreased melting point of Mel 
(Figure 20B). The first obvious and big endothermic peak of the curve appearing from 30 °C 
to 150 °C is mainly related to the absorbed moisture evaporation (Kian et al., 2017). The 
second endothermic peak is connected to the melting point of Mel (264 °C) and the enthalpy 
was decreased due to the large amount of MCC, which covered the characteristic peak of 
PVA as well, compared to nanoMel. 
The curve of lyoMel represents the peak of PVA (197 °C) and the melting temperature of Mel 
(251 °C) (Figure 20B). According to the literature (Sussich et al, 2008) and our 
measurements, during the process, the total amount of trehalose transformed into an 
amorphous form and the lyophilized trehalose maintains its amorphous form. The big 
endothermic peak of the curve appearing from 30 °C to 150 °C is connected to the absorbed 
water evaporation as well. 
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The crystallinity of Mel in nanoMel and the transformed solid-state products was calculated 
by the enthalpy changes of the drug occurring during the DSC measurement (Table 11). Each 
sample was compared to its own physical mixture. According to the crystallinity of the 
nanoMel (13.43%) sample, the crystallinity of the fluidMel sample did not change (12.98 %), 
for the lyoMel sample partial recrystallization (40.11%) occurred.  
Table 11. Enthalpy and calculated crystallinity values of the characteristic peak of Mel in the 
samples 
Sample Enthalpy 
(J/g) 
Crystallinity of Mel 
(%) 
Crystallinity of Mel 
after 6 months of 
storage (%) 
nanoMel 12.24 13.43 - 
fluidMel 11.83 12.98 13.02 
lyoMel 36.54 40.11 40.16 
 
After 6 months of storage (23 ± 2 °C, 45 ± 5% RH), the degree of crystallinity of solidified 
samples (fluidMel and lyoMel) was determined again. The results did not show a significant 
change (p>0.05) compared to the non-stored, fresh samples (Table 10). There was no sign for 
the recrystallization of trehalose. 
5.3.4. Drug content determination 
The theoretical drug content was 7.50 mg as single dose/oral. For the nanoMel sample this 
amount was 7.12mg and fluidMel showed 6.83 mg of Mel. The latter can be related to the 
yield of the fluidization technique (95.93%). During the lyophilization process the Mel 
content of the sample (lyoMel) was 7.12 mg. 
5.3.5. Solubility testing of MEL in the samples  
The solubility of nanoMel increased significantly (9.4 ± 0.5 µg/ml) in comparison with the 
rawMel (6.5±0.2 µg/ml). The reduced particle size enhanced the wettability of the 
hydrophobic particle when using PVA, therefore increased the thermodynamic solubility of 
Mel. The fluidization process did not affect the solubility of Mel (9.6 ± 0.4 µg/ml). In the case 
of lyoMel, solubility was increased (11.2 ± 0.5 µg/ml) because of the presence of trehalose.  
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5.3.6. In vitro dissolution studies 
The in vitro dissolution extent of the samples was investigated in gastric juice (pH=1.2). Mel 
has a week acidic character, therefore its solubility in this medium is very poor (1.6 ± 0.2 
µg/ml, at 37 °C). Figure 21 clearly demonstrates that the particle size reduction of Mel in the 
nanosuspension (nanoMel) influenced the dissolution rate of Mel, but resulted in only 40% of 
drug release in 5 minutes, and then the curve took a stagnant profile. The initial rapid drug 
release can be associated with the nanoscale Mel and its amorphous structure. The 2-hour test 
did not result in any more favorable results. Although the distribution of the nanoparticles of 
Mel in the nanosuspension is suitable, a large volume of acidic medium (900 ml) may 
increase the aggregation of the nanoparticles. In this case, the protective effect of the polymer 
(PVA) is unsatisfactory. 
 
Figure 21. In vitro dissolution of Mel from investigated samples. Medium: artificial gastric 
juice (pH: 1.2) 
 
For fluidMel and lyoMel samples, a rapid initial phase is observed (about 60% of the drug is 
dissolved in 15 minutes), followed by a slowing but rising profile. About 75% of Mel was 
dissolved within 2 hours. In the case of the solid-state forms, carriers (MCC and trehalose) 
help to uniformly distribute the nanoparticles of Mel, thereby maintaining the uniqueness of 
the nanoparticles. 
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5.3.7. In vivo studies 
The plasma concentration of the samples in rats is shown in Figure 22. The calculated plasma 
concentration of Mel at zero min (C0min) was 10,607 nM, and then the plasma concentration 
decreased exponentially. A very small amount of Mel was absorbed from nanoMel sample, 
regardless of the particle size of the drug. The plasma concentration of Mel was constant in 
the investigated time period. The results show that the nanosuspension (nanoMel) has not got 
advantageous properties. 
 
Figure 22. Plasma levels of MEL after the administration of different samples in rats. The 
preparations were administered orally (nanoMel, fluidMel and lyoMel) or intravenously (IV) 
as a single dose of 300 μg/kg. 
The initial blood levels of the fluidMel and lyoMel samples show a big difference. At 15 
minutes, the lyoMel sample (5,712.98 nM) shows more than twice the value of fluidMel 
(Table 11). In practice, this value is similar as the maximum plasma level for the lyophilized 
product (C30min 5,814 nM). The peak blood concentration of fluidMel, is about 6,000.00 nM at 
50 minutes that is comparable with the blood concentration reached by IV injection at 5 min. 
This result also confirms that the solid products contained Mel in an adequate amount, and 
that the total amount thereof dissolved and absorbed. 
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 The plasma curves of the different samples containing Mel show a very slow elimination 
after the distribution phases. That can be explained by the very high (99%) plasma binding 
property of Mel in rat, and this ratio is the same in human (Busch et al., 1998). It seems that 
the eliminated portion of Mel is replenished from the protein bounded fraction for a quite long 
period of time. Our measuring time was only 3 hours, longer detection period can provide 
appropriate information about the whole elimination process. The peak MEL concentrations 
of from lyoMel and fluidMel preparations have reached the similar level that of IV formula 
(Figure 22). The lyoMel sample resulted in higher plasma concentrations in 15 minutes as 
compared with nanoMEL preparation. The solidified samples had nearly five-fold higher 
bioavailability than that of nanoMel (Table 12). 
Table 12. Plasma concentrations of Mel in time and its relative bioavailability in rats after IV 
and per os administration of Mel samples. Relative bioavailabilities were compared to 
nanoMel preparation 
Sample C15min 
(nM) 
C120min 
(nM) 
AUCblood 
(min·ng/ml) 
Relative 
bioavailability 
(%) 
nanoMel 1,090.02 1,123.31 190,584.52 100.00 
fluidMel 2,338.44 5,811.33 945,834.99 496.28 
lyoMel 5,712.98 5,219.52 923,117.95 484.36 
IV injection C5min 6,059.07 2,607.80 377,528.01 - 
 
5.3.8. IVIV correlation 
Comparative studies according to AUC values have shown that there are significant 
differences between the nanosuspension and the samples (fluidMel and lyoMel) within in 
vitro and in vivo groups. However, there is no significant difference between two solid 
samples either in vitro or in vivo (Figure 23). The basis of the IVIVC calculation was the 
comparison of the AUC values of the samples in the in vitro and in vivo groups. By our 
calculations, the Pearson’s correlation coefficient value between the two studies is 0.99695. 
The t value of the independent t-test of the two dissolution study series was 0.0145, the 
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calculated p value was 0.9889 and the difference is not significant at a confidence level of 
95%. As the zero hypothesis of the independent t-test, the calculation is not significant if the 
averages of the two series are equal. It can be concluded that in this system, in vitro 
dissolution studies are applicable to predict the dissolution rate-limited differences in the case 
of in vivo studies. 
 
Figure 23. IVIV correlation of Mel containing samples. Notes: Values are presented as mean 
± SD. Statistically significant differences are: ***p<0.001, compared to nanoMel separately 
in in vitro and in vivo groups; # p<0.05 compared to the indicated columns 
6. CONCLUSION 
i) The PhD work reports a wet milling process, where the planetary ball mill was combined 
with pearl milling technology to produce nano-size meloxicam (Mel) (d(0.9) < 500 nm). Mel 
as a water-insoluble highly potent NSAID was milled in the presence of the PVA, in aqueous 
solution any other stabilizer agent as surfactant.  The critical process parameters (ratio of pre-
dispersion and pearls, milling time and rotation speed of the steel jar) were optimized by 
factorial design on the particle size distribution and crystallinity of the Mel were investigated.  
It was found that the ratio of pre-dispersion and pearls 1:1 (w/w) resulted in the most effective 
grinding system without any pre-milled process (200-fold particle size reduction in one step) 
with 437 rpm and 43 min as optimized parameters.  
ii) The amount of PVA were also a critical parameter because it affected the milling 
effectiveness, the particle size distribution and the crystallinity of Mel. The different 
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concentrations of PVA in the aqueous dispersion influenced the viscosity and the electro-
kinetic property of the particle, and the stability of the dispersions. It was found that the 
milling effectiveness of low concentration of PVA (< 4%) was not satisfactory, because the 
crushing / breaking effect of the pearls could less prevail.  High concentration of PVA (˃ 5%) 
also resulted in unsatisfactory milling effectiveness, because of the formation of polymer 
layer on surface of particles which protects the particles from the fragmentation. Considering 
the effectiveness of milling, 5% PVA was proved to be an optimal quantity to meet the 
expected value (d(0.9) < 500 nm). Finally, the sample (diluted dispersion) containing 1% 
Mel and 0.5% PVA produced by the optimized wet milling procedure fulfilled the 
requirements for the nanosuspension with respect to particle size distribution (d(0.1) 
0.067µm, d(0.5) 0.130µm, d(0.9) 0.371 µm). The intermediate product showed a stable 
system with 2 weeks of holding time.  
iii) In vitro dissolution tests have shown that the particle size of the Mel and its degree of 
crystallinity are interdependent critical parameters, which plays an important role in the fast 
drug release. The human Caco-2 cell culture studies justified that the penetration of Mel from 
different PVA-containing products was significantly increased as compared to Mel suspension 
without toxic effects. From all the tested samples, the Papp value of Mel was the highest in the 
investigated sample containing 0.05% PVA, which belongs to the optimized nanosuspension. 
iv) The further aim of this work was to discover the robustness of combined wet milling 
process to determine the interval of the Mel amount and to predict the degree of crystallinity 
of the milled samples as critical parameter using DSC and XRPD measurements. The samples 
had the PVA as the stabilizing agent. By increasing the amount of the Mel, its crystallinity 
increased, and close correlation was found between the degree of crystallinity and the Mel 
amount. To achieve the desired particle size (< 500 nm), the Mel amount should be changed 
between 10.0 and 17.5% (w/w) and a PVA concentration should be used between 5.0 and 
4.58% (w/w). In this speciﬁed range, the degree of crystallinity of Mel will be changed 
between 20 and 45%. The crystallinity of Mel investigated by DSC and XRPD did not show 
any signiﬁcant difference at 95% signiﬁcance level. 
v) Mel containing (1%) nanoMel sample produced by wet milling process using optimized 
amount of PVA (0.5%) resulted in 130±5 nm as mean particle size and a significant reduction 
in the degree of crystallinity (13.43%) of Mel. The fluidization technique using 
microcrystalline cellulose (MCC) as carrier resulted a quick conversion no significant change 
in the critical product parameters. Process of lyophilization required a longer operation time, 
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which resulted in the amorphization of the crystalline carrier (trehalose) and the 
recrystallization of Mel increased its particle size and crystallinity. In accordance with this, 
the particle size (Z-average: from 284 nm to 374 nm) and the degree of crystallinity of Mel (to 
36.54%) were also changed. The 6-month storage did not cause any further changes in the 
products. 
vi) To justify applicability of surfactant-free samples containing nanonized Mel in vivo studies 
was performed. The nanonized Mel in solidified products (fluidMel, lyoMel) resulted in rapid 
absorption through the gastric membrane by passive transcellular transport. It was found that 
these products contained Mel in an adequate amount, and that the total amount thereof 
dissolved and absorbed. The fluidMel and lyoMel samples had nearly five-fold higher relative 
bioavailability than nanoMel application by oral administration. The correlation between in 
vitro and in vivo studies showed that the fixed Mel nanoparticles on the surface of solid 
carriers (MCC, trehalose) in both the artificial gastric juice and the stomach of the animals 
rapidly reached saturation concentration leading to faster dissolution and rapid absorption. 
 
New findings of this work: 
Combined wet milling is considered to be a suitable process for nanonization of active 
ingredients, since it produces a desired particle size product in a single step without using pre-
milling and surfactant (innovative technology). The novelty of the research results is the 
determination and optimization of critical process and product parameters, which is well 
demonstrated by the production of Mel containing nanosuspension (nanoMel). 
To discover the robustness of the milling process, it should also be considered that the amount 
of grinding media can be reduced by increasing the amount of the active ingredient and the 
crystallinity of the drug can be regulated. In this case, the DSC method can be suggested for 
the quantiﬁcation of the degree of crystallinity because it can be used safely with high 
amorphous content. 
The solidification of the nanosuspension not only increases the stability of the nanoparticles 
(particle size, crystallinity degree), but also allowes the preparation of surfactant-free solid 
compositions (powder, tablet, capsule) with excellent bioavailability, which may be an 
important consideration for certain groups of patients to achieve rapid analgesia. Further 
experiments are necessary to prove the therapeutic relevance of these formulations 
(innovative product). 
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Abstract: This article reports on the effects of a new combined wet milling technique on the
physicochemical properties of meloxicam (MEL). The influence of milling time on the particle
size, the crystallinity, the morphology and the dissolution rate of MEL has been studied in the
presence and absence of polyvinyl alcohol (PVA) as a stabilizer agent. Micronized MEL particles
were produced in aqueous medium which did not contain additive after milling for 10 min. For
nanonization an additive and longer milling time were required. After particle size determination
the structural and morphological characterization of the wet milled, dried products containing MEL
were studied. X-ray powder diffractometry (XRPD) and differential scanning calorimetry (DSC)
examinations revealed the change in the crystallinity of MEL. Scanning electron microscopy (SEM)
images showed that aggregates of nanosized MEL particles were formed, regardless of the presence
of PVA. The nanonized MEL crystals (D50 = 126 nm) exhibited a regular shape and a smooth surface.
The increased specific surface area resulted in a high dissolution rate and concentration of free MEL.
According to the results, the produced samples could be applied as a basic material (micronized MEL)
and intermediate product (micronized and nanonized MEL with PVA) for the design of dosage forms.
Keywords: wet milling; micronization; nanonization; physical structure; crystallinity; in vitro dissolution
1. Introduction
One of the major current challenges of the pharmaceutical industry is related to strategies that
improve the water solubility of drugs because over 40% of new drug candidates are water-insoluble
compounds [1]. Poorly water-soluble drug properties can impede the effective delivery of these drugs
into humans, and affect their dissolution rate and subsequent absorption at the site of activity [2].
Poorly soluble molecules have been successfully formulated by employing a variety of
techniques to modify the physico-chemical and biopharmaceutical properties of drugs [3,4] such as:
(i) solubilization in surfactant solutions; (ii) use of co-solvents [5], salt formation [6], complexation
with cyclodextrins [7], crystallization [8], amorphization [9], milling [10], etc.
Milling is a technique commonly applied to produce micro- or nanosized drug crystals in order to
increase the dissolution rate and absorption, and hence the bioavailability of poorly-soluble materials.
According to the Noyes-Whitney equation, the reduction of the particle sizes of drug crystals increases
the specific surface area, which can improve the rate of dissolution of the drug [11]. There are many
different well-known types of milling techniques with both advantages and disadvantages; dry and
Molecules 2016, 21, 507; doi:10.3390/molecules21040507 www.mdpi.com/journal/molecules
Molecules 2016, 21, 507 2 of 11
wet milling can be distinguished [12,13]. Wet milling requires less energy and time than dry milling.
Thanks to the environmentally isolated system, it is a dust free process and the material is less heated
up [14]. However, wet milling has some disadvantages as well, e.g., increased wear of the grinding
medium, corrosion hazards, etc. To overcome the limitations of the conventional particle size reduction
technologies for poorly-soluble drugs, new combinational methods have been developed for the
production of ultra-fine suspensions. These technologies are a relatively new approach to improve
the effectiveness of particle size reduction and to reduce the time of processes. In general, they can
be described as a combination of a bottom-up process (the building-up of particles) [15–17] followed
by a top-down technology (disintegration) [18,19]. This method involves two particle size reduction
steps. There is also a possibility for the combination of dry- and wet milling in one step, but literature
data relating to the application of this combined method are lacking. Retsch GmbH (Haan, Germany)
has recommended the combination of planetary ball milling, as dry milling, and pearl milling, as wet
milling [20] techniques.
In wet micro- and nanonization, the application of additives is required in order to retain
the individuality of the particles. Different additives are used to stabilize these particles:
poly(vinylpyrrolidone) (PVP), Poloxamer® (Poloxamer 188 = poly(ethylene)–poly(propylene glycol),
polysorbate (Tween 80® = poly(oxyethylenesorbitan monooleate)), Solutol® (Solutol HS 15 =
poly(ethylene glycol 15-hydroxystearate)), PVA (poly(vinyl alcohol)), etc. [21].
Milling and the presence of additives during milling have the ability to decrease the crystallinity
of active materials [22,23]. The amorphous phase transition usually results in improved dissolution
rates, thereby increasing the bioavailability, with the improvement being directly related to the extent
of amorphization [24]. However, physical and chemical instability of amorphous material could
be expected.
Meloxicam (MEL) is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory,
analgesic and antipyretic effects. MEL was chosen as a model crystalline drug because of its poor
aqueous solubility (4.4 µg/mL) [25] and relatively high melting point (270 ˝C) [26].
This research investigates the applicability of a wet milling method combining planetary ball
and pearl milling. We set out to utilize particle size reduction to the micro- or nanometre range. The
effects of milling time and the presence or absence of stabilizer (PVA) in reducing the particle size were
investigated. The changes in crystallinity and morphology of MEL during milling have been studied.
The effects of particle size reduction and amorphization on the dissolution rate were determined.
2. Results and Discussion
2.1. Effects of Milling Time on Particle size Distribution (PSD) and Specific Surface Area (SSA)
During our work, a combined wet milling technique (planetary ball mill and pearls, as milling
media) was investigated. Analysis of the laser diffraction results revealed that the milling in the case
of samples containing water as a dispersant medium resulted in a roughly 85% decrease in average
MEL particle size. The D10, D50 and D90 values and the SSA are reported in Table 1.
After 10 min milling, micronized MEL was observed. However, further milling led to an increase
in particle size, because MEL particles aggregated without the presence of PVA. The smallest average
particle size (3.55 µm) and the highest SSA (1.89 m2/g) were obtained during the first 10 min of
milling. During milling heat production was observed and the temperature of the samples increased
up to 40–45 ˝C. The aqueous solubility of MEL (4.4 µg/mL, 25 ˝C) increased due to the elevated
temperature (40 µg/mL, 37 ˝C), but it was not remarkable in our investigation (at about 0.04 w/v%),
and 0.8 mg MEL could be dissolved in our dispersant medium (water) of the presence 2 g of active
agent. The recrystallization of the small amount of dissolved MEL was irrelevant in terms of any
particle size increase.
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Table 1. MEL PSD and SSA in pre-dispersions containing water as dispersant.
Milling Time (min) D10 (µm) D50 (µm) D90 (µm) SSA (m2/g)
raw MEL 11.40 34.26 73.59 0.332
10 1.76 3.55 8.69 1.89
20 2.63 5.74 14.21 1.22
30 2.62 5.99 18.97 1.18
40 2.77 6.84 24.54 1.07
50 2.72 6.13 19.56 1.15
60 2.57 6.12 20.87 1.18
70 2.77 7.13 26.26 1.05
80 2.58 5.94 22.54 1.19
90 2.51 5.55 18.88 1.25
In the case of PVA-solution as a dispersant, after 10 min micronized, and after 50 min nanonized
particles were noted, with monodisperse PSD (Table 2). The average particle size decreased efficiently,
from approximately 35 µm to 126 nm, up to 50 min of milling. The SSA of MEL rose 150-fold compared
to the raw MEL. Further milling led to only a slight decrease in particle size. PVA, used as a coating
polymer helped the particles to separate from each other. Aggregation was also prevented, therefore
the stability of the system could be improved.
Table 2. MEL PSD and SSA in pre-dispersions containing PVA-solution as dispersant.
Milling Time (min) D10 (µm) D50 (µm) D90 (µm) SSA (m2/g)
raw MEL 11.40 34.26 73.59 0.332
10 0.24 2.96 29.40 7.71
20 0.084 0.169 2.863 34.6
30 0.090 0.337 4.180 27.2
40 0.074 0.134 1.358 46
50 0.074 0.126 0.253 49.5
60 0.072 0.122 0.219 52
70 0.070 0.121 0.225 52.6
80 0.072 0.119 0.209 53.2
90 0.064 0.116 0.219 57.9
2.2. Characterization of the Dried Products
2.2.1. Physical Structure (XRPD and DSC)
For determination the effect of milling on the crystallinity of MEL pre-dispersions, samples milled
for 10 min in water as a dispersant, and for 10 and 50 in PVA-solution as a dispersant were dried
and characterized.
The XRPD diffractogram of raw MEL and of MEL in the physical mixture of MEL-PVA
demonstrated its crystalline structure, as expected. The characteristic peaks are located at the following
2θ values: 13.22˝, 15.06˝ and 26.46˝. Ten min of milling in the water-containing sample caused the
loss of the crystalline structure of the drug, and only 3% of the drug remained crystalline (Table 3).
The intensities of the characteristic peaks were decreased in the case of the treated product (Figure 1).
During the further milling aggregation was observed, because of the lack of PVA. At the end of milling
(90 min), 9% of MEL remained crystalline.
In the PVA-solution containing sample in the course of milling, a decrease in crystallinity was
perceptible. After milling for 10 min, ~47% of the drug remained crystalline. After 90 min milling
amorphization was detected, the degree of crystallinity was 2% (Table 3). The intensities of the
characteristic peaks decreased due to the milling (Figure 2).
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DSC was employed to investigate the melting of MEL in the raw form, the physical mixture and
in the milled dried products (Figure 3). The DSC curves of the raw MEL and of MEL in the physical
mixture of MEL-PVA revealed a sharp endothermic peak at 259.1 and 255.9 ˝C, reflecting its melting
point and confirming its crystalline structure. In case of water-containing samples the most significant
decrease of crystallinity was observed after 10 min milling (peak: 227.0 ˝C). Increasing the milling
time, aggregation was detected. Using PVA-solution as dispersant, DSC curves exhibited a broad
endothermic peak for MEL, indicating that the crystallinity of the drug was decreased (Table 4). The
residual MEL crystals in the products melted at a lower temperature than the crystals of raw MEL due
to the smaller particle size and the increased degree of amorphization which was directly proportional
to the duration of milling. This process was promoted by PVA, which was softened at 43 ˝C as glass
transition temperature (Tg) value.
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Table 4. Thermoanalytical evaluation of MEL_raw, MEL_PVA_pm and dried milled products.
Parameters Raw MEL pm Dried MEL_W Samples Dried MEL_W_PVA Samples
Milling time (min) - - 10 50 60 90 10 50 60 90
∆H * (J/g) ´148.5 ´29.9 ´7.5 ´40.1 ´64.4 ´40.8 ´60.3 ´70.9 ´32.4 ´46.4
Onset (˝C) 258.4 235.9 217.9 23 .5 8.5 2 .1 23 . 23 . 20 . 20 .
Peak (˝C) 259.1 255.9 227.0 238.7 250.7 250.2 239.8 240.1 216.7 217.4
Endset (˝C) 261.0 255.9 230.0 240.4 250.8 251.6 243.1 243.2 222.3 222.3
* ∆H: normalized integral.
It can be concluded that combined milling resulted in partial amorphization of MEL which could
results in a higher dissolution rate compared to the raw drug and its physical mixtures.
2.2.2. Particle Shape and Size
In the following SEM images (Figure 4) the morphology of the modified particles is demonstrated.
Dried products produced by milled p -dispersion in water for 10 min and MEL micronized and
nanonized in the presence of PVA (10 an 50 m n) were investigated. How the surfa e and sh pe
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changed after the milling process, compared with raw MEL, was checked. After taking samples after
10 min of milling in the case of water as a dispersant and 10 and 50 min of milling in the case of
PVA-solution as the medium, the suspensions were dried and characterized. The raw MEL consisted
mainly of angular, prismatic crystals with a broad size distribution. In the case of the water-containing
samples, it was shown that micro-sized aggregates consisting of nanonized particles were formed.
In the case of PVA-solution-containing sample, 10 min of milling resulted in irregular particle shapes,
with the approximately 3 µm D50 value. MEL crystals could be detected between the amorphous
PVA particles. After 50 min, nanonized MEL crystals (at about 120 nm) embedded in the PVA-film,
with regular shape and smooth surface were perceived. The particle endurance during the treatment
accounts for the smooth surfaces of the particles.
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Figure 4. SEM pictures of MEL_raw (A); MEL_W 10 min (B); MEL_W_PVA 10 min (C) and
MEL_W_PVA 50 min (D).
2.2.3. In Vitro Dissolution Tests
The in vitro dissolution test was performed at pH 7.4, which could represent the media of the
intestinal system where the absorption of MEL could be totally achieved. At pH 7.4 the conditions
of the lung, nasal and skin epithelia could also be imitated. The in vitro dissolution showed the poor
solubility and slow dissolution of MEL (D50 = 34.26 µm), and after 60 min approximately 10%, and
after 2 h around 22% of the drug was liberated. Application of PVA (in the reference sample, where
the size of the MEL did not decreased significantly) as hydrophilic wetting agent, could improve
the dissolution rate by 2-fold. The micronization of the drug without PVA (D50 = 3.55 µm) could
influence the dissolution rate 3-fold. Producing individual micronized (D50 = 2.96 µm) and nanonized
(D50 = 0.126 µm) MEL drug particles in the presence of PVA, the extent of dissolution was enhanced
significantly by the increased specific surface area. The amorphous character and the submicron range
of the drug resulted in a very fast dissolution, with more than 70% of MEL liberated after the first
5 min (Figure 5).
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3.2.1. Combined Milling
A wet milling technique (a combination of planetary ball and pearl milling) was employed.
The drug (2 g) was first suspended in the dispersant medium (18 g), consisting of water and
aqueous solution of PVA (the use of lower concentrations of PVA led to extensive aggregation of
the MEL particles because of the lesser effectiveness in overcoming the cohesive forces). The resulting
suspensions (10% drug content) were wet milled at 400 rpm in the milling chamber (50 mL) of a
planetary ball mill (PM 100 MA, Retsch GmbH, Haan, Germany). The milling balls were 0.3 mm ZrO2
beads. As a preliminary experiment, the effects of different pearl weights (10, 20, 50 and 150 g) on
the particle size reduction were investigated, and milling was also carried out without pearls as a
benchmark. The most effective milling was observed when 20 g of pearls was applied. Increasing
the weight of pearls did not result in further particle size reduction, therefore 20 g of beads were
used for further experiments. The milled suspensions were separated with a 150 µm mesh size sieve.
Suspension sampling was carried out at milling times of 10, 20, 30, 40, 50, 60, 70, 80 and 90 (end of
milling) min to perform the particle size analysis.
3.2.2. Determination of Particle Size Distribution and Specific Surface Area by a Laser Diffraction Method
The volume based particle size distribution (PSD) of the raw MEL was measured by laser
diffraction (Mastersizer 2000, Malvern Instruments Ltd., Worcestershire, UK) with the following
parameters: 300RF lens; small volume dispersion unit (2500 rpm); refractive index for dispersed
particles 1.720; refractive index for dispersion medium 1.330. The Dynamic Laser Light Scattering
method was used to determine the PSD. The particle size of the MEL was determined directly on
the initial suspension in water in which PVA was dissolved. The size analysis was repeated three
times. Water was used as dispersant medium and the obscuration was in the range 11%–16% for
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all measurements. In all cases, the volume weighted particle size distributions, D10, D50, and D90
(where for example D50 is the maximum particle diameter below which 50% of the sample volume
exists–also known as the median particle size by volume) were determined and evaluated. The specific
surface area was derived from the particle size distribution data. The assumption was made that all
the measured particles were spherical.
3.2.3. Preparation of Solid Products for Physical-Chemical Investigations of Products
After the particle size determination, the selected pre-dispersions were dried in a vacuum dryer
(Binder GmbH, Tuttlingen, Germany) at 40 ˝C in order to obtain solid products for physicochemical
investigations. The abbreviations of solid state samples are summarized in Table 5.
Table 5. Sample abbreviations.
Sample Name MEL (%) PVA (%) Description
MEL_raw 100 - untreated MEL
MEL_PVA_pm 80 20 physical mixture of MEL and PVA
MEL_W 10 min 100 - dried MEL, milled for 10 min in water
MEL_W 50 min 100 - dried MEL, milled for 50 min in water
MEL_W 60 min 100 - dried MEL, milled for 60 min in water
MEL_W 90 min 100 - dried MEL, milled for 90 min in water
MEL_W_PVA 10 min 80 20 dried product of milling for 10 min in PVA-solution
MEL_W_PVA 50 min 80 20 dried product of milling for 50 min in PVA-solution
MEL_W_PVA 60 min 80 20 dried product of milling for 60 min in PVA-solution
MEL_W_PVA 90 min 80 20 dried product of milling for 90 min in PVA-solution
3.2.4. Further Investigations of the Products
Structural Analysis
The physical state of the MEL in the samples was evaluated by XRPD. XRPD patterns were
produced with a Bruker D8 Advance diffractometer (Bruker AXS GmbH, Karlsruhe, Germany) system
with Cu K λI radiation (λ = 1.5406 Å). The samples were scanned at 40 kV and 40 mA from 3˝ to
40˝ 2θ, at a scanning speed of 0.05˝/s and a step size of 0.010˝. The crystallinity (Xc) of the MEL
in dried pre-dispersions, milled for 10, 50, 60 and 90 min was determined semi-quantitatively in
case of both dispersant medium via the mean of the decrease of the total area beneath the curve of
3 characteristic peaks (Acrystalline) compared to the raw MEL and MEL–poly(vinyl alcohol) physical
mixture (MEL_PVA_pm) (Acrystalline + Aamorphous):
Xc “
Acrystalline
Acrystalline ` Aamorphous ˆ 100 (1)
DSC measurements were carried out with a Mettler Toledo DSC 821e thermal analysis system
equipped with the STARe thermal analysis program V9.0 (Mettler Inc., Schwerzenbach, Switzerland).
Approximately 2–5 mg of pure drug or product was examined in the temperature range between 25 ˝C
and 300 ˝C. The heating rate was 5 ˝C¨min´1. Argon was used as carrier gas at a flow rate of 10 L¨h´1
during the DSC investigations.
Image Analysis (SEM)
The shape and surface characteristics of the samples were visualized by using a scanning electron
microscope (Hitachi S4700, Hitachi Scientific Ltd., Tokyo, Japan). The samples were sputter-coated
with gold–palladium under an argon atmosphere, using a gold sputter module in a high-vacuum
evaporator and the samples were examined at 15 kV and 10 µA. The air pressure was 1.3–13 MPa.
The milling-produced suspensions were dried in order to obtain solid products for SEM analyses.
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In Vitro Release
The paddle method with the USP dissolution apparatus (USP dissolution apparatus, type II
Pharma Test, Heinburg, Germany) was used to examine MEL (1.67 mg), MEL_PVA_pm and the
products (2.0875 mg). The medium was 100 mL of phosphate buffer of pH 7.4 ˘ 0.1. The basket was
rotated at 100 rpm and sampling was performed up to 120 min. After filtration (filtration pore size
0.22 µm; applying a Millex-HV syringe-driven filter unit, Millipore Corporation, Bedford, MA, USA)
and dilution, the MEL contents of the samples were determined by spectrophotometry (ATI-UNICAM
UV/VIS Spectrophotometer, Cambridge, UK) at 362 nm.
4. Conclusions
A combination of planetary ball and pearl milling (using pearls as milling media) can be applied
as a wet milling procedure to decrease the particle size and change the crystal morphology of MEL.
Wet milling in aqueous medium adheres to green technology principles as the product does not contain
organic solvent residues. Besides several advantages of wet milling, it is necessary to calculate the
wear of pearls during milling.
During our work at constant rotation rate in the presence and absence of a stabilizer, the effects
of milling time on the particle size reduction was determined (Table 6). Without additive, in the case
of water-containing samples micronization could be achieved (D50 = 3.55 µm). In the presence of
PVA, depending on the milling time, the particle size of the drug could be reduced to the micro-(after
10 min), (D50 = 2.96 µm) or nanometre range (after 50 min, D50 = 126 nm). The effect of milling on
the crystallinity of MEL was investigated. XRPD and DSC examinations revealed a decrease in the
crystallinity of MEL. In the case of water-containing samples (without PVA) aggregation occurred
during the course of milling. In the PVA-containing samples amorphization was determined (the
degree of MEL crystallinity was 2% at the end of the milling at 90 min). SEM images revealed the
aggregation of nanosized particles in water-containing samples. In the presence of additive milling
for 10 min resulted in irregularly shaped particles. The nanonized MEL crystals exhibited a regular
shape and smooth surface. The in vitro dissolution tests showed that the reduction of the particle size
of MEL, the increased SSA and the structural transformation of drug resulted in a rapid dissolution in
case of nanonized MEL-containing product. The amorphous form of the drug does not require lattice
energy to break the bonds during the dissolution process as in the crystalline state case.
Table 6. Summarized information about the determined properties of the samples.
Sample D50 (µm) Crystallinity (%) Dissolved MEL at 30 min (%)
MEL_raw 34.26 100 8.53
MEL_PVA_pm 20.15 80 29.22
MEL_W 10 min 3.55 3 37.82
MEL_W_PVA 10 min 2.96 48 64.73
MEL_W_PVA 50 min 0.126 12 82.16
The combined wet milling technology was suitable for preparation of micronized MEL without
the use of stabilizer and, depending on the milling time, of micronized and nanonized drug
particles-containing pre-dispersions in the presence of PVA. Milling in the presence of additive could be
the first step of pre-formulation and further formulation procedures. Decreased particle size (especially
accessing the nanosize range) and the amorphization of drug could ensure higher dissolution rate
and better bioavailability of poorly-water soluble drugs, though instability problems could occur in
the case of amorphous forms of materials. To check the stability of the systems further investigations
are needed.
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Because of the low need for dispersant medium, the combined method can be used for efficient
milling, and it is also suggested for the preparation of the pre-dispersions with micro- and nanosized
particles, and recommended for the development of particle size-controlled therapeutic systems.
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Abstract: The paper reports a wet milling process, where the planetary ball mill was combined 
with pearl milling technology to produce nanosize meloxicam (Mel). Mel as a water-insoluble 
highly potent nonsteroidal anti-inflammatory drug was milled in the presence of different 
amounts of the stabilizer agent, poly(vinyl alcohol) (PVA), in aqueous solution. The pearl 
amount, the milling time, and the rotation speed of the jar were optimized to reach the particle 
size range of 100–500 nm. The novelty of this study is the optimization of PVA amount in order 
to reach the required particle size distribution of Mel (milling efficiency) and the investigation 
of the effect of PVA concentration on the physicochemical properties of the milled dispersion 
(viscosity, zeta potential) to predict the stability of the nanosuspensions. It was found that 
the ratio of predispersion and pearls 1:1 (w/w) resulted in the most effective grinding system 
(200-fold particle size reduction in 1 step) with optimized process parameters, 437 rpm and 
43 min. Nanosuspension (1% Mel and 0.5% PVA) as an intermediate product showed a stable 
system with 2 weeks of holding time. This optimized nanosuspension enhanced the penetration 
of Mel across cultured intestinal epithelial cell layers without toxic effects. The dissolution 
rate of Mel from the PVA-stabilized nanosuspension justified its applicability in the design of 
innovative per oral dosage form (capsule) in order to ensure/give a rapid analgesia.
Keywords: nanonization, meloxicam, milled dispersion, milling efficiency, zeta potential, 
intermediate product
Introduction
The planetary ball milling belongs to the group of high-energy milling methods. The 
process is mainly used in laboratory-scale research work. It is a common technique 
for dry milling,1,2 nevertheless it is also suitable for wet grind.3–5 Dry milling with this 
technique is usually used for micronization with a particle size range of 1–2,000 µm.6 
In general, additives are not required for micronization, but for dry nanonization, 
application of them and a long milling time (2–4 h) can be necessary. Additives 
decrease the cohesion between the nanosize particles and the collision energy during 
the milling process; thereby, the risk of the decomposition of the active agent can 
be reduced.7
Wet milling is a top–down process, where the raw material is broken down via 
mechanical forces. In this method, a sufficiently concentrated dispersion of drug 
particles in an aqueous or nonaqueous liquid medium is treated. Increased mill 
capacity, lower energy consumption, and easier handling of materials can be perceived 
as advantages of the process. However, it must be said, in the course of the milling 
process, increased wear of the milling medium and corrosion can occur, and the 
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instability of the active agent must be taken into account. 
Wet milling is applicable for micronization in the particle 
size range of 1–50 µm, in this case, colloid mill, toothed 
high-shear inline mixers, and cone mill can be used,8 but 
for nanonization, high-pressure homogenization (1–20 µm) 
and pearl milling technique (20–200 nm)9–11 can be applied. 
It should be noted that in case of high-pressure homog-
enization and pearl milling techniques, the preparation of 
pretreated dispersions (particle size reduction to 1–10 µm) 
is required to reach the nanosize range.
The pearl milling process has been proven to be a robust 
technique for the production of nanoparticle suspension of 
poorly water-soluble drugs.12 With this method, nanosuspen-
sions are produced through the use of high-shear media or 
pearl mills. Pearl milling is a continuous process wherein the 
drug suspension is pumped through the milling chamber in 
order to reduce the particle size of the suspended material. 
The milling medium consists of glass, zirconia, or highly 
cross-linked polystyrene resin.13 The physical characteris-
tics of the resulting nanocrystals depend on the number and 
size of the milling pearls, the amount of the drug, and the 
stabilizer(s).14,15
Thanks to the high efficiency of a smaller pearl size16 
and the high mechanical forces of the planetary mill, Retsch 
GmbH (Haan, Germany) recommends the combination of the 
planetary ball and pearl milling as a novel milling technique 
in order to prepare drug nanodispersions.17 In the literature, 
there are few articles about the combinative method, where 
various active agents were co-milled. In the presence of 
d-tocopherol polyethylene glycol 1000 succinate as a stabi-
lizer agent, nanoparticle range was achieved; however, the 
production efficiency was very low.18,19
Our team uses different milling techniques (dry and wet) 
in order to nanonize different water-insoluble drugs, eg, 
meloxicam (Mel), to provide a faster dissolution, a higher 
saturated concentration, a faster absorption, and, in this 
context, a better bioavailability. Mel as a nonsteroidal anti-
inflammatory agent is often used in malignant and nonma-
lignant pain therapy, but its bioavailability is unsatisfactory 
thanks to its poor solubility in the gastrointestinal tract. One 
strategy to address these problems is the particle size reduc-
tion (eg, nanonization), which increases the dissolution rate 
of the poorly soluble drug resulting in faster absorption and 
faster action in pain therapy.
In our earlier studies, we investigated the applicability of 
the combined wet milling technique,20–23 and these prelimi-
nary studies showed that for the nanonization of Mel, PVA 
as a stabilizer agent and an increased milling time (.50 min) 
were required. The influence of milling time was also studied 
on the particle size distribution, crystallinity, and dissolution 
rate of Mel.
During the use of the combined wet milling technique, 
the type and amount of PVA are very important because it 
has a dual role. On the one hand, it promotes the grinding 
efficiency in the concentrated predispersion, and on the other 
hand, it stabilizes the milled dispersion and later the final 
nanosuspension in a diluted medium.
PVA is a nonionic polymer with very different molecular 
weights. It is frequently used as a stabilizer agent.20 Polymer 
adsorption on the solid–liquid interface can be influenced 
by the various conformations of the polymer chains and the 
interaction of the polymer segments with the solvent and the 
surface of the solid as well. PVA with low molecular weight 
(about 20,000 g/mol) is adsorbed on the colloid particles and 
thus stabilizes the colloid suspension (coating the particles 
and providing the repulsion among them), whereas PVA with 
high molecular weight (about 1,000,000 g/mol) flocculates 
the dispersed systems.24
The prediction of permeability features of drug candi-
dates across biological barriers is of great importance in the 
early phase of drug development.25 Oral drug formulations 
are the most widespread in human therapy, and therefore 
intestinal drug absorption is the most studied in pharma-
ceutical research. The human Caco-2 cell line, presenting 
many of the structural and functional aspects of the epithe-
lium of small intestine, is a routinely used culture model of 
intestinal drug penetration showing good correlation with 
in vivo data.26
The aim of this work was to optimize the process param-
eters (pearl amount, milling time, and rotation speed) of the 
combined wet milling technique (planetary ball and pearl 
milling), using Mel as an active agent and PVA as a stabiliz-
ing agent in the predispersion. We basically investigated the 
influence of the amount of low molecular weight PVA on 
the grinding efficiency in concentrated predispersion. Our 
aim was also to get to know the effect of mechanical forces 
on polymer viscosity and drug–polymer interaction as well. 
To describe the stability of nanosuspensions, their particle 
size was monitored for 2 weeks. Furthermore, the optimized 
Mel formulations were tested on the cell culture model of 
intestinal epithelium.
The novelty of this study is the application of PVA and 
the combined wet milling process and optimization of the 
amount of the additive and the process parameters in order 
to produce Mel nanosuspension (particle size range of 
100–500 nm) without any pretreating procedure.
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Materials and methods
Materials
Mel was obtained from EGIS Ltd. (Budapest, Hungary). 
PVA-Mowiol 4-98 (M
w
 ~27,000) (Sigma-Aldrich Co. LLC, 
St Louis, MO, USA) was used as a stabilizing agent. Reagents 
were purchased also from Sigma-Aldrich. Zirconium oxide 
(ZrO
2
) beds with a diameter of 0.3 mm were obtained from 
Netsch (Netsch GmbH, Selb, Germany). All reagents were 
purchased from Sigma-Aldrich, Ltd. (Budapest, Hungary) 
for the in vitro cell culture experiments, unless otherwise 
indicated.
Methods
combined wet media milling
Optimization of process parameters
The samples were milled with the steel jar with 50 mL 
volume of the Retsch PM 100 planetary ball mill (Retsch 
PM 100 MA, Retsch GmbH) combined with 0.3 mm ZrO
2
 
beads as the grinding media. The concentrated (10% w/w) 
predispersions (2 g of Mel suspended in 18 g of dispersant 
medium containing PVA) were added to the ZrO
2
 beads. 
In the first step, the effect of different amount of ZnO
2
 pearls 
on the particle size reduction was investigated. The ratio of 
the amount of predispersion and pearls (w/w) was 1:0.5, 1:1, 
1:2, and 1:4; and the milling times were 10, 30, and 50 min. 
In these cases, the concentration of PVA solution was 2.5% 
(w/w), and the rotation speed was 400 rpm. In the second 
step, design and analysis of experiments with 3 levels were 
used to optimize the milling time (10, 30, and 50 min) and 
the rotation speed (200, 350, and 500 rpm) as independent 
variables. The amount of the pearls was chosen on the basis 
of the optimization study. The temperature of the samples 
was measured immediately after milling. This value did not 
exceed 39°C.
Optimization of PVa concentration
Various amounts of PVA (2.5%–7.5%) were applied to pre-
pare the concentrated predispersions. The concentration of 
the PVA solutions was increased in the half percent range. 
Mel content was 10% (w/w), and the optimized process 
parameters were used during the milling. The degree of 
particle size reduction and particle size distribution were the 
main factors for the optimization of the PVA concentration 
(Figure 1).
The concentrated milled dispersions were filtered by a 
sieve with 150 µm mesh size in order to remove the pearls. 
For the washing of the pearls, 180 g of distilled water was 
used. In all cases, the milled dispersions were 10-fold diluted 
products with 1% of Mel (w/w) content. The samples were 
selected on the basis of the particle size range (100–500 nm) 
and the holding time (2 weeks).
investigation of the samples
Particle size measurement
The volume-based particle size distribution was measured by 
laser diffraction (Mastersizer S 2000, Malvern Instruments 
Ltd, Worcestershire, UK) with the following parameters: 
300RF lens; small volume dispersion unit (1,000 rpm); 
refractive index for dispersed particles 1.596; and refractive 
index for dispersion medium 1.330. Water was used as a 
dispersant, and the obscuration was in the range of 11%–16% 
for all measurements. In all cases, the particle size distribu-
tions were characterized by the d(0.1), d(0.5), and d(0.9) 
(where, eg, d(0.5) is the maximum particle diameter below 
which 50% of the sample volume exists), and the Span values 
were calculated according to equation. A high Span value 
(.1) denotes a broad particle size distribution.27
 
Span
(0.9) (0.1)
(0.5)
= d d
d
−
 
rheological measurement
To investigate the viscosity changes during the milling 
process, the initial and milled PVA solutions and the con-
centrated milled dispersions were used. Rheological measure-
ments were carried out with Physica MCR101 rheometer 
???????????????????????????????????????????????????????????????????????
??????????????????????????????
???????????????????????????????????????????????????????? ???????????
????????????????????????????????????????????????????????????????????????
?????????????????????????????? ??????????????????????
????????????????????? ????????????????????????????
?????????????????????????????????????????????????????????????
Figure 1 Protocol of sample preparation for the optimization of PVa content.
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol).
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(Anton Paar, Graz, Austria). A concentric cylinder measuring 
device with a diameter of 17 mm was used. The flow curves 
of the samples were determined at 25°C, where the shear rate 
was increased from 0.1 to 100 L/s. The shearing time was 
300 sec. In this paper, viscosity values were given at 100 L/s 
shear rate. Two parallel measurements were run.
Zeta potential
The zeta potential of the dispersions was measured using 
a Malvern Zeta Nano ZS (Malvern Instruments Ltd). For 
the zeta potential determination, Malvern DTS 1070 folded 
capillary cell was used. The diluted milled dispersions were 
further diluted with water (25-fold) for the measurements.
raman spectroscopy
For the investigation of Mel degradation as a function of 
the pearl amount and milling time in the dispersion, Raman 
spectra were acquired with a Thermo Fisher DXR Dispersive 
Raman (Thermo Fisher Scientific Inc., Waltham, MA, USA) 
equipped with a CCD camera and a diode laser operating 
at a wavelength of 532 nm. Raman measurements were 
carried out with a laser power of 4 and 8 mW at 25-µm slit 
aperture size on a 2 µm spot size. The spectra of the indi-
vidual substances as Mel and PVA were collected using a 
2-sec exposure time, a total of 48 scanning in the spectral 
range of 3,300–200 cm–1 with cosmic ray and fluorescence 
corrections.
Morphology of the particles (scanning electron 
microscopy)
For the investigation of the morphology of the particles, 
the diluted milled dispersions were dried in a vacuum dryer 
(Binder GmbH, Tuttlingen, Germany) at 40°C in order to 
obtain solid products for physicochemical investigations. 
After drying, the shape and surface characteristics of the 
samples were visualized using a scanning electron micro-
scope (Hitachi S4700, Hitachi Scientific Ltd., Tokyo, Japan). 
The samples were sputter-coated with gold–palladium under 
an argon atmosphere, using a gold sputter module in a high-
vacuum evaporator, and the samples were examined at 10 kV 
and 10 mA. The air pressure was 1.3–13 MPa.
Differential scanning calorimetry (Dsc)
DSC measurements were carried out with a Mettler Toledo 
DSC 821e thermal analysis system with the STARe thermal 
analysis software V9.0 (Mettler Inc., Schwerzenbach, 
Switzerland). Approximately 2–5 mg of pure Mel and PVA 
as well as dried samples were examined in the temperature 
range of 25°C–270°C. The heating rate was 10°C/min in the 
presence of argon as a carrier gas with a flow rate of 10 L/h.
X-ray powder diffraction analysis (XrPD)
The crystallinity state of Mel in the dried samples was evalu-
ated by XRPD. XRPD patterns were produced by a Bruker 
D8 Advance diffractometer (Bruker AXS GmbH, Karlsruhe, 
Germany) system with Cu K λI radiation (λ=1.5406 Å). 
The samples were scanned at 40 kV and 40 mA from 3 to 
40 2θ, at a step time of 0.1 sec, and a step size of 0.010°. 
The instrument was calibrated by using SI standard. 
The semiquantitative determination of Mel crystallinity 
(Cryst. %) was performed using the total area under the 
curve of 3 characteristic peaks (13.06, 14.94, and 18.61 
2θ) of Mel. The area under the curve value of the peak of 
raw material without milling (rawMel) and the dried milled 
dispersions (MelD) was calculated and compared according 
the following formula:
 
Cryst. % = AUCMelD
AUCrawMel
100×
 
Drug content determination
The loss of weight of Mel was controlled in the milled 
suspension. Seventy-five milligram of the liquid products 
with 0.75 mg of theoretical Mel was dissolved in 100 mL of 
phosphate buffer pH 7.4±0.1. The sample was stirred with a 
magnetic stirrer at 25°C for 24 h and then filtered (0.1 µm, Fil-
terBio PES Syringe Filter) (Labex Ltd., Budapest, Hungary), 
and the concentration of the dissolved Mel was analyzed 
spectrophotometrically (Unicam UV/VIS) (Thermo Fisher 
Scientific Inc.) at 364 nm wavelength. The investigations 
were repeated 3 times.
in vitro dissolution test
To determine the dissolution extent of Mel from disper-
sions, the paddle method (USP dissolution apparatus, type II 
Pharma Test, Heinburg, Germany) was used. About 750 mg 
of the dispersion with 7.5 mg of Mel (therapeutic dose) was 
filled into hard gelatin capsules within 5 sec and put promptly 
into the medium. The medium contained 900 mL of artificial 
gastric fluid at pH 1.2±0.1 and intestinal fluid (pH 6.8±0.1). 
The paddle was rotated at 100 rpm, and sampling was 
performed up to 60 min. The Mel contents of the samples 
were determined using a spectrophotometer (ATI-UNICAM 
UV/VIS Spectrophotometer) at 362 nm (gastric juice) and 
364 nm (enteric fluid). The number of parallel runs was 3.
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in vitro cell culture studies
human caco-2 intestinal epithelial cell line
Caco-2 intestinal epithelial cell line was purchased from 
ATCC (Manassas, VA, USA) (cat. no HTB-37) and used 
until passage 60 for the experiments. The cells were grown 
in DMEM (Gibco, Life Technologies, Carlsbad, CA, USA) 
and supplemented with 10% fetal bovine serum (Pan-Biotech 
GmbH, Aidenbach, Germany) and 50 µg/mL gentamycin 
in a humidified incubator with 5% CO
2
 at 37°C. All plastic 
surfaces were coated with 0.05% rat tail collagen in sterile 
distilled water before cell seeding in culture dishes and the 
medium was changed every 2 days. The stock solutions for 
cell culture experiments were the following: Mel, 100 mg/
mL; PVA, 5% (w/w), and 3 products containing 100 mg/mL 
Mel with various amounts of PVA (2.5%, 5%, or 7.5%). The 
working solutions were diluted in the cell culture medium 
or Ringer–Hepes buffer and contained 1 mg/mL of Mel for 
the Mel and formulation groups. The final concentrations of 
PVA were 0.025%, 0.05%, and 0.075% (w/w).
cell viability measurement by impedance
Impedance was measured at 10 kHz using the RTCA-SP 
instrument (RTCA-SP instrument, ACEA Biosciences, San 
Diego, CA, USA). This method is label-free, noninvasive 
and follows cell adherence, growth, number, and viability 
real time. We have successfully tested the cellular effects 
of peptides and pharmaceutical excipients by impedance 
kinetics.28–30 For background measurements, a 50 µL cell 
culture medium was added to the wells; then, cells were 
seeded at a density of 6×103 cells/well to 96-well plate with 
gold electrodes (E-plate 96, ACEA Biosciences) coated with 
collagen. Cells were cultured for 5 days in a CO
2
 incubator 
at 37°C and monitored every 10 min until the end of experi-
ments. At the beginning, plateau phase of growth cells were 
treated with Mel, PVA, and Mel+PVA samples diluted in a 
cell culture medium, and the effects were followed for 8 h. 
Triton X-100 detergent (1 mg/mL) was used as a reference 
compound to induce cell toxicity. Cell index was defined 
as R
n
-R
b
 at each time point of measurement, where R
n
 is 
the cell–electrode impedance of the well when it contains 
cells and R
b
 is the background impedance of the well with 
the medium alone.
Permeability study on cell culture model
Transepithelial electrical resistance (TEER) reflects the tight-
ness of the intercellular junctions closing the paracellular 
cleft, and therefore reflects the overall tightness of cell lay-
ers of biological barriers. TEER was measured every 2 days 
to check the barrier integrity by an EVOM volt-ohmmeter 
(World Precision Instruments, Sarasota, FL, USA) combined 
with STX-2 electrodes and was expressed relative to the 
surface area of the monolayers as Ω×cm2.
Caco-2 cells were seeded onto Transwell inserts (polycar-
bonate membrane, 0.4 µm pore size, 1.12 cm2 surface area; 
Corning Life Sciences, Tewksbury, MA, USA) and cultured 
for 3 weeks.31,32 The culture medium was changed and TEER 
was checked every second day.
For the permeability experiment, inserts were transferred 
to 12-well plates containing 1.5 mL Ringer–Hepes buffer 
in the lower (basal) compartments. In the upper (apical) 
compartments, the culture medium was replaced by 0.5 mL 
buffer containing treatment solutions of Mel, PVA, and Mel 
formulation groups for 1 h. Permeability marker molecules 
fluorescein (10 µg/mL; M
w
: 376 Da) and albumin (10 mg/mL; 
M
w
: 65 kDa) labeled with Evans blue (167.5 µg/mL) were 
used for verifying the cell layer integrity. Treatment solu-
tions from both compartments were collected and the Mel 
level was detected using a Thermo Spectronic Helios Alpha 
UV-Vis spectrophotometer (Thermo Fisher Scientific Inc.).
The concentrations of the permeability marker molecules 
of collected samples were determined by a fluorescence 
multi-well plate reader (Fluostar Optima, BMG Labtech, 
Offenburg, Germany; for fluorescein: excitation wavelength, 
485 nm; emission wavelength, 535 nm and for Evans blue-
labeled albumin: excitation wavelength, 584 nm; emission 
wavelength, 680 nm).
The apparent permeability coefficients (P
app
) were calcu-
lated as described previously.28 Briefly, the cleared volume was 
calculated from the concentration difference of the tracer in 
the lower/basal compartment (Δ[C]
B
) after 30 min and upper/
apical compartments at 0 h ([C]
A
), the volume of the lower/
basal compartment (V
B
, 1.5 mL) and the surface area available 
for permeability (A, 1.1 cm2) using the following equation:
 
P
C V
A C tapp
A A
L
(cm/s)
[ ]
=
∆ ×
× × ∆[ ]
 
Determination of holding time
Since the diluted dispersions are intermediate products, it 
was necessary to specify the “holding time” of the sample 
through the particle size distribution. The products were 
stored in sealed glass bottles at room temperature (25°C±1°C) 
for 2 weeks. The particle size distribution of the Mel in the 
samples was analyzed on the day of production (day 0) and 
after 14 days of storage.
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statistical analyses
Data were expressed as mean±SD, and groups were com-
pared by using Student’s t-test. For the evaluation of cell 
culture results, GraphPad Prism 5.0 software (GraphPad 
Software Inc., San Diego, CA, USA) was used. All cul-
ture data presented are mean±SD; values were compared 
using analysis of variance followed by Bonferroni post-
test. Differences were considered statistically significant 
when p,0.05.
Results and discussion
Optimization of process parameters (pearl 
amount, milling time, and rotation speed)
The effect of pearl amount and milling time on particle size 
of d(0.5) was investigated. This study was performed using 
2.5% PVA solution.23 The ratio of the concentrated predisper-
sion (2.0 g of Mel+18.0 g of PVA aqueous solution) and pearl 
amount was different: 1:0.5, 1:1, 1:2, and 1:4 (w/w). It can be 
established that the pearl amount and the milling time have 
a great effect of on the d(0.5) value (Table 1). The milling 
efficiency was not satisfactory in case of ratio 1:0.5, but it 
increased linearly on increasing the amount of the milling 
media and the milling time except in case of ratio 1:4. It was 
found that the increase of the amount of the milling media 
(up to 1:2 w/w or more) causes gray coloring because of the 
high friction between the pearls and the wall of the steel jar. 
Therefore, the pearl milling amount was optimized at the 
ratio of 1:1 (20 g of concentrated predispersion and 20 g of 
pearls), and the milling time was investigated as an indepen-
dent variable in the factorial experimental design. Another 
advantage of the small amount of the grinding media may 
be the reduction of the product loss.
During the factorial experimental design, the influence 
of the milling time and the rotation speed on the particle size 
reduction was investigated. The ratio of the predispersion 
and the pearls was also 1:1 (w/w). Figure 2 shows that the 
efficiency of the particle size reduction was improved by 
increasing the milling time and the rotation speed. Based on 
the results, 437 rpm and 43 min are the optimal parameters 
of the milling process.
Optimization of PVa concentration
Influence of PVA amount on the milling effectiveness
Concentrated predispersions with different PVA amounts 
(2.5%–7.5%) were milled with optimized parameters 
(2 g of Mel+18 g of PVA aqueous solution, 20 g pearls, 
437 rpm, 43 min). The results show (Figure 3) that the lower 
Table 1 Particle size of Mel (d[0.5]) in milled dispersion as a func-
tion of different pearl amounts and milling time (d[0.5] of raw Mel 
was 34.260±4.860 µm)
 Ratio of predispersion and pearl amount (w/w)
1:0.5 1:1 1:2 1:4
Particle size (µm)
10 min 4.015±0.06 2.426±0.029 2.383±0.016 0.149±0.03
30 min 0.293±0.008 0.145±0.007 0.190±0.003 0.137±0.006
50 min 0.202±0.003 0.140±0.004 0.140±0.002 0.130±0.004
Abbreviations: Mel, meloxicam; d(0.5), the maximum particle diameter below 
which 50% of the sample volume exists; w/w, weight/weight (concentration).
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Figure 2 Three-dimensional illustration of the particle size changes during the 
second factorial experimental design.
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Figure 3 Particle size reduction effectiveness according to PVa concentrations and 
the span values for the demonstration of particle size distribution (d[0.1] values are 
not shown).
Abbreviations: PVa, poly(vinyl alcohol); span, calculated value for a broad particle 
size distribution; d(0.1), d(0.5), d(0.9), the maximum particle diameter below which 
10%, 50%, and 90% of the sample volume exists.
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concentration of PVA (from 2.5% to 3.5%) was not suitable 
to reach the nanosize range (100–500 nm). A higher concen-
tration of PVA (6.0%–6.5%) also resulted in unsatisfactory 
milling effectiveness. Over 6.5% a robust protecting layer 
was probably formed on the solid particles, and nanoniza-
tion was not possible. The curve of the Span follows the 
different particle size distribution of the samples. The best 
particle size distribution was measured in the range of 4.0% 
and 5.5% of PVA. Based on the results, the concentrated 
milled dispersion containing 5.0% of PVA was selected as 
the optimized PVA amount.
Influence of PVA amount on the physicochemical 
properties of milled dispersions
After the optimization of the wet milling process and the PVA 
amount, in order to understand the influence of the amount of 
PVA on the physicochemical properties of the samples, the 
milled dispersions with 3 different concentrations of PVA 
were investigated. These were the following: 2.5%, 5.0% 
(as optimized), and 7.5% of PVA.
Viscosity changes during the milling
In order to exclude the viscosity changes because of the high 
mechanical forces during the milling, the viscosity of 3 raw 
PVA solutions (2.5%, 5%, and 7.5%) was investigated before 
the milling process, after the process (437 rpm, 43 min), and 
after the milling in addition with Mel. The polymer solutions 
showed Newtonian flow behavior as their shear viscosity 
was independent of the applied shear rate. The viscosity of 
the polymer solutions increased with increasing the polymer 
concentration (Table 2). There were no remarkable differ-
ences between the viscosity of the polymer solution before 
and after the milling procedure, which may indicate there 
are no changes in the polymer structure. 10% Mel amount 
in the dispersions increased the viscosity of the systems and 
did not change the flow behavior – they remained Newtonian. 
Adding Mel to the polymer solutions, the smallest shift in the 
viscosity could be detected in case of the highest polymer 
concentration. This can be explained by the more consider-
able viscosity changing effect of the polymer concentration 
than that of the Mel particles. It can be concluded that the 
mechanical influence did not change the viscosity of the 
polymer solutions, and therefore, the structure of the PVA 
chains did not change.
Zeta potential changes
To determine the electrokinetic changes of the diluted dis-
persions, the zeta potential of the samples was measured. 
The results show that the increase of the PVA amount 
decreases the zeta potential in comparison to the sample 
without PVA (Table 3). The main reason for the zeta potential 
reduction can be linked to the nonionic polymer adsorption 
on the surface of the solid particles, which causes a decrease 
of the diffuse layer charge. A greater zeta potential-lowering 
effect can be observed between 0% and 0.25% of PVA than 
between 0.25% and 0.50. At 0.50% of PVA, the surface of 
particles is saturated by the PVA chain; therefore, the change 
of zeta potential is smaller. In case of a higher concentration 
of PVA (.0.50%), the steric hindrance stabilizes the system 
but hampers the disintegration/abrasion of the particles.
investigation of the diluted dispersions to select 
nanosuspension as an intermediate product
raman investigation
Raman spectrograms and chemical maps of raw materials 
and products are presented in Figures 4 and 5. The individual 
spectrum of Mel (A) shows that the absorption peaks are con-
centrated in the region from 1,600 to 1,000 cm-1 (fingerprint 
region), whereas the individual spectra of PVA (B and C) 
Table 2 Viscosity values (η) of the raw PVa solutions before 
milling (PVa %) and after milling (PVa % milled), and the PVa 
solutions after milling in addition with Mel (Mel PVa % milled)
 η, mPa*s SD ±, mPa*s
PVa 2.5% 3.14 0.02
PVa 5.0% 7.38 0.02
PVa 7.5% 20.55 0.07
PVa 2.5% milled 3.12 0.27
PVa 5.0% milled 7.09 0.02
PVa 7.5% milled 20.05 0.07
Mel PVa 2.5% milled 4.42 0.07
Mel PVa 5.0% milled 8.46 0.01
Mel PVa 7.5% milled 21.65 0.07
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol); η, viscosity.
Table 3 Zeta potential values of the diluted dispersions as a 
function of the PVa concentration and particle size distribution 
of Mel (±sD)
Samples Particle size distribution Zeta 
potential 
(mV)
d(0.1) d(0.5) d(0.9)
Particle size (µm)
Mel PVa 0% 2.508±1.100 5.762±2.700 135.640±12.900 -30.7
Mel PVa 0.25% 0.070±0.001 0.150±0.009 1.478±0.0400 -20.9
Mel PVa 0.50% 0.067±0.001 0.130±0.005 0.371±0.010 -16.1
Mel PVa 0.75% 1.235±0.006 2.611±0.018 5.560±0.070 -15.7
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol); d(0.1), d(0.5), d(0.9), the 
maximum particle diameter below which 10%, 50%, and 90% of the sample volume 
exists.
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show just 1 characteristic and extended peak from 3,000 to 
2,800 cm-1. This is the CH stretching vibration region that 
results a medium-to-strong intensity in Raman spectra. The 
spectrograms of diluted dispersions (D, E, and F) show 
the same characteristic region with the spectra of Mel – there 
are no detectable differences among them. Two peaks (one 
more characteristic in 2,437 cm-1 and another smaller one 
in 482 cm-1) appear in the spectra of PVA-containing dis-
persions and in spectra of aqueous Mel dispersion as well. 
The chemical mapping of dried dispersions profiled to this 
peak in 2,437 cm-1 shows that this peak cannot detected 
in this map. This peak can show a dissociated -OH group 
of Enol which is presented when Mel is in an aqueous 
medium, but it is disappeared in dried form, so the change 
is reversible. The chemical map of dispersion profiled to 
Mel spectrogram shows homogenous distribution of Mel. 
It can be summarized that there is no chemical degradation 
or interaction in dispersion which could be detectable with 
Raman technique.
Morphology of particles (scanning electron microscopy)
In order to investigate the effect of milling and PVA amount 
on the morphology of milled Mel, the water was evaporated 
from dispersion and the dried samples were characterized.
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Figure 4 investigation with raman spectroscopy: (A) (a) spectrum of raw Mel, (b) spectrum of raw PVa, (c) spectrum of raw PVa (0.50%) containing solution. 
(B) comparison study of raw materials (Mel and PVa) and the dispersions, (d) spectrum of dispersion containing 1% Mel and 0.25% PVa, (e) spectrum of dispersion 
containing 1% Mel and 0.50% PVa, (f) spectrum of dispersion containing 1% Mel and 0.75% PVa.
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol).
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Figure 5 investigation with raman spectroscopy: (A) comparing raw Mel and aqueous dispersion of Mel- and PVa-containing dispersions, (a) spectrum of raw Mel, 
(d) spectrum of dispersion containing 1% Mel and 0.25% PVa, (e) spectrum of dispersion containing 1% Mel and 0.50% PVa, (f) spectrum of dispersion containing 1% Mel and 
0.75% PVa, (g) spectrum of aqueous 1% Mel-containing dispersion without PVa. (B) chemical mapping of Mel-containing dispersion (1% Mel and 0.50% PVa) and chemical 
mapping of its dried form profiled to peak in 2,437 cm-1.
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol).
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Figure 6 shows the raw Mel in physical mixture (Mel 
PVA 0.50% PM) which has an irregular shape with 
34.260±4.860 µm as average particle size. In this PM, the 
PVA particles with size ,6 µm are located on the surface of 
Mel crystals. While the aqueous dispersions had a different 
amount of PVA in solution form and after drying the polymer 
formed think film in the system, therefore the dried samples 
present only the Mel particles. In case of 0.25% contain-
ing PVA (Mel PVA 0.25%), the particle size of Mel has 
decreased, but aggregation of the fragmented particles can 
be observed. Mel particles are in homogeneous disperse dis-
tribution in sample (Mel PVA 0.50%), resulting in ,500 nm 
(average particle size: 0.130±0.005 µm). High concentration 
of PVA (Mel PVA 0.75%) helped the recrystallization of 
Mel (nanocrystals with smooth surface) thanks to increased 
solubility of Mel in aqueous PVA solution. Otherwise, the 
sample shows heterogeneous disperse system with nano- and 
microparticles.
crystallinity characterization of Mel in the dried 
dispersions (Dsc and XrPD)
DSC was used to investigate the melting of raw Mel and raw 
PVA and the dried samples (Figure 7). The DSC curve of 
the raw Mel revealed a sharp endothermic peak at 268.66°C, 
reflecting its melting point and an instantly following exo-
thermic peak at 278.09°C can be observed. The DSC curve 
of raw PVA as a semi-crystalline polymer has 2 endothermic 
peaks at 169.51°C and at 222.74°C. The first peak of PVA 
signifies a particular decrystallization of PVA and the second 
peak is the melting temperature.33 The DSC curves of the 
dried products exhibited lower melting points of Mel than 
that of raw Mel. It is connected to the premelting of PVA, 
which induces the earlier melting of Mel in proportion to 
the amount of PVA and decreases the crystallinity degree of 
Mel. Therefore, the XRPD investigation was used to check 
the amorphization of the active agent.
The XRPD investigations justified the change of crystal-
linity degree of Mel in the dispersions with different PVA 
amounts. Figure 8 shows the fingerprints of raw materials 
(Mel and PVA) and the dried dispersions. The samples show 
the characteristic peaks of Mel at 2θ values: 13.06°, 14.94°, 
and 18.61°. It was found that the PVA content of the samples 
fundamentally influenced the decrease of the crystallinity 
degree of Mel. As it was established earlier in this study, 
low (2.5%) and high (7.5%) concentrations of PVA in the 
milled dispersion did not result in suitable milling efficiency. 
In this case, the crystallinity degree of Mel was 75.82% at 
low PVA content (2.5%), and it decreased to 51.44% at high 
concentration of PVA (7.5%). These results are connected 
to the milling effectiveness. In this study, the 5.0% PVA-
containing milled dispersions showed smaller crystallinity 
(13.43%) and the highest milling efficiency.
Drug content determination
The spectrophotometrically measured drug content of the sam-
ples was less than the theoretical value (7.5 mg Mel). The drug 
?????????????
????????????????????????????? ??????? ????????????????????????????? ???????
????????????????
??????????????????????????? ??????
????????????????????????????? ???????
????????????? ?????????????
Figure 6 seM pictures of physical mixture (Mel PVa 0.25% PM) and different PVa concentrations containing dried dispersions.
Abbreviations: seM, scanning electron microscopy; Mel, meloxicam; PVa, poly(vinyl alcohol); PM, physical mixture.
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contents, converted to 750 mg dispersion quantity, are 
as follows: 7.36 mg for aqueous sample (without PVA), 
7.19 mg for 0.25% PVA, 7.12 mg for 0.50% PVA, and 
7.23 mg for 0.75%. It can be stated that the washing method 
of the pearls resulted in greater loss of Mel in PVA-containing 
dispersion (3.60%–5.06%) than in case of the aqueous sample 
without PVA (1.80%). The amount of PVA did not signifi-
cantly affect the loss of weight of Mel.
in vitro dissolution study
In case of each sample, the liberation from the hard gela-
tin capsules occurred within 2 sec. Mel has a weak acidic 
character (pK
a
 4.8), and therefore, its solubility in gastric 
juice (pH=1.2) is very poor (1.6±0.2 mg/L, at 37°C). In this 
medium, the greatest dissolved amount of Mel with 0.25% 
and 0.50% PVA content was maximum, 37%, within 20 min 
(Figure 9A). This result is due to the wetting effect of PVA 
(0.25% and 0.50%), which could increase the solubility 
of Mel, and the reduction of the particle size of Mel in the 
dispersions. In contrast, a higher amount of PVA (0.75%) 
hinders the dissolution because a thicker polymer layer is 
formed on the Mel particles.
In intestinal fluid (pH=6.8), the dissolved amount was 
higher in all cases because of the better solubility of Mel 
(0.272±0.001 mg/mL, at 37°C). Figure 9B shows that the 
concentration of PVA influences the amount of dissolved 
????
????
????
? ?? ???θ?????? ?? ??
?????????????????????????????????????? ???????????????????????????????
Figure 8 XrPD diffractograms of the Mel, PVa, and the dried dispersion.
Abbreviations: XrPD, X-ray powder diffraction; Mel, meloxicam; PVa, poly(vinyl 
alcohol).
??
? ? ? ? ? ? ? ? ? ? ?? ?? ?? ?? ???
?? ?? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? °?
?????????????????????????? ???????????????????
????
?
????
Figure 7 Dsc curves of raw Mel and PVa and dried dispersions with different PVa concentrations.
Abbreviations: Dsc, differential scanning calorimetry; Mel, meloxicam; PVa, poly(vinyl alcohol).
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Mel as in the case of gastric juice, but its extent is bigger. 
In this study, the dispersion containing 0.50% of PVA had 
the most satisfying dissolution behavior from among the 
4 samples. It is followed by the dispersions containing 0.25% 
and 0.75% of PVA, and finally the dispersion without PVA. 
The results justify the need of the polymer (PVA) and the 
correct choice of its quantity.
cell viability assay
Impedance measurement, as a sensitive method to detect 
cellular effects, did not show significant cell damage after 
treatments with Mel, PVA, and Mel formulation groups, as 
reflected by unchanged cell index values (Figure 10). As a 
comparison, cells treated with the detergent Triton X-100 
were lysed and a 100% toxicity was measured. The curves 
show the kinetics of the cellular effects of treatment solu-
tions (Figure 10A), whereas the columns show the effect 
of Mel, PVA and Mel formulations at the 8-h time point 
(Figure 10B).
Permeability study on intestinal barrier model
Caco-2 monolayers showed high TEER values (2,660±181 
Ω×cm2, n=20) before permeability experiments, indicating 
tight barrier properties. The average apparent permeability 
coefficients of marker molecules were also low (fluores-
cein: 0.81±0.13×10-6 cm/s; albumin: 0.08±0.03×10-6 cm/s), 
??
??
??
??
??
??
??
?
??
?
???
????
????
?????
?
? ?? ?? ???? ??????? ?? ?? ??
?????????????????????????????????????????????
? ? ??
?
???
????
????
?????
?
?? ???? ??????? ?? ?? ??
?????? ????????? ????????? ?????????
? ?
Figure 9 In vitro dissolution curves of Mel in artificial gastric juice (A) and intestinal juice (B).
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol).
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Figure 10 cell viability kinetics (A) and results 8 h after treatment (B) in caco-2 intestinal epithelial cells with Mel, PVa, and formulations measured by impedance.
Notes: Values are presented as mean±sD, n=6–12. Statistical analysis: ANOVA followed by Dunett’s test. Statistically significant differences are: *p,0.05, compared to 
control group.
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol); TX-100, Triton X-100; anOVa, analysis of variance.
Drug Design, Development and Therapy 2018:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
12
Bartos et al
in agreement with the TEER values and the formation of 
tight cell layers.
The permeability of Mel suspension and Mel formulations 
was significantly higher than that of marker molecules. The 
penetration of Mel from the 3 investigated products across 
cell layers was significantly increased as compared to Mel 
suspension. From all the tested samples, the P
app
 value of 
Mel was the highest in the formulation containing 0.05% 
PVA (Figure 11).
holding time determination
Since the investigated dispersions are intermediate products, 
the change of particle size distribution and the crystallinity 
index are very important during storage. In general, the time 
period before the dispersion used for the preparation of differ-
ent dosage forms is 1 or 2 h, or possibly longer. The measure-
ments have proven that 0.50% of PVA-containing dispersion 
had no significant changes in the particle size, particle 
size distribution, and crystallinity up to 2 weeks (Table 4).
Conclusion
Based on our results, it can be stated that the combination 
of planetary ball mill and the pearl milling technology is 
a new possibility to nanonize the Mel as a nonsteroidal 
anti-inflammatory agent to reach the particle size range of 
100–500 nm. This combinative wet technology resulted 
in significant particle size reduction without premilling 
(pretreatment of raw agent). In addition to the process 
parameters (the pearl amount, the milling time, and the 
rotation speed of jar), the amount of PVA was also a critical 
parameter because it affected the milling effectiveness, the 
particle size distribution, and the crystallinity of Mel. The 
different concentrations of PVA in the aqueous dispersion 
also influenced the viscosity and the electrokinetic property 
of the particle, according the DLVO theory,34 and thus, the 
stability of the dispersions.
It was found that the milling effectiveness of low con-
centration of PVA (,4%) was not satisfactory, because the 
crushing/breaking effect of the pearls could less prevail. High 
concentration of PVA (.5%) also resulted in unsatisfactory 
milling effectiveness because of the formation of polymer 
layer on surface of particles, which protects the particles from 
the fragmentation. In connection with this, the crystallinity 
of Mel decreased with the increase of milling effectiveness, 
which plays an important role in the fast drug release.
In this work, the combined wet milling process was also 
used successfully to prepare Mel-containing nanosuspen-
sion as an intermediate product to design the final dosage 
form(s) for per oral administration. The optimized process 
parameters (1:1 ratio of predispersion and pearls, 437 rpm, 
and 43 min) resulted in 200-fold particle size reduction 
of Mel. Considering the effectiveness of milling, 5% PVA 
was proved to be an optimal quantity to meet the expected 
value (100–500 nm). The optimized nanosuspension (1% 
Mel and 0.50% PVA) as an intermediate product showed a 
stable system with 2 weeks of holding time.
The human Caco-2 cell culture studies justified that the 
penetration of Mel from different PVA-containing products 
was significantly increased as compared to Mel suspension 
without toxic effects. From all the tested samples, the P
app
 
value of Mel was the highest in the investigated sample 
containing 0.05% PVA, which belongs to the optimized 
nanosuspension.
Based on the above results, the milling process and the 
composition of the nanosuspension can be recommended 
to produce innovative dosage forms (eg, capsule) with fast 
dissolution rate of Mel. During the development of dosage 
form(s), the stabilization of the amorphous Mel particle may 
Table 4 Particle size distribution changes (µm) during the stability 
testing
 Day 0 2 weeks
d(0.1) d(0.5) d(0.9) d(0.1) d(0.5) d(0.9)
Mel PVa 0.25% 0.070 0.150 1.478 0.080 0.152 2.073
Mel PVa 0.50% 0.067 0.136 0.371 0.068 0.140 0.427
Mel PVa 0.75% 1.207 2.232 5.224 0.244 2.611 5.560
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol); d(0.1), d(0.5), d(0.9), 
the maximum particle diameter below which 10%, 50%, and 90% of the sample 
volume exists.
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Figure 11 evaluation of permeability of Mel across caco-2 epithelial cell layers 
treated with Mel and optimized Mel PVa formulations for 1 h.
Notes: Values are presented as mean±sD, n=4. statistical analysis: anOVa followed 
by Bonferroni posttest. Statistically significant differences are: ***p,0.01, compared 
to control group; ###p,0.01 compared to the indicated columns.
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol); Papp, apparent permeability 
coefficients.
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also be an important viewpoint to ensure the dissolution 
profile of the active ingredient.
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Abstract
The aim of this work was to discover the robustness of combined wet milling process to determine the interval of the Mel
(meloxicam) amount and to predict the degree of crystallinity of the milled samples using DSC and XRPD measurements.
The samples had the poly(vinyl alcohol) (PVA) as the stabilizing agent. By increasing the amount of the Mel, its
crystallinity increased and close correlation was found between the degree of crystallinity and the Mel amount. To achieve
the desired particle size range (100–500 nm), the Mel amount should be changed between 10.0 and 17.5% (w/w) and a
PVA concentration should be used between 5.0 and 4.58% (w/w). In this specified range, the degree of crystallinity of Mel
will be changed between 20 and 45%. The crystallinity of Mel investigated by DSC and XRPD did not show any significant
difference at 95% significance level. During the milling process to predict the amorphous content of the active agent, the
DSC method can be suggested for the fast quantification of the degree of crystallinity.
Keywords Crystallinity  Meloxicam  Nanoparticles  Poly(vinyl alcohol)  Wet milling
Introduction
Dry and wet milling technologies as disintegration methods
are conventionally and commonly used in the pharmaceu-
tical industry [1, 2]. Drugs which belong to Class II of BCS
(Biopharmaceutical Classification System) have low water
solubility and high permeability; therefore, their bioavail-
ability can increase with the decrease in particle size to the
nanosize range, resulting in a high specific surface and a
fast dissolution rate. During milling, amorphization of
active agent can occur due to the high energy impact [3, 4].
Amorphization is also a well-known possibility to enhance
the dissolution rate of drugs with low water solubility. Due
to the lack of crystalline structure and the crystal lattice
breaking force, less energy is needed for solubilization.
Nevertheless, additional stabilization is needed for the
preservation of the amorphous form from recrystallization
[5–7].
Our main research topic is the nanonization of different
active agents using a wet milling process, where the
planetary ball mill is combined with pearl milling tech-
nology [8, 9]. In our previous research to reach a
nanoparticle size range (100–500 nm), the process
parameters (milling time, rotation speed, amount of pearl
and the ratio of drug to excipient) were optimized. The
samples were produced with the addition of the aqueous
solution of poly(vinyl alcohol) (PVA) as the stabilizing
agent. The main purpose of this work was to increase the
dissolution rate and extent of poorly water-soluble
meloxicam (Mel) as a nonsteroidal anti-inflammatory drug.
In this system, the Mel amount was 10% (w/w) and 5% (w/
w) of PVA proved to be an optimal quantity to meet the
expected particle size range. During the milling, a high
level of amorphization was detected with DSC and XRPD
examinations [10]. In this milling system, the ratio of the
started pre-suspension and pearls 1:1 (w/w) resulted in
about 200-fold particle size reduction in one step. In con-
nection with this result, questions arose: (1) whether the
amount of the active ingredient has a milling effect and (2)
whether the particle size distribution and the degree of
crystallinity can be designed by varying the amount of the
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active ingredient. These questions are important for the
robustness of the process and the extent of scale-up [11].
Based on the above, the aim of the present work was to
discover the robustness of our optimized combined wet
milling process to determine the interval of the Mel amount
which can be successfully nanonized (100–500 nm) and in
this connection to predict the crystallinity degree of the
milled samples using DSC as a fast analyzing method and
to verify it with XRPD measurements.
Experimental
Materials
Meloxicam (raw Mel) was obtained from EGIS Ltd. (Bu-
dapest, Hungary). PVA-Mowiol 4-98 (Mw * 27,000)
(Sigma-Aldrich Co. LLC, St Louis, MO, USA) was used as
a stabilizing agent. Zirconium oxide (ZrO2) beds with a
diameter of 0.3 mm were obtained from Netzsch (Netzsch
GmbH, Selb, Germany). All reagents were purchased from
Sigma-Aldrich Ltd. (Budapest, Hungary).
Design of the sample series
Eight samples were prepared from 2.5 to 20.0% of Mel
with 2.5% increment per sample. As the stabilizing agent,
5.0% of PVA aqueous solution as initial concentration was
added up to 20.0 g to each sample, which was selected on
the basis of our previous experiments [10]. Thus, the PVA
concentration with 0.14% increment per sample was
between 4.44 and 5.42%. The Mel and PVA concentrations
of the samples are shown in Table 1. For the DSC and
XRPD investigations, the samples were desiccated in a
vacuum desiccator at 40 C to constant mass.
Combined wet media milling
The samples were ball-milled in a 50-mL steel jar (Retsch
PM 100 MA, Retsch GmbH, Haan, Germany) with 0.3-mm
ZrO2 beads as the grinding media. The process parameters
optimized in our pervious work were as follows: 437 rpm,
43 min and 20 g of milling media which was used for
every process (dispersion to grinding media ratio 1:1) [10].
The temperature of the samples, measured immediately
after milling, did not exceed 39 C.
Particle size measurement
The volume-based particle size distribution was measured by
laser diffraction (Mastersizer S 2000, Malvern Instruments
Ltd., Worcestershire, UK). The refractive index for Mel was
1.596. Water was used as a dispersant with a refractive index
of 1.330. In all cases, the particle size distributions were
characterized by d(0.1), d(0.5) and d(0.9) (where, for
example, d(0.5) is the maximum particle diameter below
which 50% of the sample volume exists). Span values were
calculated according to Eq. 1. A high span value ([1)
denotes a broad particle size distribution [12].
Span ¼ dð0:9Þ  dð0:1Þ
dð0:5Þ : ð1Þ
Differential scanning calorimetry
Differential scanning calorimetry (DSC) was performed
with a Mettler–Toledo DSC 821e (Mettler–Toledo GmbH,
Switzerland) instrument. DSC curves were evaluated with
STARe Software. The starting and final temperatures were
25 C and 300 C with 10 C min-1 heating rate. Argon
atmosphere of 100 mL min-1 was used in all cases as an
inert gas. Eight physical mixtures equal to the treated
samples were examined as a reference scale. The calcula-
tions of Mel crystallinity (Cryst%) were performed using
the total area under the curve (AUC) of the melting
enthalpy of the milled samples (AUCMelM) and the
physical mixtures (AUCMelPM). The values were com-
pared using Eq. 2:
Cryst% ¼ AUCMelM
AUCMelPM
 100: ð2Þ
Thermogravimetric analysis—water content
determination
To monitor the water content of the sample after desicca-
tion, TG measurements were performed. The water content
determination was conducted based on the mass loss of the
sample during heating in the interval of 25–120 C.
Table 1 Mel and PVA concentrations in the samples
Sample name Mel%/w/w PVA%/w/w
Mel_0.5 g 2.50 5.42
Mel_1.0 g 5.00 5.28
Mel_1.5 g 7.50 5.14
Mel_2.0ga 10.00 5.00
Mel_2.5 g 12.50 4.86
Mel_3.0 g 15.00 4.72
Mel_3.5 g 17.50 4.58
Mel_4.0 g 20.00 4.44
aOptimized sample
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Thermogravimetric analysis was carried out with a Met-
tler–Toledo TGA/DSC1 (Mettler–Toledo GmbH, Switzer-
land) instrument. Curves were evaluated with STARe
Software. The starting and final temperatures were 25 C
and 300 C with 10 C min-1 heating rate. Sample mass
varied between 10 and 12 mg.
X-ray powder diffractometry (XRPD)
The X-ray powder diffraction patterns (XRPDs) were
obtained with Bruker D8 Advance (Bruker AXS, Germany)
equipped with a Sycos H-Hot (Ansyco GmbH, Karlsruhe,
Germany) programmable plate holder. Results were
detected with a Va˚ntec-1 detector. The patterns were
recorded at a tube voltage of 40 kV and tube current of
40 mA, applying a step size of 0.01 A˚ 2 h in the angular
range of 3–40 A˚ 2 h. Eight physical mixtures equal to the
treated samples were examined as a reference scale. The
determination of Mel crystallinity (Cryst%) was also per-
formed using the total area under the curve (AUC) of three
characteristic peaks (13.06, 14.94 and 18.61 2H) of the
milled samples and the physical mixtures. The calculation
was the same as in the case of DSC measurements.
Results and discussion
Particle size measurements
Using the optimized process parameters, based on the
change in the amount of Mel, the particle size distribution
is one of the critical parameters. In this respect, the com-
parison is based on the particle size of the optimized
sample ‘‘Mel_2.0 g’’, which had 10% of MEL and 5% of
PVA (Table 2).
After milling, the different Mel amounts containing
nanosuspensions showed same d(0.5) value, which means
that the maximum particle diameter of 50% of the sample
volume is less than 150 nm. By contrast, the d(0.9) values,
in the case of smaller and higher amounts of Mel, were
already outside the upper range of the desired value
(500 nm). It can be assumed that the smaller amount of
Mel (\ 10%) decreased the number of successful collisions
of Mel and the milling media. The larger amount of Mel
([ 17.5%), however, increased the density of the sample
and reduced milling efficiency. Span values, which contain
the d(0.1) values, confirm the suitability of particle size
distribution in the range of 10% (Mel_2.0 g) and 17.5% of
Mel (Mel_3.5 g).
TG measurements
PVA is a hygroscopic agent; therefore, its residual water
content was controlled. This is a semicrystalline polymer
with a well-defined glass transition temperature at
45–50 C in the case of less than 1.5% water content.
Higher water content of PVA can drastically decrease the
glass transition temperature (up to 20 C), which can
influence the thermal behavior of PVA-containing com-
positions [13]. Mel has a hydrophobic character; its water
content is less than 0.01%. TG curves between 25 and
160 C showed fast and then slow mass loss, which is
connected to the PVA amount. The samples with smaller
Mel and higher PVA concentration showed more water
content. It can be stated that the polymer amount has a
significant role in the residual water content of the samples
and, consequently, the glass transition temperature (Fig. 1).
DSC analysis
For the crystallinity characterization of Mel, first raw Mel
and PVA were investigated (Fig. 2). The DSC curve of raw
Mel has a sharp characteristic melting peak at 268.66 C
(onset 266.83, endset 273.27 C), and an instantly fol-
lowing exothermic peak can be observed at 279.09 C.
PVA has two endothermic peaks at 169.51 C andTable 2 Results of the particle size measurements
Sample name d(0.5)/lm d(0.9)/lm Span
Mel_raw 34.26 ± 4.86 73.59 ± 27.11 1.815
Mel_0.5 g 0.138 ± 0.027 1.273 ± 0.134 8.662
Mel_1.0 g 0.142 ± 0.023 1.949 ± 0.117 10.207
Mel_1.5 g 0.141 ± 0.018 0.87 ± 0.076 5.676
Mel_2.0ga 0.136 ± 0.003 0.371 ± 0.043 2.240
Mel_2.5 g 0.139 ± 0.006 0.413 ± 0.037 2.655
Mel_3.0 g 0.145 ± 0.008 0.436 ± 0.045 2.956
Mel_3.5 g 0.141 ± 0.013 0.448 ± 0.050 2.700
Mel_4.0 g 0.140 ± 0.021 0.974 ± 0.072 6.448
aOptimized sample
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Fig. 1 Water content of the milled samples
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222.74 C. Since PVA is a mixture of crystalline and
amorphous fractions, it is assumed that the first endothermic
peak shows a structural change in part of the crystalline
fraction and the second one presents the melting point of
PVA. It should be noted that PVA has deacetylation in the
temperature range 160–400 C and the total degradation
corresponds to the degradation of vinyl acetate and
vinylpyrrolidone at 396 C and 484 C, respectively [14].
The DSC curves of the samples exhibit that the increase
in the Mel amount ([10.0%) results in a sharper
endothermic peak, approaching the melting point of raw
Mel. In accordance with this, the signs of PVA are weak-
ened, which can be associated with its reduced amount
(\ 5.0%). By decreasing the Mel amount (\ 10.0%), the
endothermic peaks will be less sharp and the signs of PVA
are strengthened. It is connected to the higher amount of
PVA ([5.0%). The areas of the melting enthalpies already
predict the change in the degree of crystallinity of Mel.
In order to determine the degree of crystallinity of Mel,
taking into account the influence of PVA, the physical
mixtures of the milled samples formed the basis.
Figure 3 presents the degree of crystallinity measured
by DSC as a function of the Mel amount in the sample. By
increasing the Mel amount, the crystallinity of the milled
products was increased. A close correlation (R2 = 0.9587)
was found between crystallinity and the Mel amount. It can
be seen that increasing the amount of Mel ([ 10%) sig-
nificantly increased the degree of crystallinity of the milled
sample (from 21.21 to 48.86%). However, the small
amount of Mel lowered this value (from 21.21 to 10.28).
XRPD measurements
To verify the DSC results, the crystallinity of the physical
mixtures and the milled samples was investigated by XRPD
analysis. Figure 4 presents the fingerprints of raw Mel and
PVA and the milled samples. The characteristic peaks of
Mel are at 2H value: 13.06, 14.94 and 18.61, and PVA
has the typical diffraction peak at 2H value: 19.9 [15].
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The intensity of the characteristic peaks shows a change
in the crystallinity of the milled products. The quantitative
analysis of the degree of crystallinity also resulted in a
close correlation (R2 = 0.9763) between the degree of
crystallinity and the Mel amount (Fig. 5).
Conclusions
In this work, the interval of the Mel amount which can be
successfully nanonized (100–500 nm) was determined by
the optimized wet milling process, where the planetary ball
mill was combined with pearl milling technology. To dis-
cover the robustness of the optimized process, the influence
of the amount of Mel was investigated on the particle size
distribution and the degree of crystallinity.
The comparison was based on the 10% of Mel (w/w)
and 5% of PVA (w/w) containing sample (Mel_2.0 g)
milled by using the following process parameters: 1:1 ratio
of pre-suspension and pearls, 437 rpm and 43 min. The
milled sample resulted in the expected particle size range,
and the degree of crystallinity of Mel was decreased to
20%.
Based on our current results, it can be stated that the
increase in the Mel amount ([ 10%) helped milling effi-
ciency without increasing the amount of milling media
(pearls), and the smaller concentration of Mel (\10%) did
not provide the desired particle size distribution. In the first
case, the invested mechanical energy was transferred to
reduce the particle size, while in the second case to break
the crystal structure.
The presence of PVA also affected the degree of particle
size reduction. It was found that the milling effectiveness
of a lower concentration of PVA (\ 5.0%) provided suf-
ficient protective effect against the aggregation of
nanoparticles in the case of samples with 10.0–17.5% of
Mel concentration. This protective effect was not satis-
factory (aggregation was observed) for higher Mel content
(20.0%) and lower PVA concentration (4.44%). A high
concentration of PVA ([5%) also resulted in unsatisfactory
milling effectiveness because a polymer layer was formed
on the surface of the particles, protecting them from
fragmentation.
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The degree of crystallinity was basically influenced by
the Mel amount, but the PVA content also affected it. By
increasing the Mel amount, the crystallinity of the milled
product was increased measured by the DSC and XRPD
techniques and a close correlation was found between
crystallinity and the Mel amount by both of them.
It should be noted that recently the characterization of
the investigated materials (e.g., crystallinity) using DSC as
a semiquantitative conventional method has become com-
mon in scientific research [7–9]. It provides a possibility to
predict the crystallinity of the examined materials, but to
verify the accuracy of thermoanalytical measurements, the
X-ray powder diffraction test is required [10, 11]. In our
work, it was found that the degree of crystallinity of Mel
investigated by DSC and XRPD did not show any signifi-
cant difference at 95% significance level. It can be related
to the low degree of crystallinity (\ 50%). It is known that
the advantage of DSC over X-ray diffraction is that high
amorphous content can be detected [16].
In this system, for the required particle size range, the
Mel amount should be changed between 10.0 and 17.5%
(w/w) and a PVA amount should be used between 5.0 and
4.58% (w/w). For product stability, it is recommended to
keep the PVA amount below 5.0% and at the same time the
critical water content below 1.5%. In this specified range,
the amount of Mel can be changed to design the degree of
crystallinity of Mel between 20 and 45% in the final pro-
duct as well.
To discover the robustness of the milling process, it
should also be considered that the amount of grinding
media can be reduced by increasing the amount of the
active ingredient. It is an important viewpoint because of
the reduction in product loss (removing pearls). The DSC
method can be suggested for the quantification of the
degree of crystallinity because it can be used safely with
high amorphous content.
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Purpose: The aim of this work was to study the influence of solidification of meloxicam (Mel) 2 
containing nanosuspension (nanoMel) on the physical stability and drug bioavailability of the 3 
products. The nanoMel sample had poly(vinyl alcohol) (PVA) as a protective polymer, but no 4 
surfactant as a further stabilizing agent because the final aim was to produce a surfactant-free 5 
solid phase products as well. 6 
Methods: The solidified samples produced by fluidization and lyophilization (fluidMel, lyoMel) 7 
were examined for particle size, crystallinity, and in vitro release of Mel compared to similar 8 
parameters of nanoMel. The products were subjected to an animal experiment using per oral 9 
administration to verify their bioavailability. 10 
Results: Mel containing (1%) nanoMel sample was produced by wet milling process using 11 
optimized amount of PVA (0.5%) which resulted in 130 nm as mean particle size and a significant 12 
reduction in the degree of crystallinity (13.43%) of Mel. The fluidization technique using 13 
microcrystalline cellulose (MCC) as carrier resulted a quick conversion no significant change in 14 
the critical product parameters. Process of lyophilization required a longer operation time, which 15 
resulted in the amorphization of the crystalline carrier (trehalose) and the recrystallization of Mel 16 
increased its particle size and crystallinity. The fluidMel and lyoMel samples had nearly five-fold 17 
higher relative bioavailability than nanoMel application by oral administration. The correlation 18 
between in vitro and in vivo studies showed that the fixed Mel nanoparticles on the surface of 19 
solid carriers (MCC, trehalose) in both the artificial gastric juice and the stomach of the animals 20 
rapidly reached saturation concentration leading to faster dissolution and rapid absorption. 21 
Conclusion: TThe solidification of the nanosuspension not only increased the stability of the Mel 22 
nanoparticles, but also allowed the preparation of surfactant-free compositions with excellent 23 
bioavailability which may be an important consideration for certain groups of patients to achieve 24 
rapid analgesia.  25 
Keywords: solidification, fluidization, lyophilization, surfactant-free product, rapid drug 26 
absorption, IVIV correlation 27 
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Introduction 1 
Nanosuspensions can be defined as colloidal dispersions of nanosized drug particles (< 500 nm) 2 
that are produced by different nanonization processes and stabilized by various excipients.1 3 
Nanonization of drugs with different top-down methods (wet-bead milling, high-pressure 4 
homogenization and microfluidization) is a proven effective strategy to decrease the particle size 5 
by mechanical processes and to enhance the dissolution rate, saturation solubility and 6 
bioavailability of poorly water-soluble active ingredients, such as BCS class II (poorly soluble and 7 
high permeable) and Class IV (poorly soluble and permeable).2,3 Nanosuspensions produced by 8 
milling are generally unstable, therefore stabilizing agents (polymers, surfactants) and its 9 
transformation to the  solid state have an important role in the formulations with long-term 10 
stability.4,5 Water-soluble polymers, such as 2.4 -19.6 % of cellulose ethers,6 30 % of poly(vinyl 11 
pyrrolidone),7,8 and 50 % of poly(vinyl alcohol)9, 10 , are mainly used in wet milling.The most 12 
commonly used surfactants and their amount in relation to the amount of active ingredient are as 13 
follows: CremophorR (100%),11 Poloxamer 188 (60%),12 Poloxamine 908 (20%),13 Tyloxapol (20 14 
%),14 sodium lauryl sulfate (0.15%),15  and Polysorbate 80 (1%).16,17 In the absence of stabilizers, 15 
the high surface energy of nanosized drug particles can induce aggregation/agglomeration in the 16 
system.18 The main functions of a stabilizers in nanosuspensions are to wet drug particles during 17 
the milling process, and to prevent Ostwald’s ripening (crystal growth in colloidal suspensions)19 18 
and agglomeration in order to yield a physically stable formulation by providing steric or ionic 19 
barriers. Different concentrations of stabilizer agents (e.g. polymers) can also influence the 20 
viscosity and the electro-kinetic property of the particles, according to the DLVO theory,20 and 21 
thus the stability of the nanosuspension as well. Surfactants help to wet the particles and thus 22 
reduce their aggregation tendency. In addition to the advantages of surfactants, they have the 23 
biggest disadvantage of increasing the speed/energy of motion of the milling balls during wet 24 
milling, which can lead to the degradation of the active ingredient. When used as an external 25 
surfactant to solidify the nanosuspension, its solubility-enhancing effect may be emphasized, 26 
thereby increasing the degree of crystallinity of active agent in the solid product and reducing its 27 
dissolution rate.21 Conventional formulations contain these excipients in common, but the new 28 
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tendency is to ignore the surfactants and look for other options to stabilize the nanoparticles in 1 
the products and achieve the desired biological effect.22-24 2 
Crystalline state is one of the most important parameters affecting drug stability, 3 
dissolution extent, and efficacy. The high energy wet milling techniques tend to create a partially 4 
amorphous active agent. The high energy amorphous particles are unstable, especially in the 5 
presence of crystalline particles, and inclined to convert to low energy crystalline state over time. 6 
The saturation solubility between amorphous and crystalline nanoparticles is different, therefore 7 
the diffusion process will be similar to Oswald’s ripening, leading to a rapid conversion of 8 
amorphous nanoparticles to crystalline state.25 9 
Of course, the nanosuspensions can be applied as final liquid dosage forms using further 10 
different excipients (viscosity enhancer, flavoring, preservative agents, etc.), however, their 11 
stabilization is a major challenge.26 It is well known that, despite the stabilization, 12 
nanosuspensions have a short expiration time, and there are patients who do not prefer this form 13 
or the presence of a surfactant. One way to overcome the instability and surfactant problem is to 14 
design solid nanosuspension produced by spray drying, spray freeze drying and freeze drying 15 
(lyophilization). It is well known that the dry nanosuspensions can cause difficulty in hydration and 16 
redispersibility24,27.  ,Other processes for transforming a nanosuspension into a solid-state forms 17 
(tablets, capsules) are very different: deposition as coatings, incorporation in granules and pellets  18 
and the 3D printing technologies.28  19 
Spray drying and lyophilization (freeze drying) are the commonly used techniques for the 20 
solidification of nanosuspension because of their easy application and industrial acceptability.29 21 
The powders produced by these processes often suffer from poor flowability and high 22 
hygroscopicity, therefore other technologies are applied to transform nanosuspensions into oral 23 
dosage forms as tablets and capsules.30 24 
Layering of nanosuspension onto the surface of granules, pellets, sugar beads, etc. using 25 
a fluidization technique is used as an alternative method for solidification of nanosuspension.30-32 26 
The advantage of this process that may be used various additives in order to achieve the desired 27 
purpose, e.g. i) different polymers stabilize the nanosuspension, and act as a coating materials 28 
resulted in fast dissolution rate, ii) surfactants prevent the aggregation of nanoparticle and can 29 
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modify the drug release.33  In any case, the fluidization technique also provides an opportunity to 1 
stabilize the broken structure of the ground crystals in the nanosuspension by using crystallization 2 
inhibitors.34 3 
Mel, a member of the oxicam family of NSAIDs (non-steroidal anti-inflammatory drugs), 4 
as a moderately selective cyclooxygenase (COX-2) inhibitor can have a role in acute pain therapy 5 
but a basic requirement is rapid absorption through the gastric mucosa. Mel has a weak acidic 6 
character with pKa of 3.43, therefore its solubility in gastric juice (pH=1.2) is very poor but its 7 
logPapp is 2.43 (pH=2.0), which predestines the fast absorption from the stomach.35-37 Since the 8 
solubility of Mel is very poor in gastric juice, the preparation of a nanosuspension with a fast 9 
dissolution rate may be a solution. 10 
 In our previous work we developed a wet milling procedure for the nanonization of Mel, 11 
which was reported in the DDDT in 2018.10 We optimized the critical process parameters by 12 
factorial design (ratio of predispersion and pearls, milling time and rotation speed of the steel jar) 13 
and investigated the PVA amount on the particle size distribution and crystallinity of the Mel. The 14 
optimized process parameters and PVA amount have allowed the use of no surfactant during 15 
milling to prevent aggregation. We had also the surfactant free nanosuspension as intermediate 16 
product showed a stable system for critical product parameters with 2 weeks of holding time. 17 
 18 
The main purpose of the work was to produce a surfactant-free product by solidifying of 19 
Mel containing nanosuspension. Critical product parameters were considered to be the particle 20 
size distribution of the drug (d(0.9) < 500 nm), stabilization of the degree of crystallinity altered 21 
during milling, and enhancement of the bioavailability of the solid product with fast absorption 22 
from the stomach for rapid analgesia. The transformation of the nanosuspension was done by 23 
fluidization and lyophilization. 24 
 25 
 26 
Materials and Methods  27 
Materials 28 
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Mel (rawMel) was obtained from EGIS Ltd. (Budapest, Hungary). PVA-MowiolR 4-98 (Mw ~ 1 
27,000) (Sigma Aldrich Co. LLC, St. Louis MO, USA) was used as a stabilizing agent. Zirconium 2 
oxide (ZrO2) beds with a diameter of 0.30 mm were obtained from Netsch (Netsch GmbH, Selb, 3 
Germany). Microcrystalline cellulose (MCC) (AvicelR PH 101, FMC Biopolymer, Philadelphia 4 
USA) was used as a carrier material for the fluidized product. D-(+)-trehalose dihydrate as a cake-5 
forming agent was purchased from Karl Roth GmbH + Co. KG. (Karlsruhe, Germany). 6 
 7 
Methods 8 
Preparation of nanosuspension (nanoMel) 9 
For the production of the Mel nanosuspension, a planetary ball mill was combined with pearl 10 
milling technology. PVA was used as a stabilizing additive, 1.0 g of PVA was dissolved in 17.0 g 11 
of distilled water as a dispersant medium, in which 2.0 g of Mel was suspended. The milling was 12 
executed using a Retsch PM 100 planetary ball mill (Retsch GmbH, Haan, Germany) at 437 rpm 13 
rotation speed for 43 min in addition with 20.0 g of 0.3 mm ZrO2 beads as a milling medium. After 14 
the milling process, to eliminate the grinding medium from the sample, a 0.150-mm sieve was 15 
used. The nanosuspension was removed from the beads by cleaning with distilled water, while 16 
the milled sample was ten-fold diluted. The yield of the milling process was 94.93%. The final 17 
concentration of the components can be seen in Table 1. 18 
Table 1 Composition of the investigated samples 19 
Sample Mel 
(%) 
PVA 
(%) 
Water 
(%) 
MCC 
(%) 
Trehalose 
(%) 
nanoMel 1.00 0.50 98.50 - - 
fluidMela 1.94 0.97 - 97.09 - 
lyoMelb 15.38 7.70 - - 76.92 
Notes: a,bbased on dry material 20 
Abbreviations: Mel, meloxicam; PVA, poly(vinyl alcohol); MCC, microcrystalline cellulose  21 
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Transformation of nanosuspension into solid state form 1 
In preformulation study, surfactant-free and external surfactant-containing (Polysorbate 80) 2 
samples were produced by fluidization to study the critical parameters of the products. It was 3 
found that the external surfactant used to solidify the nanosuspension (nanoMel) increased the 4 
degree of crystallinity and decreased the dissolution rate of Mel. This change is related to the 5 
solubility-enhancing effect of the surfactant. It was concluded that, in the absence of surfactant, 6 
the critical product parameters can be fulfilled by optimization of process parameters of fluidization 7 
and lyophilization.  8 
 9 
Fluidization (fluidMel) 10 
MCC as the carrier material was used in a Strea-1 (Niro Aeromatic, Bubendorf, Switzerland) fluid 11 
bed chamber. A batch size of 100.0 g was used. The powder was inserted and fluidized in the 12 
preheated chamber for a period of 10 min and at constant air velocity of 2.5 m/s. NanoMel as 13 
liquid dispersion was transported by a peristaltic pump (Roto Consulta, Ebikon/Luzern, Schweiz), 14 
the applied pump speed was 9 rpm. One batch of 200.0 g of nanoMel dispersion was atomized 15 
onto the surface of the material. The process took 50 minutes, the inlet temperature was 55 °C 16 
and the outlet temperature was 38 °C. The final concentration of the components in percentage 17 
is shown in Table 1. The yield of the process was calculated based on the proportion of the mass 18 
of the components before and after operation. 19 
 20 
Lyophilization (lyoMel) 21 
Freeze-drying was performed in Scanvac CoolSafe 100-9 Pro type equipment (LaboGene ApS, 22 
Lynge, Denmark) equipped with a 3-shelf sample holder unit, recessed into the drying chamber. 23 
In each cuvette 750 mg of diluted milled suspension was filled (7.5 mg Mel content in every 24 
cuvette, the unit dose of Mel). As a cake-forming additive, 37.5mg of (5.0%) trehalose was 25 
dissolved in the nanosuspensions. The components of the final product can be seen in Table 1. 26 
The process was controlled by a computer program (Scanlaf CTS16a02), the temperature and 27 
pressure values were recorded continuously. The whole process took 71 hours and 52 minutes. 28 
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The initial temperature was 25 °C. During the freezing period, after 18 hours and 34 minutes, the 1 
sample temperature was decreased to -40 °C. The subsequent drying process was conducted at 2 
0.013 mbar air pressure for 50 hours and 50 minutes, the temperature increased from -40 °C to -3 
7 °C. Finally, the secondary drying session took 2 hours and 28 minutes. The final temperature 4 
of the dried products was 30 °C. 5 
 6 
Characterization of nanosuspension and the solid state forms 7 
Particle size measurements 8 
The investigations on the particle size of rawMel el and nanoMel via laser diffraction were 9 
executed (Malvern Mastersizer S 2000, Malvern Instruments Ltd, Worcestershire, UK) with the 10 
following parameters: 300RF lens; small volume dispersion unit (1,000 rpm); refractive index for 11 
Mel: 1.596; and refractive index for dispersion medium: 1.330. During the measurements, distilled 12 
water was used as a dispersant, and obscuration was in the range of 11%–16% for all 13 
measurements. In both cases, the particle size distributions were qualified by d(0.1), d(0.5), and 14 
d(0.9) (d(0.5) is the particle diameter below which 50% of the sample volume exists). 15 
In the case of the solid state products (fluidMel and lyoMel), the particle size of Mel was 16 
determined by using Scanning Electron Microscopy (SEM) images (Hitachi S4700, Hitachi 17 
Scientific Ltd., Tokyo, Japan). The size of the particles was calculated by ImageJ software for 18 
Windows (Phase GmbH, Lübeck, Germany).38 By specifying the unit length, which is shown in 19 
each image (depending on the magnification this is a different value), the actual particle size can 20 
easily be determined by drawing the diameter of the captured particles. A diameter of a hundred 21 
captured particles was determined in the case of two solid state samples. 22 
For nanoMel and lyoMel samples, the Z-average particle size and the polydispersity index (PDI) 23 
of Mel were measured using a Malvern Zeta Nano ZS (Malvern Instruments Ltd). In case of the 24 
particle size determination, Malvern DTS 1070 folded capillary cell was used. The samples were 25 
further diluted with water (25-fold) for the measurements. 26 
 27 
Morphology of the samples (SEM) 28 
9 
 
For SEM investigations, nanoMel samples was dried in a vacuum dryer (Binder GmbH, Tuttlingen, 1 
Germany) at 40 °C in order to obtain solid products and fluidMel and lyoMel were visualized as 2 
well. The samples were sputter-coated with gold–palladium under an argon atmosphere, using a 3 
gold sputter module in a high-vacuum evaporator, and the samples were examined at 10 kV and 4 
10 mA. The air pressure was 1.3–13 MPa. 5 
 6 
Differential scanning calorimetry (DSC) 7 
To investigate the occurring physico-chemical changes and to predict the crystallinity of the solid 8 
state products, DSC measurements were carried out with a Mettler Toledo DSC 821e thermal 9 
analysis system with the STARe thermal analysis software V9.0 (Mettler Inc. Schwerzenbach, 10 
Switzerland). Approximately 2-5 mg of the physical mixtures (PM) and the product samples were 11 
examined in the temperature range of 25-300 °C. The heating rate was 20 °C/min in the presence 12 
of argon as a carrier gas with a flow rate of 10 L/h. The calculations of Mel crystallinity (Cryst %) 13 
were performed using the area under the curve (AUC) of the melting enthalpy of the products 14 
(AUCMel) and the physical mixtures (AUCMelPM).39 The values were compared using the 15 
following formula: 16 
𝐶𝑟𝑦𝑠𝑡 % =  
𝐴𝑈𝐶𝑀𝑒𝑙
𝐴𝑈𝐶𝑀𝑒𝑙𝑃𝑀
∗ 100 17 
 18 
Stability test 19 
The products (fluidMel and lyoMel) were stored in a well-closed container, at room temperature 20 
(23 ± 2 °C, 45 ± 5% RH) for 6 months. The crystallinity of Mel was investigated compared to 21 
freshly measured products. 22 
 23 
Drug content determination  24 
The Mel content of the samples was controlled in the following way. The unit dose of the products 25 
with 0.75 mg of theoretical Mel was dissolved in 100 mL of phosphate buffer pH 7.4 ± 0.1. The 26 
sample was stirred with a magnetic stirrer at 25 °C for 24 h and then filtered (0.1 μm, FilterBio 27 
PES Syringe Filter) (Labex Ltd., Budapest, Hungary), and the concentration of the dissolved Mel 28 
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was analyzed spectrophotometrically (Unicam UV/VIS) (Thermo Fisher Scientific Inc., Waltham, 1 
MA, USA) at 364 nm wavelength. The investigations were repeated three times. 2 
 3 
Solubility testing of MEL in the samples  4 
The solubility of Mel in the samples (nanoMel, fluidMel and lyoMel) was determined. The 5 
dispersions were stirred with a magnetic stirrer at 25 °C for 24 h and then filtered (0.1 μm, FilterBio 6 
PES Syringe Filter) (Labex Ltd., Budapest, Hungary), and the dissolved drug content was 7 
analyzed spectrophotometrically (Unicam UV/VIS) (Thermo Fisher Scientific Inc., Waltham, MA, 8 
USA) at 364 nm wavelength (n = 3). 9 
 10 
In vitro dissolution test 11 
To determine the dissolution extent of Mel from different products, the paddle method (USP 12 
dissolution apparatus, type II Pharma Test, Heinburg, Germany) was used. The medium was 900 13 
ml of artificial gastric fluid at pH 1.2 ± 0.1. The paddle was rotated at 100 rpm and sampling was 14 
performed up to 120 min. The Mel content of the samples was determined with a 15 
spectrophotometer (ATI-UNICAM UV/VIS Spectrophotometer, Cambridge, UK) at 362 nm. The 16 
number of parallels was three. 17 
 18 
Statistical analyses 19 
Data from the above methods were expressed as means ±SD, and groups were compared by 20 
using Student’s t-test. Differences were considered statistically significant when p<0.05. 21 
 22 
In vivo studies  23 
All experiments involving animal subjects were carried out with the approval of the National 24 
Scientific Ethical Committee on Animal Experimentation (permission number: IV/1247/2017). The 25 
animals were treated in accordance with the European Communities Council Directives 26 
(2010/63/EU) and the Hungarian Act for the Protection of Animals in Research (Article 32 of Act 27 
XXVIII). Each sample contained 60 µg/ml of Mel and 30 µg/ml of PVA in distilled water. For per 28 
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os delivery, the different formulations were individually diluted and were given at a single dose of 1 
300 μg/kg of Mel to male Sprague–Dawley rats (8 weeks old, 240-260 g, n = 6) in a volume of 0.5 2 
ml by gastric gavages. All animals fasted 16 hours before the per os administration of drugs. In 3 
order to facilitate the absorption, the solid-state forms were re-dispersed in water immediately 4 
before administration. In a comparison study for intravenous administration, animals were treated 5 
with a 300 µg/kg bolus of Mel via the tail vein. 6 
Intravenous (IV) injection was prepared by the dilution of passable injection with a concentration 7 
of 15 mg/1.5 mL (Meloxicam-Zentiva, Prague, Czech Republic) to reach the final concentration 8 
(0.15 mg/mL). The ingredients of the injection were meglumine, poloxamer 188, glycine, sodium 9 
hydroxide (for pH adjustment), sodium chloride, glycopherol, and water for injection. Blood 10 
samples were collected from the tail vein before and at 15, 30, 60, 75, 90, 120 and 180 minutes 11 
post-dosing. Plasma samples were collected into EDTA containing polyethylene tubes, 12 
centrifuged at 1,500 g for 10 min at 5 °C. Separated plasma samples were stored at -80 °C until 13 
extraction and analysis. 14 
 15 
Determination of Mel from rat plasma  16 
Preparation of plasma samples, calibration standards and quality control samples  17 
To 90 µL of plasma sample, 10 µL of 0.1 % aqueous formic acid and 300 µL of acetonitrile 18 
containing piroxicam (internal standard at 12.5 ng/mL concentration) were added and the mixture 19 
was vortex-mixed for 60 s. The mixture was allowed to rest for 30 min at -20 °C to support protein 20 
precipitation. Supernatant was obtained by the centrifugation of the mixture for 10 min at 10,000 21 
g at 4 °C and 20 µL was diluted with 380 µL of 0.1 % aqueous formic acid. Finally, 5 µL was 22 
injected into the LC–MS/MS system for analysis. 23 
Rat plasma calibration standards of meloxicam were prepared by spiking the working standard 24 
solutions (1–1000 ng/mL) into a pool of drug-free rat plasma and the procedure described above 25 
was followed. Calibration standards consisted of 90 µL of pooled drug-free plasma, 10 µL of 26 
meloxicam standard solution (in 0.1 % aqueous formic acid) and 300 µL of acetonitrile containing 27 
piroxicam (internal standard at 12.5 ng/mL concentration). Solutions containing 6.25 ng/mL and 28 
25 ng/mL of meloxicam were used as QC samples. 20 µL of supernatant was taken out from both 29 
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of the calibration standards and the QC samples, diluted with 380 µL of 0.1 % aqueous formic 1 
acid, and 5 µL was analyzed by LC–MS/MS. 2 
 3 
LC–MS/MS analysis of meloxicam 4 
The quantitative analysis of meloxicam was performed by mass spectrometry after the 5 
chromatographic separation of analytes. An Agilent Liquid Chromatography System series 1100 6 
(Micro Vacuum Degasser, Capillary Pump, µ-WPS autosampler) (Agilent Technologies, 7 
Waldbronn, Germany) was connected to a Q ExactiveTM Plus Orbitrap mass spectrometer 8 
(Thermo Fisher Scientific, San Jose, US) equipped with a heated ESI ion source. Gradient 9 
chromatographic separation was performed at room temperature on a LunaR 5 µm C8(2) Mercury 10 
column (20 mm x 2.0 mm) protected by a C8 guard column (2x2 mm) (Phenomenex, Torrance, 11 
USA) using ammonium formate (15 mM, pH = 3) as Solvent A and acetonitrile as Solvent B (Table 12 
2). The calibration curve was shown to be linear over the concentration range of 1–1000 ng/mL 13 
Table 2 The gradient elution program applied for analysis 14 
t (min) B (%) Flow rate (µL/min) 
0 40 250 
0.5 40 250 
2 70 250 
2.1 90 600 
2.5 90 600 
2.6 40 600 
4.0 40 600 
4.1 40 250 
4.5 40 250 
13 
 
Abbreviation: B, solvent (acetonitrile) 1 
The mass spectrometer was used in positive mode with the following parameters of H-2 
ESI source: ion spray voltage at 3.5 kV, capillary temperature at 253 °C and aux gas heater 3 
temperature at 406 °C, sheath gas flow rate at 46 l/h, aux gas flow rate at 11 l/h, sweep gas flow 4 
rate at 2 l/h and S-lens RF level at 50.0 (source auto-defaults). Multiple-reaction-monitoring 5 
(MRM) mode was used for quantification by monitoring the transitions: m/z 352→115 and 6 
352→141 for meloxicam (collision energy 24V) and m/z 332→95 and 332→121 for piroxicam 7 
(collision energy 29V). A divert valve placed after the analytical column was programmed to switch 8 
flow onto MS only when analytes of interest elute from the column (plasma samples: 0.7-2.0 min) 9 
to prevent the excessive contamination of the ion source and ion optics.  10 
Data acquisition and processing were carried out using Xcalibur and Quan Browser (version 11 
4.0.27.19) software (Thermo Fisher Scientific, San Jose, US).  12 
The area under the curve (AUC) of the time (min)-concentration (ng/ml) curves of each 13 
animal and the statistical analysis were performed with Prism 5.0 software (GraphPad Software 14 
Inc., La Jolla, CA, USA). All data presented are means ± SD. The unpaired t-test was used to 15 
determine statistical significance. Changes were considered statistically significant at p < 0.05. 16 
The ratio of AUC value, after the per oral application of the transformed samples (AUCfluidMel, 17 
AUClyoMel) in comparison with the AUC of the peroral application of nanoMel (AUCnanoMel) as 18 
relative bioavailability (rel.BA) was determined according to the formula below.40 19 
 20 
𝑟𝑒𝑙. 𝐵𝐴 𝑓𝑜𝑟 𝑝𝑙𝑎𝑠𝑚𝑎 (%) =  
𝐴𝑈𝐶𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
𝐴𝑈𝐶𝑛𝑎𝑛𝑜𝑀𝑒𝑙
∗ 100 21 
 22 
In vitro-in vivo correlation calculation 23 
In vitro–in vivo correlation (IVIVC) is a biopharmaceutical tool for the investigation of the mutual 24 
relationship of the dissolution characteristics of the in vitro and in vivo absorption studies.41 In 25 
our case, the Pearson’s correlation coefficient of the AUC values of the in vitro and in vivo results 26 
was calculated by Microsoft Excel (Microsoft Corporation, Redmond, Washington, U.S.) and 27 
Statistica for Windows (StatSoft GmbH, Hamburg, Germany). The three prepared samples were 28 
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correlated with each other in groups of in vitro and in vivo. To determine statistical significance, 1 
the unpaired t-test was used. 2 
 3 
Results and discussion 4 
Particle size measurements 5 
Different techniques have been used to determine the particle size of Mel for reasons of accuracy 6 
and comparability. The particle size distribution of the rawMel and nanoMel samples was 7 
investigated via laser diffraction. A combined wet milling process resulted in a 200-fold particle 8 
size reduction in the case of nanoMel (d(0.50), 130±5 nm) compared to the raw drug particle size 9 
(d(0.50), 34.26±4.86 µm). The nanoMel product showed a monodisperse distribution (d(0.10), 10 
67±1nm; d(0.50), 130 ± 5 nm; d(0.90), 371±12 nm).  11 
For fluidMel sample, Mel particles adhered to the carrier surface (MCC) was analyzed by 12 
ImageJ technique and the particle size of Mel in the nanoMel and lyoMel samples was compared 13 
with dynamic light scattering technique (Malvern nanoZS), too. The results demonstrate that the 14 
d(0.50) value of the Mel nanoparticles measured on the surface of solid phase product (fluidMel) 15 
does not show a significant difference regarding the d(0.50) value of the nanoMel (Figure 1a). In 16 
the case of lyoMel, compared to the Z-average of Mel in nanoMel, a significant difference can 17 
already be detected which was caused by the recrystallization of the Mel (Figure 1b). Both 18 
samples have a same polydispersity index (nanoMel: 0.273 and lyoMel: 0.287) which also 19 
confirms the monodispersity of nanoMel and shows the excellent redispersibility of lyoMel. The 20 
6-month storage did not cause any further changes in the mean particle size of the products 21 
(Figure 1a, 1b). 22 
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 1 
(A) 2 
3 
(B) 4 
Figure 1 (from left to the right)  5 
Main particle size of nanoMel (measured by laser diffraction), fluidMel fresh and fluidMel stored (6 6 
months) (measured by SEM images) (A) and Z-average of nanoMel, lyoMel fresh, and lyoMel stored (6 7 
months) measured by Zeta nano ZS) (B) 8 
Abbreviations: Mel, meloxicam; SEM, scanning electron microscopy 9 
 10 
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SEM measurements 1 
Figure 2A and Figure 2B clearly show the particle size difference between the rawMel and 2 
nanoMel and the change in the particle habit. The latter particles have smooth surfaces with 3 
rounded edges and corners. High mechanical impact results in the fracture and abrasion of the 4 
crystals. 5 
 6 
 Figure 2 SEM image of rawMel (A), nanoMel (B), fluidMel (C1 and C2) and lyoMel (D1 and D2) 7 
Abbreviations: Mel, meloxicam; SEM, scanning electron microscopy During the fluidization 8 
process, the nanoparticles are uniformly adhered to the surface of MCC (Figure 2C1). Their habit 9 
is the same as that of the nanoparticles in the nanoMel (Figure 2C2). There is no sign indicating 10 
the aggregation of the nanoparticles on the surface of MCC. The adhesion of the Mel particles to 11 
17 
 
the carrier surface is also supported by the effect of the PVA adhesive property and the rapid 1 
evaporation of water. 2 
The SEM image of the lyoMel sample (Figure 2D1) shows large, consistent formulas at 3 
low magnification. The texture at higher magnification contains smaller, larger pores resulting in 4 
a big surface with honeycombed structure, where the surface area is determined by the size of 5 
the ice crystals.42 The SEM picture does not show any trehalose-like crystals in the structure 6 
(Figure 2D2). 7 
 8 
DSC measurements, crystallinity determination 9 
The DSC curves of the components and the products are shown in Figure 3. The rawMel has a 10 
relative high melting point at 268°C, PVA as semi-crystalline material has two endothermic peak 11 
at 169°C and at 222°C. MCC shows any characteristic peak, in contrast the trehalose is a 12 
crystalline material (Figure 3a).  13 
 14 
(A) 15 
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 1 
(B) 2 
Figure 3 DSC curves of rawMel (black), PVA (red), MCC (blue) and trehalose (purple) (A), and nanoMel 3 
(orange) fluidMel (green) and lyoMel (yellow) (B) 4 
Abbreviations: DSC, differencial scanning calorimetry; Mel, meloxicam; PVA, poly(vinyl 5 
alcohol)The thermograms of the products are shown in Figure 3b. It is clear, that the melting point 6 
and the enthalpy of Mel in the case of the nanoMel decreased due to the partial amorphization.  7 
The curve of the fluidMel shows the peak of MCC and the decreased melting point of Mel (Figure 8 
3B). The first obvious and big endothermic peak of the curve appearing from 30 °C to 150 °C is 9 
mainly related to the absorbed moisture evaporation.43 The second endothermic peak is 10 
connected to the melting point of Mel (264 °C) and the enthalpy was decreased due to the large 11 
amount of MCC, which covered the characteristic peak of PVA as well, compared to nanoMel. 12 
The curve of lyoMel represents the peak of PVA (197 °C) and the melting temperature of Mel (251 13 
°C) (Figure 3B). According to the literature44 and our measurements, during the process, the total 14 
amount of trehalose transformed into an amorphous form and the lyophilized trehalose maintains 15 
its amorphous form. The big endothermic peak of the curve appearing from 30 °C to 150 °C is 16 
connected to the absorbed water evaporation as well. 17 
The crystallinity of Mel in nanoMel and the transformed solid-state products was 18 
calculated by the enthalpy changes of the drug occurring during the DSC measurement (Table 19 
3). Each sample was compared to its own physical mixture. According to the crystallinity of the 20 
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nanoMel (13.43%) sample, the crystallinity of the fluidMel sample did not change (12.98 %), for 1 
the lyoMel sample partial recrystallization (40.11%) occurred.  2 
Table 3 Enthalpy and calculated crystallinity values of the characteristic peak of Mel in the samples 3 
Sample Enthalpy 
(J/g) 
Crystallinity of Mel 
(%) 
Crystallinity of Mel 
after 6 months of storage 
(%) 
nanoMel 12.24 13.43 - 
fluidMel 11.83 12.98 13.02 
lyoMel 36.54 40.11 40.16 
Abbreviation: Mel, meloxicam 4 
After 6 months of storage (23 ± 2 °C, 45 ± 5% RH), the degree of crystallinity of solidified 5 
samples (fluidMel and lyoMel) was determined again. The results did not show a significant 6 
change (p>0.05) compared to the non-stored, fresh samples (Table 3). There was no sign for the 7 
recrystallization of trehalose. 8 
 9 
Drug content determination 10 
The theoretical drug content was 7.50 mg as single dose/oral. For the nanoMel sample this 11 
amount was 7.12mg and fluidMel showed 6.83 mg of Mel. The latter can be related to the yield 12 
of the fluidization technique (95.93%). During the lyophilization process the Mel content of the 13 
sample (lyoMel) was 7.12 mg. 14 
 15 
Solubility testing of MEL in the samples  16 
The solubility of nanoMel increased significantly (9.4 ± 0.5 µg/ml) in comparison with the rawMel 17 
(6.5±0.2 µg/ml). The reduced particle size enhanced the wettability of the hydrophobic particle 18 
when using PVA, therefore increased the thermodynamic solubility of Mel. The fluidization 19 
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process did not affect the solubility of Mel (9.6 ± 0.4 µg/ml). In the case of lyoMel, solubility was 1 
increased (11.2 ± 0.5 µg/ml) because of the presence of trehalose.  2 
 3 
In vitro dissolution studies 4 
The in vitro dissolution extent of the samples was investigated in gastric juice (pH=1.2). Mel has 5 
a week acidic character, therefore its solubility in this medium is very poor (1.6 ± 0.2 µg/ml, at 37 6 
°C). Figure 4 clearly demonstrates that the particle size reduction of Mel in the nanosuspension 7 
(nanoMel) influenced the dissolution rate of Mel, but resulted in only 40% of drug release in 5 8 
minutes, and then the curve took a stagnant profile. The initial rapid drug release can be 9 
associated with the nanoscale Mel and its amorphous structure. The 2-hour test did not result in 10 
any more favorable results. Although the distribution of the nanoparticles of Mel in the 11 
nanosuspension is suitable, a large volume of acidic medium (900 ml) may increase the 12 
aggregation of the nanoparticles. In this case, the protective effect of the polymer (PVA) is 13 
unsatisfactory. 14 
 15 
Figure 4 In vitro dissolution of Mel from investigated samples. Medium: artificial gastric juice (pH: 1.2) 16 
Abbreviations: Mel, meloxicam 17 
For fluidMel and lyoMel samples, a rapid initial phase is observed (about 60% of the drug 18 
is dissolved in 15 minutes), followed by a slowing but rising profile. About 75% of Mel was 19 
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dissolved within 2 hours. In the case of the solid state forms, carriers (MCC and trehalose) help 1 
to uniformly distribute the nanoparticles of Mel, thereby maintaining the uniqueness of the 2 
nanoparticles. 3 
 4 
In vivo studies 5 
The plasma concentration of the samples in rats is shown in Figure 5. The calculated plasma 6 
concentration of Mel at zero min (C0min) was 10,607 nM, and then the plasma concentration 7 
decreased exponentially. A very small amount of Mel was absorbed from nanoMel sample, 8 
regardless of the particle size of the drug. The plasma concentration of Mel was constant in the 9 
investigated time period. The results show that the nanosuspension (nanoMel) has not got 10 
advantageous properties. 11 
 12 
Figure 5 Plasma levels of MEL after the administration of different samples in rats. The preparations 13 
were administered orally (nanoMel, fluidMel and lyoMel) or intravenously (IV) as a single dose of 300 14 
μg/kg 15 
Abbreviations: Mel, meloxicam 16 
The initial blood levels of the fluidMel and lyoMel samples show a big difference. At 15 17 
minutes, the lyoMel sample (5,712.98 nM) shows more than twice the value of fluidMel (Table 4). 18 
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In practice, this value is similar as the maximum plasma level for the lyophilized product (C30min 1 
5,814 nM). The peak blood concentration of fluidMel, is about 6,000.00 nM at 50 minutes that is 2 
comparable with the blood concentration reached by IV injection at 5 min. This result also confirms 3 
that the solid products contained Mel in an adequate amount, and that the total amount thereof 4 
dissolved and absorbed. 5 
 The plasma curves of the different samples containing Mel show a very slow elimination 6 
after the distribution phases. That can be explained by the very high (99%) plasma binding 7 
property of Mel in rat, and this ratio is the same in human.45 It seems that the eliminated portion 8 
of Mel is replenished from the protein bounded fraction for a quite long period of time. Our 9 
measuring time was only 3 hours, longer detection period can provide appropriate information 10 
about the whole elimination process. The peak MEL concentrations of from lyoMel and fluidMel 11 
preparations have reached the similar level that of IV formula (Figure 5). The lyoMel sample 12 
resulted in higher plasma concentrations in 15 minutes as compared with nanoMEL preparation. 13 
The solidified samples had nearly five-fold higher bioavailability than that of nanoMel (Table 4). 14 
 15 
Table 4 Plasma concentrations of Mel in time and its relative bioavailability in rats after IV and per os 16 
administration of Mel samples. Relative bioavailabilities were compared to nanoMel preparation. 17 
Sample C15min 
(nM) 
C120min 
(nM) 
AUCblood 
(min·ng/ml) 
Relative 
bioavailability (%) 
nanoMel 1,090.02±13.11 1,123.31±14.24 190,584.52 100.00 
fluidMel 2,338.44±17.25 5,811.33±18.34 945,834.99 496.28 
lyoMel 5,712.98±28.36 5,219.52±20.86 923,117.95 484.36 
IV injection C5min 
6,059.07±15.76 
2,607.80±19.52 377,528.01 - 
Abbreviations: Mel, meloxicam; C15min, C120min, plasma concentrations of Mel in time; AUCblood, area under 18 
the time-concentration curve AUC interval is t0min-t180 min 19 
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IVIV correlation 1 
Comparative studies according to AUC values have shown that there are significant differences 2 
between the nanosuspension and the samples (fluidMel and lyoMel) within in vitro and in vivo 3 
groups. However, there is no significant difference between two solid samples either in vitro or in 4 
vivo (Figure 6). The basis of the IVIVC calculation was the comparison of the AUC values of the 5 
samples in the in vitro and in vivo groups. By our calculations, the Pearson’s correlation coefficient 6 
value between the two studies is 0.99695. The t value of the independent t-test of the two 7 
dissolution study series was 0.0145, the calculated p value was 0.9889 and the difference is not 8 
significant at a confidence level of 95%. As the zero hypothesis of the independent t-test, the 9 
calculation is not significant if the averages of the two series are equal. It can be concluded that 10 
in this system, in vitro dissolution studies are applicable to predict the dissolution rate-limited 11 
differences in the case of in vivo studies. 12 
 13 
Figure 6 IVIV correlation of Mel containing samples. Notes: Values are presented as mean ± SD. 14 
Statistically significant differences are:  ***p<0.001, compared to nanoMel separately in in vitro and in 15 
vivo groups; # p<0.05 compared to the indicated columns 16 
Abbreviations: Mel, meloxicam; AUC, area under the time-concentration curve; IVIV correlation, in 17 
vitro-in vivo correlation; SD, standard deviation 18 
 19 
Conclusion 20 
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Mel-containing surfactant-free nanosuspension (nanoMel) as intermediate product was produced 1 
by wet milling process (planetary ball mill was combined with pearl milling technology). The 2 
energy invested in the milling decreased the mean particle size of Mel (130 nm) and broke the 3 
crystal structure of the nanoparticles (crystallinity index: 13.43%). This can be considered a labile 4 
system, so stabilizing a suspension as a final dosage form without a surfactant does not work, 5 
therefore the solidification of the nanoMel produced by fluidization and lyophilization was chosen 6 
to ensure the critical product parameters (particle size, degree of crystallinity). We studied also 7 
the influence of solidification of nanoMel on the physical stability and drug bioavailability of the 8 
products. The nanoMel product had an optimized amount of PVA (0.5%) as a protective polymer, 9 
but no surfactant as a further stabilizing agent because the final aim was to produce a surfactant-10 
free solid phase products as well. 11 
The solidification studies showed that the critical product parameters of the intermediate 12 
product (nanoMel) were primarily provided by the fluidization technique which resulted no 13 
significant change in mean particle size and crystallinity degree of Mel compared to the nanoMel. 14 
It is connected to the short operation time (50 min), the large surface area of the MCC which fixed 15 
the nanoparticles with the sticking effect of the PVA and the crystallization inhibitory property of 16 
the fibers.34 The lyophilization required a longer operation time (72 hours), which resulted in the 17 
amorphization of the crystalline carrier (trehalose)46 and the recrystallization of Mel with an 18 
increased particle size and crystallinity degree. Finally it was found that the physical stability of 19 
the solid phase products (fluidMel, lyoMel) was no change in particle size and crystallinity at 6 20 
months of storage at room temperature (23 ± 2 ° C, 45 ± 5% RH) compared to freshly measured 21 
products. 22 
In our pervious work (DDDT, 2018)10, there was performed a human Caco-2 intestinal 23 
epithel cell line viability assay. Impedance measurement did not show significant cell damage 24 
after treatments with Mel, PVA-Mel formulations, as reflected by unchanged cell index values. 25 
The epithelial electrical resistance studies predicted the rapid penetration of nanonized Mel. In 26 
vivo studies justified the predicted data. The nanonized Mel in solidified products (fluidMel, lyoMel) 27 
resulted in rapid absorption through the gastric membrane by passive transcellular transport. It 28 
was found that the solid products contained Mel in an adequate amount, and that the total amount 29 
25 
 
thereof dissolved and absorbed. It has to be noted that the Mel shows a very slow elimination 1 
because of very high plasma binding (99%) in rat, and its replenishing time is quite long period. 2 
MEL blood concentrations of lyoMel and fluidMel were similar as level of IV form. 3 
The solidified samples had nearly five-fold higher relative bioavailability than nanoMel 4 
application by oral administration and IVIV correlation was found between the in vitro and in vivo 5 
studies. The correlation between in vitro and in vivo studies showed that Mel nanoparticles fixed 6 
on solid carrier (MCC, trehalose) in both the artificial gastric juice and the stomach of the animals 7 
rapidly reach saturation concentration leading to rapid absorption. These products show about 5 8 
times greater bioavailability than the nanosuspension, in which the Mel nanoparticles can be 9 
aggregated in the stomach.  10 
It can be stated that in the present study the solidification of the nanosuspension 11 
(nanoMel) not only increased the stability of the nanoparticles, but also allowed the preparation 12 
of surfactant-free solid compositions (powder, tablet, capsule), which may be an important 13 
consideration for certain groups of patients to achieve rapid analgesia. Further experiments are 14 
necessary to prove the therapeutic relevance of these innovative formulations.  15 
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